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ABSTRACT OF DISSERTATION 
 
 
 
THE ROLE OF BATF2 IN LPS/IFNγ POLARIZED MACROPHAGES 
 
Transcription factors regulate distinct macrophage functions by regulating gene 
expression in response to micro-environmental cues.  This functional plasticity is critical 
for regulating innate and adaptive immune responses during infection and during chronic 
disease processes including inflammatory diseases and cancer.  Microarray analysis of 
macrophages polarized to a pro-inflammatory (M1) phenotype with LPS and IFNγ revealed 
that basic leucine zipper transcription factor ATF-like 2 (Batf2), a member of the AP1 
transcription factors, is selectively upregulated in M1 macrophages compared to anti-
inflammatory IL-4-polarized (M2) macrophages.  The initial hypothesis was that Batf2 is 
a master regulator of gene expression that orchestrates M1 polarization.  To investigate a 
potential role of Batf2 during macrophage polarization, its expression in M1 polarized 
macrophages was examined.  Batf2 mRNA appears within 60 minutes following LPS/ IFNγ 
treatment and is sustained for at least 48 hours.  To address the hypothesis that Batf2 acts 
as a master transcriptional factor driving a functional M1 phenotype, we have established 
macrophage cell lines that constitutively express Batf2.  Batf2 overexpression did not 
enhance key M1-associated genes, including iNOS and H2-Aa, but did enhance LPS/IFNγ-
driven Cxcl10.  Batf2 overexpression also failed to suppress key M2-associated genes 
including Fizz1 and Mrc1.  Batf2 overexpression also failed to alter multiple non-
immunity-related genes established or predicted to be downstream of Batf2 in macrophages 
or other cells.  Overall, contrary to our initial hypothesis, constitutive Batf2 expression by 
itself does not appear to broadly induce M1 gene expression; rather, it appears to enhance 
only select genes.  Since other Batf family members interact with members of the IRF 
family, I discuss the possibility that Batf2 works in conjunction with a limiting cofactor, 
possibly Irf family members and/or other regulatory proteins. 
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Chapter I 
INTRODUCTION  
1.1.  Purpose 
 This study aims to examine the function of the transcription factor basic leucine 
zipper transcription factor, ATF-like 2 (Batf2) in the context of macrophage polarization.  
Master transcription factors commonly control transcriptional repertoires during 
development and polarization, and such a factor or even the major factors for macrophage 
polarization to the LPS/IFNγ activated macrophages (herein termed M1 macrophages) 
remains unclear.  Batf2, a member of the Batf subset of AP-1 transcription factors 
involved in polarizing immune cells, was proposed as a master transcription factor for 
macrophage polarization.  A series of studies were designed and carried out to 
demonstrate a role for Batf2 as master regulator.  However, we found that Batf2 by itself 
did not induce M1 polarization. 
 
1.2.  Importance    
 Immune function plays a major role in the health of an individual.  Appropriate 
inflammatory responses kill pathogens and tumor cells.  Inappropriate inflammation, or 
lack of inflammation, contributes to many diseases including sepsis, atherosclerosis, 
meningitis, cancer, AIDS, etc.  For this reason, we seek to understand and control the 
inflammatory processes: first, to understand which responses are appropriate in which 
situation; second, to initiate these responses at the correct time or dampen them when 
they are detrimental.  This project focuses on the first goal by identifying transcription 
factors regulating multiple genes during M1 polarization of macrophages. 
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 Although such transcription factors have been discovered for other cells, the study 
of macrophages has been complicated by their plasticity and sensitivity.  Macrophages 
express polarization-associated genes in response to a large variety of common 
endogenous stimuli, mechanical stresses, and media components such as cholesterol, etc.  
Moreover, primary macrophage responses may be skewed by epigenetic programming in 
vivo.  Prior studies have uncovered several transcription factors, but until recently no 
factor that acts similarly to master transcription factors in other cell types.  This study 
makes use of a reductionist, highly controllable model to study gene expression control.  
We use a macrophage cell line isolated in an early myeloid precursor stage, genetically 
engineered to differentiate in vitro in response to a non-polarizing stimulus.  Thus, we can 
detect gene changes upregulated or downregulated in the inflammatory state more clearly 
than other systems due to the minimal M1/M2 polarization in the resting state.   
 
1.3.  Results and analysis 
 In the context of the PUER macrophage cell system, we describe a recently 
discovered M1-associated transcription factor, Batf2.  Batf2 belongs to the AP-1 group of 
bZIP transcription factors, and it was recently discovered that knockdown of Batf2 alters 
a variety of M1-assicated genes1.  Contrary to expectations, we demonstrate that 
constitutive high expression of Batf2 alone in PUER cells did not induce most of the 
hallmark M1-associated genes or suppress most of the hallmark M2-associated genes, nor 
did it induce or suppress non-immune genes downstream of Batf2 or closely related Batf 
and Batf3 in other cells.  However, it did appear to enhance LPS/IFNγ-induced 
expression of the M1-associated chemokine Cxcl10 and suppress expression the IL-4-
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induced M2-associated enzyme Arg1.  We further begin to explore the mechanisms of 
Batf2 activity by analyzing potentially limiting binding partners and cofactors and the 
genes they control.  Binding partners required for Batf2 activity are present in PUER 
cells but not associated with polarization.  On the other hand, potential cofactor Irfs, are 
expressed in M1-polarized cells and may be required for Batf2 activity.   
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Chapter II 
BACKGROUND 
2.1.  Macrophages: Non-specific cells of the immune system with diverse function  
2.1.1. Macrophages  
Transcription factors serve a critical role in dictating macrophage differentiation 
from a myeloid precursor, as well as functional polarization and activation of monocytes 
and macrophages2.  Macrophages arise from a precursor for all immune cells of myeloid 
lineage3.  This highly heterogeneous group plays critical roles in non-specific defense and 
assists the adaptive defense against a variety of pathogens.  It fulfills many homeostatic 
functions such as tissue repair, muscle regeneration, and iron transport3.  These cells arise 
from a common myeloid progenitor, as opposed to the other lymphocytes that arise from 
a common lymphoid progenitor.  This common myeloid progenitor differentiates, under 
the guidance of the key transcription factors that shape the chromatin landscape and 
initiate transcription of lineage-specific proteins, into macrophages and their cerebral 
counterpart microglia, dendritic cells, neutrophils, eosinophils, and basophils, and the 
more distantly related mast cells, megakaryocytes, and erythrocytes2. 
 Macrophages play critical roles initiating and resolving infection-induced or 
sterile inflammation as well as maintaining tissue homeostasis.  Here transcription factors 
also guide the translation of environmental cues into cellular activity2.  Appropriate 
activation of transcription factors by signaling pathways orchestrates an appropriate 
response, such as generation of reactive oxygen species to damage an invading pathogen.  
Inappropriate activation of these pathways, however, can lead to the generation of 
detrimental responses, such as the generation of tissue-damaging inflammation in the 
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absence of infection in chronic inflammatory diseases4,5.  Preventing and manipulating 
such inappropriate responses requires an understanding of the signaling pathways and 
transcription factors involved in each response.  Therefore, we are investigating key 
transcription factors for specific macrophage functions.   
 
2.1.2. Transcription factors integrate environmental cues during macrophage 
development 
 Each step in commitment to a lineage and thus to a function is under the control 
of a specific combination of chromatin remodeling and transcription factors6.  The first 
stages of differentiation from a common stem cell occur during embryogenesis.  
Microglial and some resident tissue macrophages, notable for their self-renewal capacity, 
arise from the yolk sac hematopoietic stem cell (HSC) population78.  Some HSCs, 
destined to become microglia, migrate to the brain region.  Transcription factors direct 
microglia-specific marker expression around embryonic day 9 in mice78.  Others migrate 
to various tissues of the embryo and become tissue macrophages residing long-term in 
the liver (Kupffer cells), kidney, spleen, lung, and skin (Langerhans cells).  A second 
wave of myeloid cells develops later in the fetal liver from HSCs.  This HSC pool 
differentiates into a common myeloid precursor, then macrophage and dendritic cell 
progenitor, then monocytic cell, then fully differentiated macrophage cells3,8.  These fetal 
liver derived macrophages have two distinct types: those bound to be resident 
homeostatic tissue macrophages similar to the yolk-sac derived microglia and tissue 
macrophages, and those bound for immune-related activities such as fighting infection or 
healing wounds (“inflammatory” macrophages)3,8.   
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 In spite of the differences in environment and origin, these macrophage 
populations share some similar transcription factor requirements guiding their 
development.  Some of the unique factors required for macrophage and microglial 
development have been defined.  Early stages of differentiation require Runt-related 
transcription factor 1 (Runx1) and high levels of PU.18,9.  PU.1 and Runx1 recruit factors 
that modify histones and DNA, beginning to shape the epigenetic landscape so that 
available genes are hematopoietic cell specific10,11.  Interferon regulatory factor 8 (Irf8) 
activity is required as well as PU.1 and Runx1 for the development of macrophages and 
microglia, likely in part as a cofactor with PU.17.  More recently, transcription factor EC 
3 (Tcef3), CCAAT/enhancer binding protein-alpha (C/EBP-alpha), BTB and CNC 
homology 1 (Bach1), and cellular repressor of E1A-stimulated genes 1 (Creg-1) have 
been associated with macrophage core gene expression, although their importance for 
polarization requires further investigation12.  However, there may also be differences 
between the development of yolk sac and fetal liver populations and differences in 
transcription factors required for macrophage types within these two lineages.  Only 
peritoneal macrophages, for example, expressed high levels of transcription factor GATA 
binding protein 6 (GATA6) compared to splenic or lung macrophages or microglia in a 
murine transcriptome analysis12,13.   
Each macrophage subset likely responds in a unique manner to the environment in 
which it develops and expresses a unique signature of transcription factors, resulting in 
the wide variety of phenotypes in resting macrophages.  Differentiation to these various 
tissue associated macrophages has been extensively studied and has been reviewed by 
Gautier et al. and Okabe and Medzhitov12,13.  In summary, microglia and macrophages 
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share similar developmental pathways guided by transcription factors including PU.1, 
Runx1, and Irf8.   
 
2.1.3. Polarization of macrophages 
 After development, transcription factor-guided polarization allows resting 
macrophage cells to respond uniquely to environmental cytokines.  Often, this is 
accomplished through a few “master” transcription factors2,14.  These transcription factors 
were first described as factors sufficient for determining cell type.  T cells provide well 
described examples of immune cells controlled by master transcription factors.  Tbet 
transduction drives helper T cell type 1 (Th1) cell differentiation, forkhead Box P3 
(Foxp3) drives regulatory T cell (Treg) development, B cell CLL/lymphoma 6 (Bcl6) 
drives follicular helper T cell (Tfh) differentiation, GATA3 drives helper T cell type 2 
(Th2) differentiation, and RORγt (encoded by RAR-related orphan receptor C gene 
[Rorc]) drives Helper T cell type 17 (Th17) differentiation14–20.  These master 
transcription factors accomplish this by driving expression of key lineage- and function-
specific genes and other transcription factors, thus controlling a specific transcriptional 
program of multiple effector proteins.  For example, as reviewed in Lazarevic et al., Tbet 
induces interleukin 12 (IL-12) receptor beta 2 (IL-12RB2), Runx3, chemokine (C-X-C 
motif) receptor 3 (Cxcr3), H2.0-like homeobox (Hlx), CC chemokine ligand 3 Ccl3, 
Ccl4, and IFNγ, and suppresses Rorc, IL-17A, IL-4, IL5, and IL-1321.  Master 
transcription factors for macrophage polarization remain unclear, however, and this study 
contributes to current work on this topic.   
 Initially, macrophage function consisted of two categories: “classically activated” 
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(M1) or “alternatively activated” (M2)22.  Bacterial cell wall component 
lipopolysaccharide (LPS) and cytokine interferon gamma (IFNγ) induce polarization to 
the “classically activated/inflammatory/M1” phenotype, promoting inflammation and 
infection clearance through production of Th1-associated responses, such as production 
of chemokine (C-X-C motif) ligand 10 (Cxcl10)23,24.  In contrast, IL-4 induced an 
“alternative/M2” phenotype associated with Th2 responses and suppression of 
inflammatory responses, such as shunting L-arginine from nitric oxide (NO) production 
to ornithine and urea production by increased Arginase 1 (Arg1).  These two 
classifications and the correlating gene expression, discussed below, are shown in Figure 
2.1, page 46.  Over time, however, more sensitive studies have continued to push the 
model of macrophage polarization away from this binary model and towards a spectrum 
of responses, even switching polarization states8,22,25.  Still, four broad classifications 
have emerged that prove useful for simplification of discussion of macrophage 
polarization: M1 (classically activated or LPS/IFNγ activated), three alternative subsets 
M2a, M2b, and M2c, and the M2d/tumor associated macrophages (TAMs) 26. 
 Predominantly, LPS and/or IFNγ remain representative stimuli for inducing the 
M1, classically activated, phenotype, so named to correspond to the IFNγ-centered Th1 T 
cell response23.  IL-1β, tumor necrosis factor alpha (TNFα), and IFNs also influence M1 
macrophage polarization.  LPS (through its receptor toll-like receptor 4 [TLR4]), IFNγ, 
IL-1β, and TNFα activate major adaptor protein MyD88 in the main mechanism of signal 
transduction.  This adaptor in turn signals through inhibitor of kappa light polypeptide 
gene enhancer in B cells (IKKB) and mitogen activated protein kinase (MAPK) pathways 
to activate transcription factors nuclear factor kappa B (NF-κB) and Activator Protein 1 
9 
 
(AP-1), leading to expression of specific effector genes27.  IFNs influence gene 
expression through Janus activated kinase/signal transducer and activator of transcription 
(JAK/Stat) pathways.  Complete polarization is much more complex than simply 
activating Stat, however.  Transcription factors induced by M1-polarizing stimuli 
important for inflammatory gene expression include Stat1, Stat2, NF-κB, AP-1, Irf3, Irf5 
and HIF-1α (Figure 2.1)2,8,12,28.  These each control multiple genes, but a unique 'master 
transcription factor' that governs polarization such as exists in other immune cells 
remains unclear2,8.  Some studies have suggested Irf5 for this role, but recent evidence 
suggests that Batf2 and Irf1 may also broadly induce gene M1-associated gene expression 
in macrophages1.  Mediated by genes induced by these transcription factors, M1-
polarized macrophages participate in pathogen phagocytosis and pathogen destruction via 
iron restriction, phagosome acidification, nitric oxide production, and reactive oxygen 
species release, as well as releasing inflammatory cytokines such as IFNs, IL-12, IL-1β, 
and Cxcl10 to recruit and activate other inflammatory cells.  Most macrophage studies 
agree on the characteristic M1-polarized macrophage markers and functions, which are 
described in several recent reviews2,8,22.  In addition to the functions driven by the M1 
transcriptional program, it also suppresses gene expression of alternative functions such 
as regulatory T cell recruitment and IL-10 secretion.  All of these genes contains multiple 
transcription factor binding sites.  Therefore, the various stimuli can have additive or 
synergistic effects, and opposing stimuli can attenuate expression.  This allows a fine-
tuning of the macrophage role in an inflammatory response, critical for avoiding an 
insufficiently weak or overly destructive response or for different environments. 
 In contrast to the M1 macrophages, the phenotypes of M2 macrophages range 
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widely enough to require multiple subsets to simplify discussion.  To complicate the 
discussion, reviews from different authors rarely completely agree on M2 markers and 
phenotype.  All M2 subsets tend to overlap in transcriptional repertoires, however, and all 
exert immunosuppressive activity when they affect the immune response.  Mantovani et 
al. described the most commonly used classification schemes, defining M2a, M2b, and 
M2c subsets which reflect phenotypes alternatively activated macrophages, defined by 
polarizing cytokines26.  The “M2a” subset, IL-4/IL13 activated, associates with Th2 
cytokines and provides the best contrast to the M1 macrophages.  IL-4/IL13 activation is 
most often used when comparing classical and alternative activation, with IL-10 
providing another common alternative stimulus29.  IL-4 and IL-10 elicit many of the same 
responses, but also have some differences; IL-4 stimulates the IL-4 receptor and activates 
both  Stat3 and Stat6, while IL-10 stimulates the IL-10 receptor and activates Stat326,30–33.  
IL-4 induces IL-10, while IL-10 induces Fc fragment of IgE, low affinity II (FcR/Fcer2), 
and both induce mannose receptor C (Mrc1) and a key M2 enzyme Arg1.  Importantly for 
our study, IL-10 also induces Batf2 (discussed in section 4.2 page 76).  Genes strongly 
correlating with IL-4/IL13-activated M2a phenotype include Arg1, Ym1, Mrc1, 
transglutaminase (Tgm2) and Fizz126.  They counter the effects of M1 macrophages and 
play a role in protection against parasites, Th2 cell recruitment, tissue repair, and growth 
stimulation.  Cytokines secreted by these cells include IL-10, TGF-β, and IL-1 receptor 
antagonist (IL-1RA)22.  The Arg1 enzyme, a key M2 marker, provides important anti-
parasitic, anti-inflammatory, and wound-repair function (described below).  It is not 
unique to IL-4-polarized macrophages, since it is also induced by IL-10 and active in the 
M2b subset. 
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 Other subset classifications may be used depending on the purpose of a given 
study, and designations differ between research groups.  The subset designated M2b, 
activated by immune complexes (ICs), LPS, and viral long terminal repeats (LTR)/IL1R, 
parallels a memory immune response with B cell class switching and regulatory T cell 
recruitment.  This subset produces high amounts of IL-10 and expresses major 
histocompatibility complex II (MHCII) and CD8634,35.  The subset designated M2c, 
activated by IL-10, TGF-β, and glucocorticoids, serves as scavengers for cell debris and 
serves roles in the healing process.  These express Arg1 like the M2a subset, but also 
CD163 and CD20626.  Finally, another subset designated M2d but more commonly called 
tumor associated macrophages (TAMs) has been found in the context of tumors.  This 
phenotype can be induced with IL-6, leukocyte inhibitory factor (LIF), and monocyte-
colony stimulating factor (M-CSF).  These produce some inflammatory and anti-
inflammatory cytokines and chemokines, as well as vascular endothelial growth factor, 
and aid in tumor growth.   
 In summary, macrophages polarize to multiple functional states in response to 
various stimuli.  These states include a Th1-cytokine-associated M1 state, a Th2-
associted “M2a” state, and a variety of alternative M2 states functioning in wound repair, 
tissue homeostasis, tumor growth, and more.  Based on control of functional states in 
other cells, it is reasonable to expect macrophages to be guided by master transcription 
factors governing broad gene expression.  The master transcription factors for M1 
polarization are unclear.  The purpose of this study is to determine the function of one 
candidate for a master transcription factor, Batf2, and to identify Batf2-controlled M1-
associated genes. 
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2.1.4. M1-associated gene Cxcl10 
One of the genes influenced by the M1-associated transcription factor Batf2 is 
Cxcl10, previously known as interferon-inducible protein 10 (IP-10) or Crg-2 (cytokine 
responsive gene 2).  Cxcl10 belongs to the small, inducible, secreted protein family 
classified as chemokines36.  These proteins share structural and functional similarities: 
similar secondary structure with four similarly spaced cysteines, and the ability to attract 
other cells to the origin of chemokine production.  “CXC” chemokines belong to the 
subfamily of chemokines characterized by having cys-x-cys as the first two cysteines22.  
Other subfamilies include CC, C, and CX3C36.  Chemokines may promote inflammation, 
homeostasis, or both22.  Cxcl10 is typically induced by pro-inflammatory stimuli37–40.  In 
our study, Batf2 enhances Cxcl10 message induction, as demonstrated in Chapter 4 (see 
Figure 4.14) and discussed in Chapter 5 (see section 5.3). 
 Various stimuli generated during a pro-inflammatory state including IFNs, LPS, 
and TNFα with IFNγ rapidly stimulate Cxcl10 production from a variety of cells 
including macrophages, keratinocytes, fibroblasts, endothelial cells , mesangial cells, 
astrocytes, monocytes and neutrophils41–44.  Indeed, the Cxcl10 promoter region contains 
sites for Irf1 (activated by interferon, IL6, leukemia inhibitory factor (LIF) or TLR 
signaling), Stat1 (activated by IFNβ or IFNγ), NF-κB (activated by TNFα, TLR ligands, 
or IL1), and AP-1 sites27,37,42,45–47.  The importance of AP-1 in Cxcl10 induction remains 
unclear.  Mutating the AP-1 site did not impact TNF-induced Cxcl10 in human airway 
smooth muscle cells, but decreased HCV infection-induced Cxcl10 in a separate study in 
human hepatoma cells38,39.  In mice, deficiency of AP-1 inhibitory subunit JunB 
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decreased Cxcl1048.  In contrast, expression is inhibited by Stat3 (activated by IL-1049.  
As a general rule, pro-inflammatory stimuli upregulate Cxcl10 expression in 
macrophages. 
 Cells responsive to Cxcl10 through the receptor CXCR3 are mainly polarized Th1 
cells and natural killer (NK) cells but also macrophages, microglia, and dendritic cells 
(reviewed in Mantovani et al. and Liu et al.)22,50.  These cells have cytotoxic activity to 
kill infected cells, or can produce inflammatory cytokines and chemokines to propagate 
an immune response.  Unlike other CXC chemokines, Cxcl10 does not activate 
neutrophils22,50.  Activation by Cxcl10 stimulates cells to migrate up the concentration 
gradient to the area of its origin.  Once arrived, the recruited cells exert their protective 
functions such as resistance to intracellular pathogens and tumor cells51.  In a typical 
scenario, IFNs from an infected cell may stimulate macrophages in the surrounding area 
to produce Cxcl10 that attracts Th1 and NK cells.  These have the ability to destroy the 
infected cell and halt the viral production in that cell. 
 Besides chemotaxis, Cxcl10 has less well-characterized functions in immune and 
non-immune cells.  Thymic or splenic Cxcl10 may play a role in T cell development and 
function, can stimulate adhesion of mature T cells to endothelial cells, and enhance anti-
tumor activity36,51,52.  Cxcl10 enhances T cell and NK cell development and function 
independently of chemotaxis, and may contribute to accessibility at sites of production.  
Cxcl10 may also enhance NK cell migration and cytolysis.  Other cells that do not 
participate in the immune response may also be influenced by Cxcl10.  Vascular smooth 
muscle cells’ migration and proliferation may be enhanced, and angiogenesis is 
inhibited51.  Cxcl10 may also contribute to apoptosis and regulate cell growth in some 
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cells50.  The extent of these non-chemotactic functions in vivo are currently not well 
understood. 
 Cxcl10 production is important for protective responses to a variety of pathogens.  
Decreased Cxcl10 leads to increased susceptibility to Legionella pneumophilia and 
increased pathogenesis of cutaneous candidiasis50.  Further, increased Cxcl10 is 
protective for in Leishmania amazonesis in mice, and Cxcl10 is protective during 
Pneumocystis carinii and Cryptococcus neoformans in brains of immunized mice50 53.  In 
general, Cxcl10 is a chemokine induced by multiple M1 stimuli and promotes M1-
associated responses.  Despite its role in T cell and NK cell development and effector 
activity, the major role of Cxcl10 remains as a chemotactic signal for T and NK cells.   
 
2.1.5. M2-associated gene Arginase 1 (Arg1) 
 Arginase 1 contrasts with Cxcl10 by association with M2 responses.  Arginase 1 
is a manganese metalloenzyme that catalyzes the conversion of L-arginine into ornithine 
and urea.  In the liver, this is the final step in the urea cycle.  In IL-4 or IL-13 polarized 
macrophages, it is considered a defining marker for alternative versus M1 polarization54.  
In our study, the M1-associated transcription factor Batf2 mildly suppresses IL-4-induced 
Arg1 expression. 
 Arginase 1 plays a critical role in immune function by promoting M2 responses 
and suppressing M1 responses that may damage tissue.  One major consequence of 
arginase activity is decreased inflammation.  By converting L-arginine to urea and 
ornithine, it sequesters the pool of L-arginine available for nitric oxide synthase, an M1-
associated enzyme that produces the inflammatory and reactive nitric oxide to combat 
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pathogens55–57.  Further, decreased L-arginine availability decreases Th2 cell responses56.  
Arginase activity also plays multiple roles in homeostasis and tissue repair.  During 
homeostasis, the production of polyamines from L-ornithine by L-ornithine 
decarboxylase promotes cell growth58.  Alternatively, L-ornithine aminotransferase 
converts ornithine to collagen in tissue repair.   
 Multiple studies confirm in vitro effects with roles for arginase activity during 
certain infections.  Deficiency of Arg1 in myeloid cells worsens inflammation during 
Schistosoma mansonii infection due to hyperactive inflammation beyond the point of 
protection, thus hastening mortality56.  Additionally, the decreased arginine availability 
may affect growth of pathogens.  For example, Toxoplasma gondii lacks arginine 
synthesis ability, and arginine deficiency triggers conversion to the slow-growing 
bradyzoite stage58,59.  Through these mechanisms, Arg1 impacts some infections. 
 Notably, some evidence suggests arginase undergoes multiple layers of regulation.  
Concentrations of polyamines may influence activity, as well as L-arginine (regulated in 
part by activity of the cationic amino acid transporter 2)60.  Thus, arginase activity may be 
controlled independently of transcription. 
 In summary, arginase is a highly controlled enzyme that serves anti-inflammatory, 
anti-pathogen, and homeostatic functions.  The main importance of arginase to our study 
is as a marker of IL-4-induced M2 macrophage polarization antagonizing M1 function.   
 
2.2.  Transcription factors: Dictating the functions of myeloid cells 
2.2.1.  Transcription factors bind DNA and dictate gene expression patterns 
 Differentiation, polarization, and function rely on specific transcription factors 
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that undergo regulation by a combination of multiple extracellular and intracellular 
signals and modifications.  Transcription factors enhance or suppress transcription by 
altering the stability of the transcriptional apparatus61.  They recognize and bind 
consensus elements: short, unique nucleotide sequences.  These sequences are located 
within a gene's regulatory regions, reaching to a couple thousand base pairs upstream of 
the transcription start site, or at distant sites that loop around to contact the transcription 
apparatus.  Binding often requires dimerization and/or ternary complex formation with 
other transcription factors and non DNA-binding cofactors61,62.  The structure of the 
transcription factors promotes binding to specific DNA sequences, and transcription 
factors cluster into families by structure of the DNA-binding domain.  The four most 
abundant are C2H2 zinc finger, homeodomain, helix-loop-helix (HLH), and basic leucine 
zipper (bZIP)61.  Family groupings can be useful since transcription factor families tend 
to control genes with similar function.  However, even transcription factors in the same 
family differ in function.  Moreover, activity of any transcription factor may differ 
between cells.   
 Cell specificity and environmental specificity of transcription factors arises from 
both regulation at the transcription factor level and consensus element level61.  At the 
transcription factor level, regulatory mechanisms include altering mRNA expression 
levels of any given transcription factor, altering mRNA stability, alternative splicing of 
that mRNA, post-translational modifications, and relative levels of opposing or 
consensus-modifying transcription factors61.  Thus, any given transcription factor's 
mRNA message may be present only in some cells (at a low level for high specificity or a 
high level for increased/broader activity), spliced to an isoform with lesser or greater 
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activity, rapidly marked for degradation by ubiquitination, glycosylated for altered 
function, phosphorylated for enhanced/inhibited activity, in competition with an opposing 
transcription factor, and much more.  PU.1, an important transcription factor for 
macrophage differentiation, provides an example of a cell-specific transcription factor 
with multiple levels of regulation.  PU.1 mRNA levels are specifically induced in cells of 
hematopoietic lineage9.  High levels of PU.1 differentiate CMPs to macrophages, 
overwhelming the effects of the antagonistic GATA3 that promotes mast cell 
differentiation.  AP-1 homo- and heterodimers demonstrate multiple levels of regulation 
as well and also rely on a greater concentration of transcription-promoting subunits 
versus inhibiting subunits62,63.  Additionally, AP-1 exemplifies transcription factor 
regulation by post-translational modifications, with cJun and cFos activity well 
characterized as dependent on appropriate phosphorylation63–66.  Thus, cells generate and 
activate a specific set of active transcription factors for a given type and environment by 
regulating expression, alternative splicing, post-translational modification, and 
concentration of transcription factors. 
 At the consensus element levels, regulatory mechanisms involve altering 
accessibility via epigenetic modifications.  The current model for cell development 
postulates early “pioneering” transcription factors that create a specific epigenetic 
landscape for each cell type, allowing any given set of transcription factors access to a 
unique set of genes67.  PU.1, a pioneering transcription factor, again provides an 
important example in macrophages.  PU.1 facilitates H2K4me1 deposition via 
remodeling enzymes11,68,69, allowing access of and activation by transcription factors 
including NF-κB (activated by LPS, for example), Irf4 (role in M2 polarization), Irf5 
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(M1-associated cytokines including IL-12p40, IL-12p35, and IL23p19)70, and Irf8 (M1-
associated cytokines including IFNβ, IL-12p40, and iNOS, reviewed in Günthner et al.4). 
With these mechanisms, cells can achieve unique responses with a select set of active 
transcription factors.   
 Previous studies on other immune cells have discovered “master transcription 
factors” that are sufficient to drive broad transcriptional programs and commit to a 
functional state.  For T cells such master transcription factors include Tbet transduction 
driving Th1 cell differentiation, Foxp3 driving Treg development, Bcl6 driving Tfh 
differentiation, GATA3 driving Th2 differentiation, and RORγt driving Th17 
differentiation14–20.  Since the initial studies, the overall story has become somewhat more 
complicated with discoveries that cofactors act in concert with these master factors 
(Batf/Irf complexes being necessary for key Th2 genes along with GATA3, for 
example)71.  For a discussion on the master regulators in T cells, refer to Oestreich and 
Weinmann, et al 72.  Still, broadly-acting master factors orchestrate the majority of T cell 
responses.  Previous studies on master transcription factors in M1 macrophage 
polarization have been inconsistent due to variation in the highly plastic macrophages 
across different model systems.  Recent studies have proposed Batf2 in combination with 
Irf1 as a complex governing M1 gene expression1.  This project focuses on Batf2 and its 
role in regulating M1 gene expression.   
 In summary, specific cells produce specific responses via transcription factor 
activity regulated in multiple ways.  Each contains a specific set of transcription factor 
mRNA and protein repertoire, with specific isoforms.  Translation produces proteins 
which may be activated or suppressed by modification.  Active transcription factors then 
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have access to specific gene regulatory regions, and master transcription factors can 
induce multiple genes in a transcriptional program.   
 
2.2.2.  AP-1 Transcription factors 
 The activator protein 1 (AP-1) group of transcription factors belong to the bZIP 
transcription factor family.  One of the four most abundant transcription factor families, 
as reviewed in Vaquerizas et al.61, AP-1 family members consist of a positively charged 
segment (basic region) mediating DNA interactions and leucine repeats (leucine zipper) 
mediating protein interactions.  Two members must dimerize to bind DNA.  Common 
functions of bZIP factors include mitogen signaling, stress responses, cytokine 
stimulation, brain and ocular development, development of dendritic cells, and 
differentiation of myeloid cells65.  Importantly, bZIP factors are also involved in 
activation of macrophage cells. 
 AP-1 homo- or hetero-dimers recognize two similar consensus sequences: the AP-
1 site, also known as a tetradecanoyl phorbol acetate-responsive element (TRE), and the 
cAMP responsive element (CRE).  Several proteins of this group mix and match, forming 
activating and inhibitory complexes: Jun, cFos, cFos-related antigen 1 (Fra1), Fra2, FosB, 
JunB, and JunD62,65,73.  Some sources divide these proteins into cFos and Jun families, 
with the cFos family consisting of cFos, Fra1, Fra2, and FosB and Jun family consisting 
of cJun, JunB, and JunD (refer to Foletta et al. for an excellent review of AP-1 factors)74.  
The Jun family members can form homo- or hetero-dimers with cFos family members, 
while cFos family members cannot homodimerize.  More recently, the bZIP transcription 
factor ATF-like (Batf) family members Batf, Batf2, and Batf3, were found to have similar 
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structures, dimerization, and DNA-binding activities, and can be considered part of this 
group (Figure 2.2), reviewed in Murphy et al65,75.   
 The cFos/Jun and Batf proteins, as basic leucine zipper (bZIP) transcription 
factors, contain leucine residues that form a 'zipper' connecting two dimerizing factors.  
Most members, such as cFos and cJun, contain a known transactivation domain at one 
end, a basic region for protein-protein interactions, and a DNA-binding region at the 
other end.  Some members have two transactivation domains (cFos and FosB), while 
others lack the transactivation domain (Fra1 and Fra2), which can affect transcription 
rates65,75.  The Batf family members Batf and Batf3 are truncated to the bZIP region and 
rely on dimerization to a partner with a transactivation domain, while Batf2 contains an 
N-terminus of unknown transactivation activity76.  
 
2.2.2.1. Regulation of AP-1 proteins 
 AP-1 proteins are regulated by complex and multifactorial mechanisms to provide 
differential gene expression in different cells and environments in light of the ubiquity of 
the dimers and their target sites62.  Protein-protein interactions and phosphorylation of 
multiple residues provides the strongest regulatory mechanism.  The consequences of 
dysregulation can be severe.  The growth dysregulation and epithelial-mesenchymal 
transition of many cancers depends on dysregulation, for example.  AP-1 activating 
stimuli include growth factors, mitogens, toxins, cytokines, stress signals, and pathogens; 
functional outcomes include cell development, proliferation, differentiation, and 
survival74,77.  Regulation of activity takes place on multiple levels such as changes in 
transcription of AP-1 subunits (some subunits being inhibitory), mRNA stability, post-
translational processing, turnover of pre-existing or newly synthesized subunits, and 
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specific interactions between the AP-1 dimers and other transcription factors or cofactors 
(reviewed in Foletta et al. 1996 and Hess et al 2004)77,78. 
 Protein-protein interactions provide a critical point of regulation for both 
transactivation and DNA recognition (Table B2.1).  These include 1) hetero- or homo-
dimerization with related family members63,73,75,79–83, 2) heterodimerization with other 
bZIP transcription factors, 3) ternary complex formation with other transcription factors, 
4) ternary complex formation with other activators or coactivators.  Closely related AP-1 
members include cJun, JunB, JunD, cFos, FosB, Fra1, and Fra2; more distant bZIP 
transcription factors include V-Maf avian musculoaponeurotic fibrosarcoma oncogene 
(Maf), C/EBP, activating transcription factors (ATFs), upstream stimulatory factors 
(USFs), nuclear respiratory factor (NRF) and nuclear factor erythroid 2 (NF-E2); and 
known ternary complex-forming factors include SMADs, E26 transformations-specific 
(Ets) (of which the critical macrophage differentiation factor PU.1 is a part), 
glucocorticoid receptor, NFκB, CREB-binding protein, TATA-binding protein and 
nuclear factor of activated T cells (Nfat)65.  Other cofactors include ring-domain 
containing protein (Raco)84.  The members of the complex determine the gene to which 
the complex binds and its activity, allowing a high context specificity.  For example, cJun 
homodimers can directly bind and negatively regulate the promoter region of matrix 
metalloproteinase 12 (Mmp12) and Mmp13, while cJun/cFos hereodimers positively 
regulate the same genes63.  The complex formed also determines the preferred consensus 
sequence.  While dimers of the closely related AP-1 family members usually prefer the 
TRE (5'-TGA(C/G)TCA-3') over the CRE (5'-TGACGTCA-3'), preference depends upon 
the members of the dimer62,85.  Batf proteins complex with Irf4/Irf8 prefer the AP-1-Irf 
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element (AICE) 5'-TTTCnnnnTGACTAA-3' or 5'-GAAAATGAnTCA-3'86.  Ternary 
complexes may also allow AP-1 proteins to activate gene expression without binding 
DNA at all; in the case of IL-1β, PU.1-C/EBP β complex binds Jun at its DNA-binding 
residues, preventing Jun from binding DNA directly, but still allowing its required 
transactivating activity80.  To further add to the regulation through complex formation, at 
least some of the complexes formed change with changes in concentrations of AP-1 
members present at any given time.  For example, overexpression of cFos, which does 
not bind the AP-1 consensus sequence except as a heterodimer with Jun, blocks 
transactivation of the M-CSF receptor Csf1r presumably by saturating available AP-1 
sites87.   
 A second, critical level of AP-1 regulation involves post-translational 
modification.  Hyperphosphorylation by MAPKs is a main regulatory mechanism of cJun 
and cFos activation, but can also suppress activity64–66.  Typically, JNKs phosphorylate 
Jun proteins, and ERKs phosphorylate Fos proteins65.  Mitogens or cell stress induce the 
MAPK, which travels to the nucleus and hyperphosphorylates pre-existing Jun or Fos 
proteins64,80.  cJun then forms homodimers or heterodimers with cFos or other members 
and then binds to DNA to enhance transcription88.  Mmp13 provides an example of the 
importance of phosphorylation.  Unphosphorylated Jun/Jun homodimers act as repressors 
by recruiting nuclear receptor co-repressor 1 (NCoR1), a repressor that recruits DNA-
modifying enzymes leading to transcriptional repression63.  Phosphorylation allows 
dissolution of the complex and thus transcription.  cFos is also regulated by 
phosphorylation89.  In some cases, a member may have a phosphorylation site but no 
docking site for the kinase, and can only be phosphorylated when dimerized to a partner 
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with a docking site65.  In contrast, ubiquitination and SUMOylation can repress 
transcriptional activity, specifically studied in the case of cJun and cFos, respectively90,91.  
Finally, redox state in the cell also controls the activity of AP-1 by reducing residues on 
the proteins, enabling the cell to respond appropriately92,93. 
 In summary, the regulation of AP-1 activity is critical for correct cell function.  
Mechanisms include changes to levels of mRNA and AP-1 and non-AP-1 proteins and 
post-translational modifications.  Relative levels of interacting proteins alter the 
transactivation activity and the DNA-binding location and ability of the AP-1-containing 
complexes.   
 
2.2.2.2. Function of AP-1 proteins 
 AP-1 has a broad range of functions in all cell types.  Activities include regulating 
stress response, tumor promotion, cell death, differentiation, immune cell function, and 
much more.  Expression of many members is constitutive with activity induced rapidly 
after stimulus by post-translational modification such as hyperphosphorylation, as 
discussed above.  Dimerization and subsequent phosphorylation allows DNA binding at 
TRE, CRE, or in complex formation with cofactors at variant sites.  AP-1 can also 
regulate genes with alternative consensus elements and weak AP-1 sites by forming a 
ternary complex with other transcription factors.  Occasionally, these complexes may 
regulate genes entirely independently of AP-1 DNA binding62,80.  
AP-1 is strongly implicated in tumorigenesis.  Several of the AP-1 proteins, 
including cFos, FosB, and cJun, transform cells in vitro, and cJun and cFos are both viral 
oncoproteins94.  AP-1 activity induces transcription of tumorigenic proteins including 
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Cyclin D, GM-CSF, and Kgf/Fgf7, and suppresses anti-tumor proteins such as p5395,96.  
On the other hand, AP-1 proteins in other contexts hinders tumor growth.  JunB and JunD 
tend to have anti-tumor effects in vivo, possibly by inhibiting cJun.  Moreover, 
suppression of JunB promotes spontaneous tumor formation independently of cJun94.  
Batf2 also exhibits tumor suppression activity in multiple cell types, largely by inhibiting 
cJun activity at various genes95.  Specifically, this suppression results in decreased cell-
adhesion molecule E-cadherin and decreased growth-promoting Cyclin E, among others.  
cJun/cFos heterodimers also regulate genes involved in tumor invasiveness, such as 
Mmp12, Mmp13, Mmp1, and Mmp363,94.  AP-1, therefore, has important roles for growth 
and differentiation in diverse cell types. 
 In addition to growth, AP-1 proteins promote the differentiation and function of 
many cell types including immune cells.  In macrophages, cJun can interact with the 
major hematopoietic cell transcription factor PU.1, an important transcription factor for 
the differentiation of multiple cell lineages including macrophages and B cells.  AP-
1/PU.1 complexes are required for expression of a macrophage Fc receptor expressed 
during monocyte to macrophage differentiation 97.  Monocytic expression of Csf1r, 
receptor for the growth factor M-CSF and part of an essential pathway for growth, 
proliferation, and differentiation, also relies on AP-1/PU.187.  Indeed, cJun/cFos 
heterodimers promote expression of pro-inflammatory proteins including Mmp1463,98.  
Further, the cJun/Irf1/NF-κB complex serves as an 'enhanceosome' for inflammatory 
gene expression4,99–101.  cFos and JunB play a non-essential but nevertheless influential 
role in monocytic differentiation.  This effect was demonstrated in myeloblastic leukemic 
cells, in which expression of cFos or JunB increases their tendency to differentiate74,102–
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104.  The Batf members have a more essential role in non-monocytic cells.  Batf, for 
example, is required for differentiation of multiple immune cells including Th17 and Tfh 
CD4 T cells76.  The Batf subfamily is rapidly gaining appreciation for its role in 
differentiation and function of multiple cell types, discussed more in depth below. 
 Clearly, AP-1 proteins play complex roles in a vast variety of cell types.  
Regulation of these proteins includes transcription, post-translational modification, 
dimerization, and ternary complex formation.  Activity is highly dependent on cell type, 
epigenetic history, and environment.  Because of this, Batf2’s functions in macrophages 
cannot be extrapolated from studies of other AP-1 family members or even Batf2 
functions in other cell types. 
 
2.2.2.3. Batf subgroup: AP-1 proteins important for B, T, and cDC subset 
development and function 
 The Batf subgroup is composed of Batf (SFA2), Batf2 (SARI), and Batf3 
(JDP/p21).  Batf members, their function, and their interchangeability were recently 
reviewed in Murphy et al76.  As mentioned above, this subgroup belongs to the bZIP 
family of transcription factors and falls into the category of AP-1 proteins based on 
homology to and dimerization with classical members such as cJun and cFos.  Batf2 also 
recognizes the AP-1 TRE consensus and the similar AP-1 half of the AICE consensus 
(Figure 2.3).  Notably, however, murine Batf and Batf3 proteins are significantly smaller 
than either cJun or cFos, with truncated C-terminal domains, and lack any likely 
transactivation domains76.  Batf2 does contain a C-terminal domain, but does not contain 
known transactivation domains.   
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 Batf and Batf3 are expressed in hematopoietic cells, and Batf2 is more broadly 
expressed in multiple cell types.  Batf and Batf3 have roles in several cell types: Th1 and 
Th17 cells express both Batf2 and Batf3, Th2 cells express Batf and low amounts of 
Batf3, Tfh express Batf, and B cells, CD103+CD11b- conventional dendritic cells (cDCs), 
and CD8α+ cDCs all express Batf376,83,105–107.  Recently, cap analysis gene expression 
(CAGE) also detected high expression of Batf in natural helper cells and macrophages, 
and Batf3 in macrophages108.  Expression of Batf, Batf2, and Batf3 in macrophages have 
been confirmed in our studies and by others1,109.  At this time, expression of Batf2 has 
two notable patterns: suppressed expression in cancer cells and induced expression in 
hematopoietic cells.  Cancer cells downregulate or lose entirely expression of Batf2 
compared to normal counterparts or adjacent tissues.  M1 stimuli (IFNβ, IFNγ, and LPS) 
in vitro induce Batf2 expression in macrophages, and IL-12 treatment in vivo or 
Toxoplasma gondii infection in vivo (which induces IL-12 production) induces Batf2 
expression in CD103+ CD11b- cDCs and CD8α+cDCs1,83,95. 
 In spite of the lack of transactivation domain, the Batf members clearly serve 
critical roles in transcription.  Batf and Batf3 not only bind to TREs as heterodimers with 
another AP-1 protein, but also bind to AP-1-Irf consensus elements (AICEs) as a complex 
with Irf4 or Irf8.  Batf3, induced Batf, or induced Batf2 forms complexes with Irf8 that 
induce genes for differentiation of CD8α+ cDCs and CD103+CD11b- cDCs, inducing C-
type lectin domain family 9, member A (Clec9a), chemokine (X-C motif) receptor 
(Xcr1), inhibitor of DNA binding 2 (Id2), and Spib83,110.  Batf-induced transcription also 
plays important roles in cell development in B and some T cell subsets.  In B cells, it is 
required for the expression of activation-induced cytidine deaminase (Aid) which is 
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required for affinity maturation and class-switch recombination (CSR)107.  It is important 
for differentiation of Th17, Tfh cells, and Th9 by inducing essential genes including 
Rorc, IL17A, IL21, IL23R, Map, Bcl6, IL9, IL-10, Furin, Fes, Ets-related gene (Erg), and 
IL-1RA71,76,106,111.  In Th2 cells Batf or Batf3 both induce GATA3, IL-4, IL-10, and 
cytotoxic T-lymphocyte-associated 4 (Ctla4) (Figure 2.2).  Like Batf3, the importance of 
Batf in these cells is at least in part due to complex formations with Irf4 or Irf8 and 
subsequent binding to AICEs86.   
Interestingly, Batf3 and Batf can functionally compensate for each other, 
suggesting some redundancy in binding to both DNA elements and Irf proteins83,86.  
Batf2, on the other hand, can compensate for Batf3 in the cDC subsets, but not Batf or 
Batf3 in B cells or T cells, as discussed below.  These prior studies clarify that the Batf 
family members are partially interchangeable and this interchangeability relies on ternary 
complex formation with Irf family members, but that Batf2 has unique activity. 
 
2.3.  Batf2: An AP-1 protein distinct from Batf and Batf3, with roles in cancer 
inhibition and immunity 
 Batf2 is a relatively little-known member of the AP-1 group of the bZIP 
transcription factors, but is gaining importance for its roles in tumor suppression and cell 
differentiation.  Su et al. originally characterized it as an IFNβ -inducible early-response 
gene that inhibits tumor-promoting AP-1 activity.  Currently, investigation into Batf2’s 
value as an indicator of good prognosis as well as potential therapeutic target 
continues95,108.  Additionally, Batf proteins are emerging as critical cofactors in the 
differentiation and function of many immune cells.  Batf2 clearly behaves differently 
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from Batf and Batf3, and defining its specific contribution to immune cell functions is 
advancing our understanding of the transcriptional regulation of immune cells.    
 Mouse Batf2 shares 63% homology with human Batf2, which is 29.4 kDa.  It is 
located on chromosome 19 in mice, and 11q13.1 in humans.  Batf2 shares the functional 
domains characteristic of the AP-1 transcription factors: a basic region that binds DNA 
after dimerization and leucine zipper that binds other AP-1 and non-AP-1 proteins.  Most 
Batfs have a truncated C-terminus compared to cFos, and lack known transactivation 
domains (Figure 2.2)83.  Batf2, however, contains an extended C-terminus with unknown 
function that could encode some transactivation functions.  Batf2 protein has 47% 
homology to Batf and 43% homology to Batf3.  Conservation between Batf2 and the 
other Batf proteins is sufficient to allow some functional compensation.  Of the other 
Batfs, Batf is required for CD103+CD11b+ and CD8α+ cDC development, and Batf3 for 
Th2, Th17, and Tfh cell development and function.  While DNA-binding assays 
demonstrate Batf and Batf3 binding to AICE, Batf2's DNA-binding ability remains 
unknown86.  Batf2's ability to compensate for Batf3's ability to guide Irf4/8 to DNA in 
dendritic cell development suggests DNA-binding activity, but no DNA-binding assays 
demonstrating Batf2 binding to the AICE have been published.  Further, Roy et al state 
that Batf2 has no DNA-binding domain1, Batf2-Jun heterodimers do not bind AP-1 
consensus sequences as assessed by electromobility shift assays (EMSAs) and chromatin 
immunoprecipitation (ChIP) assays95, and Batf2 inhibits cJun activity by inhibiting its 
binding ability95,112.  At this time, Batf2's direct interaction with DNA remains unclear 
and further experiments are required to determine whether Batf2 binds a yet-unidentified 
site, or interacts with other DNA-binding proteins. 
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 While Batf2-DNA interactions remain unclear, interactions with other proteins are 
better characterized.  The leucine zipper motif of Batf2 mediates dimerization and ternary 
complex formation, and is structurally similar to Batf and Batf376.  Batf2 binds in vivo to 
cJun and inhibits its activity, and also in vitro to JunB with unexplored functional 
consequences95,113.  Activity of the Batf subfamily depends largely on ternary complex 
formation.  Batf and Batf3 guide non-DNA-binding transcription factors Irf4 and Irf8 to 
specific consensus sequences to initiate transcription.  In some contexts (discussed 
below), Batf2 can compensate for a deficiency of Batf3 in a manner dependent upon the 
leucine zipper region, supporting the importance of protein-protein interactions for Batf2 
activity.   
 In summary, Batf2 is a member of the bZIP family of transcription factors and the 
AP-1 and Batf subfamilies.  It contains a DNA-binding domain with unclear function, 
and protein-binding domain similar to Batf and Batf3 able to dimerize with AP-1 
members and form ternary complexes with other proteins including Irfs. 
 
2.3.1.  Batf2 Expression 
2.3.1.1. Normal cells and tissues 
 Batf2 is expressed constitutively in multiple cell types and tissues, and loss tends 
to correlate with malignant growth and poor outcomes in vivo.  Isolated cell types 
expressing Batf2 include common myeloid progenitor cells and macrophages, 'normal' 
immortal cell lines including primary human fetal astrocytes, mammary epithelial cells, 
prostate epithelial cells, pancreatic mesothelial cells, normal lung, and tongue epithelial 
cell lines95,114–116.  It is expressed in many immune cells with the exception of T cells76.  
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In vivo, Batf2 message is expressed in many normal tissues, although expression is 
widely variable between tissues and between samples95,115,117–119.  Message levels are 
relatively high in colon, spleen, and pancreas; and moderate in heart, kidney, liver, lung, 
and prostate95.  Low levels were detected in placenta, stomach, small intestine, and 
salivary gland.  Brain, muscle, and testis do not express Batf295. 
 IFNs induce Batf2 expression many fold over baseline.  In multiple cell lines 
including HeLa, IFNβ induces Batf2 within 2 hours, independent of protein 
synthesis95,112,114,120.  The mRNA half-life under these conditions is 2 hours.  IFNβ, IFNγ, 
and LPS also induce Batf2 in macrophages 1,109,121.  CD8α+ cDCs, and CD11b+CD103+ 
cDCs express Batf2 in vivo in response to intracellular pathogen Toxoplasma gondii or 
IL-1283.  Thus, Batf2 is an IFN-inducible transcription factor with basal expression in 
multiple cells. 
 
2.3.1.2. Batf2 in Cancers 
 Although Batf2 is expressed in many normal tissues, expression decreases in 
aggressive cancer cell lines and in vivo in tumors.  Expression correlates with survival 
and inversely correlates with aggressiveness and likely plays a contributing role.  Human 
leukemia cell lines and malignant counterparts of cell lines including glioma, prostate 
cancer, pancreatic cancer, breast cancer, melanoma, lung adenocarcinoma post-EMT, and 
oral tongue squamous cell carcinoma (OTSCC), decrease or eliminate Batf2 
expression95,114,115,117–119.  In general, Batf2 expression appears to generally correlate with 
normal cells with loss indicating progression of cancer cells.  However, Batf2 may 
remain inducible even after basal expression is lost.  In multiple cell lines in which Batf2 
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is decreased and in the HeLa cell line, IFNβ induces Batf2.  Induction occurs within 2 
hours, independent of protein synthesis95,109,112,114.  The mRNA half-life under these 
conditions is 2 hours.   
Similarly to cell line studies, Batf2 expression decreases in clinical tumor 
samples.  Loss tends to correlate with aggressiveness while maintenance correlates with 
survival.  For instance, the 52% positive expression in normal lung tissue samples 
decreases to 50% in paired non-small cell lung carcinoma (NSCLC) tissues96.  It's also 
decreased in hepatocellular carcinoma (HCC), in OTSCC, and in colorectal cancers 
compared to healthy adjacent tissues, as well as in peripheral bone marrow cells 
(PBMCs) of leukemia patients compared to PBMCs of normal volunteers117 115 112 122.  
Batf2 expression inversely correlates with tumor size, differentiation, and metastasis115–
117,120.  Importantly, expression also correlates strongly with survival when compared to 
adjacent non-tumor tissues115–117.  Batf2 may well have a causal role in survival, 
discussed below. 
 Mechanisms by which Batf2 decreases in cancers remains unclear.  In normal 
cells, IFNβ directly induces expression, and Mda7/IL24 increases Batf2 expression by 
prolonging detectable mRNA from 1.5 hours to 3.5 hours via p38 MAPK pathway (half-
life is 2 hours in HeLa)114.  One study in chronic myeloid leukemia (CML) linked Batf2 
expression inversely to BCR-ABL, JAK/Stat, and RAS/MAPK pathways122.  Inhibition 
of BCR-ABL by imatinab mesylate increased Batf2 expression, as did inhibition of 
JAK/Stat and RAS/MAPK pathways.  Therefore, Batf2 in non-hematopoietic cells is 
inducible by IFNs, enhanced by Mda7/IL24, and suppressible in at least some cell types 
by BCR-ABL, JAK/Stat, and RAS/MAPK pathways. 
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2.3.1.3. Hematopoietic cells 
 While loss of expression is notable in cancers, gain of expression is notable in 
hematopoietic cells of the immune system.  Indeed, Batf2 expression increases during 
and at least 48 hours after M1 polarization of macrophages, serving important functional 
roles discussed below.  IFNγ -induced Batf2 is important in cDC subsets, while IFNβ, 
IFNγ, and LPS all have roles in Batf2 induction in macrophage cells1,83,109,121.  Some 
reports suggest LPS enhances Batf2 induction by IFNγ1,83,121, and two reports found that 
LPS alone induces Batf2 in murine bone-marrow derived macrophages 1,83.  Bone 
marrow derived macrophages express minimal Batf2 mRNA in response to heat-killed 
Listeria monocytogenes and CpG83.  In CD8α+ cDCs and CD11b+CD103+ cDCs in vivo, 
Batf2 is inducible with IL-12 or infection with the intracellular pathogen Toxoplasma 
gondii83.  In vitro, however, purified Flt3L-DC do not produce Batf2 in response to IL-12, 
nor in response to GM-CSF or pIC, but rather to LPS.  In general, Batf2 is inducible in 
macrophages and CD8α+ cDCs or CD11b+CD103+ cDCs by M1-associated stimuli, 
especially LPS and IFNγ.  
 
2.3.1.4. Other correlations 
 Other clinical studies correlating Batf2 with disease outcomes have less clear 
connections.  Microarray analysis of high-pain versus low-pain fibromyalgia found Batf2 
to be among the top 10 most significantly differentially expressed genes in peripheral 
blood123 .  Increased Batf2 correlates with pain, but any hints at causality remain unclear.  
Batf2 is also highly upregulated in cases of common variable immune deficiency with 
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inflammation complications compared to cases without, in concert with other IFN-
responsive genes.  These studies may provide insight into the function of Batf2 or the 
mechanisms of these diseases.  Although Batf2 may simply be responding to an 
inflammatory response involving IFNs, it is possible that Batf2 contributes as well; for 
example, by orchestrating macrophage polarization that in turn aggravates inflammation.  
Defining the functions of Batf2 paves the way for the development of therapies targeting 
Batf2 that may be useful in cancer and other diseases. 
 
2.3.2.  Batf2 Function 
 Initial studies identified Batf2 as an interferon-inducible negative regulator of AP-
1 activity in transformed cancers.  Based on this activity, these studies referred to the 
Batf2 protein as suppressor of AP-1, regulated by IFN (SARI).  In vitro binding assays 
suggest that Batf2 cannot heterodimerize, but can form heterodimers in vitro with other 
AP-1 members JunB and cJun, as well as bZIP transcription factors C/EBPG, C/EBPA, 
and DNA-damage inducible transcript (Ddit3)113.  Batf2 heterodimerizes with cJun in 
vivo95.  Previous studies on Batf2 have demonstrated roles as a negative regulator of gene 
expression by AP-1 inhibition, a negative regulator of gene expression by participating in 
dephosphorylation complex, and a positive regulator of gene expression by interacting at 
AP-1-Irf consensus elements (AICEs)83,86.  Negative gene regulation by AP-1 inhibition 
(specifically cJun sequestration) and by dephosphorylation (specifically of glycogen 
synthase kinase 3 beta [GSK3β], decreasing β -catenin) occurs in normal cells and is lost 
in cancer cells, while positive gene regulation at the AICE occurs in the development of 
dendritic cell subsets83,95,124.   
34 
 
 
2.3.2.1. Cancer studies: Batf2 negatively regulates AP-1 and aids 
dephosphorylation of GSK3β 
 Studies on Batf2's role as a tumor suppressor lend insights into the mechanisms of 
Batf2's activity.  As discussed above, decreased expression in vitro occurs post-EMT and 
in malignant cells compared to normal counterparts, and decreased Batf2 in vivo 
correlates with aggressiveness and survival.  The tumor-suppressive activity occurs 
through two distinct mechanisms: AP-1 inhibition and β-catenin dephosphorylation.  
Batf2's affect as an AP-1 inhibitor appears to be the reason for its cancer-specific effects 
on growth and apoptosis and inhibition of proto-oncogenes.  In various cancer cells, 
forced expression inhibits both anchorage-dependent and -independent cell growth and 
induces apoptosis95,112.  This selective inhibition seems to arise from the reliance of these 
cancer cells on cJun, such that inhibition of cJun by Batf2 prevents gene expression for 
growth and survival.  Batf2-sensitive cells show elevated cJun, perhaps reflecting 
increased reliance on cJun for growth and survival.  Moreover, Batf2's growth-inhibiting 
activity in cancer cells is most pronounced during by Ras or Src oncogene 
transformation, which induces AP-1 activity95.   
A great deal of evidence indicates that Batf2 inhibits cJun activity by 
sequestration.  Fluorescence Resonance Energy Transfer (FRET), immunofluorescence, 
and co-immunoprecipitation assays demonstrate Batf2 binding to cJun, and Batf2's 
protein-protein interaction motif (the leucine zipper) is required for its activity, 
demonstrating that Batf2 heterodimerizes with cJun and that heterodimerization is 
necessary for anti-tumor effects95,112,113.  Moreover, forced Batf2 expression prevents 
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cJun from binding to the AP-1 consensus TRE as demonstrated by reporter assays, 
EMSAs, and AP-1-induced gene expression95,112,124.  Therefore, little doubt remains that 
Batf2 acts as a negative regulator of cJun activity by binding to it and preventing its 
binding to AP-1 consensus.  Yet, some evidence suggests that Batf2 can in fact drive 
transcription in hematopoietic cells, discussed below.   
 Batf2-inhibited AP-1 can suppress tumor growth by decreasing growth factors, 
altering cell cycle regulators, and interfering with communication with and modification 
to the extracellular environment.  Batf2 inhibits the AP-1 dependent MET in colorectal 
cell lines; MET is both a proto-oncogene and a growth factor112.  Additionally, Batf2 may 
alter cell cycle regulator expression to inhibit cell growth.  Forced Batf2 expression 
inhibits cyclin D1 and cyclin E expression in HeLa cells84.  These AP-1-regualted cyclins 
mediate transition into S phase, encouraging cell growth.  Batf2 may thus block cell cycle 
in part by inhibiting cell cycle progression. 
 Batf2 also interferes with AP-1-dependent factors promoting invasiveness by 
communication with and modification of the extracellular environment, specifically CCN 
family member 1 (Ccn1)-induced integrin signaling, and MMP expression.  Aggressive 
breast and prostate carcinoma cell lines displayed elevated AP-1 activity, elevated 
integrin-MAPK signaling, and enhanced invasiveness and anchorage-independent growth 
by both AP-1 and integrin-MAPK pathways.  Batf2 transduction reduced the feed-
forward loop of AP-1-induced cJun and Ccn1 expression124.  Functionally, this resulted in 
reduced growth and invasiveness.  Batf2 activity seems to vary between cells, however, 
since CCN1 was not affected by Batf2 in colorectal cancers112.  Another way Batf2 
influences the environment to prevent aggressive cancers is through Mmps.  Mmps in 
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general contribute to EMT, and can increase growth factor availability by releasing 
molecules from the extracellular matrix, but Batf2 inhibits Mmp2 and Mmp7 by 
decreasing AP-1 expression125 112.  Mmp2 in particular can increase tumor growth by 
promoting vascularization, and both Mmp2 and Mmp7 are associated with modulation of 
the immune response towards a tumor-promoting environment 125.  Therefore, Batf2 may 
modulate tumor growth through inhibition of integrin signaling and modification of the 
extracellular matrix, in addition to inhibition of cell cycle progression and growth factor 
signaling. 
In addition to anti-cancer activity by AP-1 inhibition, Batf2 participates in a 
dephosphorylation complex that leads to B-catenin inhibition.  Wang et al discovered this 
activity in lung adenocarcinoma119.  Batf2 inhibits the epithelial-mesenchymal transition 
(EMT) through activation of GSK3β and subsequent inactivation of β -catenin.  During 
EMT, cells change morphology, increase migratory ability, lose the adhesion factor and 
pre-EMT marker E-cadherin, and increase the intermediate filament vimentin.  While 
lung adenocarcinoma cell lines pre-EMT express higher levels of Batf2, post-EMT cell 
lines lose Batf2 expression.  Forced Batf2 in post-EMT cells, however, reverts cells back 
to pre-EMT morphology, migratory ability, E-cadherin expression, and vimentin 
expression.  On the other hand, knockdown of Batf2 in pre-EMT cells increased post-
EMT morphology, decreased E-cadherin, and increased vimentin.  Batf2 therefore plays 
an important role in EMT in lung adenocarcinoma.  These effects are not due to Batf2's 
transcriptional activity; rather, Batf2 inhibits the Wnt/ β-catenin signaling pathway by 
activating the β -catenin inhibitor GSK3β.  Batf2's mechanistic role in this process 
remains unclear, but is required for GSK3β activation by protein phosphatase 2 (Pp2a).  
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The interaction involves physical contact between GSK3β, Pp2a, and Batf2.  Possibly, 
Batf2 acts as a scaffold in this complex.  Increased GSK3β activity results in decreased β 
-catenin and β –catenin-induced EMT-associated factors.  Batf2 expression in post-EMT 
lung adenocarcinoma increases active GSK3β and inhibits β -catenin, including that 
induced through Wnt pathway activation. 
 Batf2 manipulation in xenografts demonstrates the importance of Batf2 in vivo as 
well as in vitro.  Decreasing Batf2 in lung adenocarcinoma tumors with anti-Batf2 with 
small interfering RNA increased lymph-node metastases and metastatic sites with 
mesenchymal characteristics and reversed severity-associated changes to vimentin and E-
cadherin119.  In the reverse experiment using colorectal cancer cells, forced Batf2 
expression led to decreased tumor size, proliferation, and proto-oncogene MET 
expression112.  In a similar experiment, Batf2 abrogated Ccn1-induced growth and 
aggressiveness114.  Therefore, the mechanisms by which Batf2 prevents tumor growth in 
vitro do indeed translate to in vivo models. 
 Clinical data also support Batf2's role as an anti-tumor transcription factor, and 
also suggest Batf2 may be a useful diagnostic marker or therapeutic target.  Batf2 loss 
correlates with tumor aggressiveness in hepatocellular carcinoma, OTSCC, leukemic cell 
number in chronic myeloid leukemia, lung adenocarcinoma and lung squamous cell 
carcinoma, colorectal cancer, and esophageal squamous cell carcinoma112,115–117,119,122,126. 
 Although the correlations with differentiation, metastasis, and invasiveness vary 
between cancer types, Batf2 may be a predictor of these factors in specific cancers.  
Moreover, Batf2 has a much more useful correlation in all cancers previously studied: 
survival.  Batf2 served as an independent predictor of survival in hepatocellular 
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carcinoma, oral tongue squamous cell carcinoma, and colorectal cancer112,115,117.  
Therefore, Batf2 may prove useful in the future as a diagnostic marker predicting poor 
prognosis of various cancers, depending on the cell type. 
 Overall, Batf2's ability to inhibit AP-1 activity and β-catenin activity is revealed 
through studies on its role as a tumor-suppressor.  In vitro, Batf2 inhibits growth factors, 
modulates communication and interaction the extracellular environment, suppresses B-
catenin-mediated changes required for aggressiveness, and inhibits EMT.  In vivo, Batf2 
slows xenograft growth, and loss is associated with increased aggressiveness and 
decreased survival in multiple cancer types. 
 
2.3.3.  Hematopoietic cell development and function: Batf2 as an AP-1 
transcription factor 
 Although Batf2 has a negative regulatory role in some conditions, studied in 
multiple non-hematopoietic cell types, it also has a positive regulatory role, studied in 
hematopoietic cell development and function alongside closely related Batf and Batf3.  
Batf and Batf3 have been known transcription factors important for multiple immune 
cells.  Batf3 forms a ternary complex with Irf8 or Irf4 to drive expression of genes for 
CD8α+ and related CD103+CD11b- cDCs including CD103 and Xcr76.  Normally, these 
cells do not produce Batf2, and thus mice deficient in Batf3 lack this population; 
however, Toxoplasma gondii infection or IL-12 treatment in vivo induces Batf2, which 
can partially compensate for Batf3 deficiency in the development of these CD subsets83.  
Table B2 lists the situations in which Batf2 can and cannot compensate for other Batfs.  
This suggests that Batf2 does have some transcriptional activation activity. 
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 Interestingly, Batf2 seems unique among the Batf factors, and its role in activating 
transcription remains unclear.  Batf and Batf3 are largely interchangeable in the 
development of cells, complexing with Irf4 or Irf8 and subsequently binding to the AP-
1/Irf Composite Element (AICE) (5'-TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA-
3') in regulatory regions of many genes necessary for immune cell development (Figure 
2.3).  Batf and Batf3 drive Th2 cell development, being necessary for genes including 
GATA3, IL-4, IL-10, and Ctla4.  Batf or ectopic Batf3 is required for genes involved in B 
cell class switching (Aid), Th17 development (Rorc, IL17A, IL21, IL23R), and Tfh 
development (Maf, Bcl6) and Th9 development (IL21, IL-10, Furin, Fes, Erg, IL-
1RA)76,111.  Batf2, however, can only compensate for Batf3 in the cDC subsets, and not 
Batf3 in Th2 development, or Batf in B cells, Th17, or Tfh cells. 
 Two components critical for the function of the bZIP transcription factors are the 
leucine zipper, critical for protein-protein interaction, and the basic region, critical for 
DNA binding.  Batf2 presumably binds to Irf4 or Irf8 to compensate for Batf3 
development in the cDC subsets, and heterodimerizes with cJun as demonstrated in 
cancer cell studies.  However, it has not been shown to bind DNA.  Fusion of the Batf2 
basic region with Batf3 leucine zipper produces a chimera that functions in cDCs but not 
Th17, similar to wild-type Batf2.  Moreover, Roy et al. in an investigation of Batf2 in 
macrophage cells asserts that Batf2 does not contain a DNA-binding domain109. 
 Recently, Batf2's importance in macrophage polarization was explored in 
BMDMs.  As in other immune cells, this study suggests the requirement for a cofactor, 
specifically the M1-specific Irf1.  Batf2 knockdown with small interfering RNA (siRNA) 
abolished the expression of several genes important to macrophage polarization.  Batf2 
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complexed with Irf1, and knockdown of Irf1 mimicked knockdown of Batf2.  However, 
recognition of a consensus region by Batf2-Irf1 complex was not explored, so it remains 
unknown whether this complex indeed recognizes a consensus element, perhaps the 
AICE or simply the Irf1 element, in macrophages.  Batf2’s function in vivo in regards to 
immune function remains only briefly explored. Batf2-/- mice, produced by Tussiwand et 
al., appear to possess normal hematopoietic cell populations at homeostasis83.  The only 
macrophage populations altered significantly in these mice were the lung-resident 
CD103-CD11b-, and this deficiency only appeared after Toxoplasma gondii infection.  
Whether the macrophages contribute to the increased mortality is unclear.  Of note, this 
study focused on dendritic cell populations, so macrophage populations were not reported 
in detail. 
 In summary of previous studies, Batf2 has important roles as both a tumor-
suppressor and inhibitor of AP-1 activity, as well as a differentiation and polarization 
factor in some immune cells as an activator of AP-1 activity.  This study complements the 
previous and current work on Batf2 by exploring its function in a macrophage cell line 
with advantages over BMDMs.  The conclusions of Batf2 having an activating role on its 
own are contradicted, but the importance of a cofactor or other environmental factor 
specific to M1-polarized macrophages is supported. 
 
2.3.4.  Studying Batf2’s role as a transcription factor in PUER macrophages 
 The work in this dissertation adds to this body of research by constitutively 
expressing Batf2 in an in vitro macrophage system, the PUER cells.  Initial microarray 
analysis from our lab found Batf2 highly upregulated in LPS/IFNγ (M1) polarized 
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macrophages relative to resting or IL-4 (M2) polarized PUER macrophages, in agreement 
with the recent studies in bone marrow macrophages.  My hypothesis was that Batf2 is a 
master regulator of M1 polarized macrophages.  To test this hypothesis, I investigated the 
function of Batf2 in the PUER macrophage model. 
 
2.3.4.1. Model system: PUER macrophages 
 Previous studies have multiple discrepancies due in part to sensitivity and 
plasticity of macrophages to a wide variety of stimuli and to variation in animal colonies.  
PUER cells uniquely permit study of differentiation of macrophages without the previous 
epigenetic programming seen in primary macrophages, macrophage-differentiation 
cytokines M-CSF and granulocyte-macrophage colony stimulating factor (GM-CSF), 
stress, or polarizing stimuli during purification.  All of these can alter gene expression 
independently of the experimental stimulus and may account for much of the variability 
in the literature that used cells isolated from animals23,127,128.  PUER cells are common 
myeloid progenitors from fetal liver of PU.1-/- mice constructed in the lab of Harinder 
Singh.  Homozygous knockout of PU.1 is embryonic or newborn lethal.  In the liver, the 
development of the myeloid lineages is blocked at the CMP stage.  IL-3 dependent fetal 
CMPs were cloned and myeloid development potential was restored by inserting a gene 
for a chimeric protein containing the PU.1 DNA binding domain with the hormone 
binding domain of a modified tamoxifen-sensitive estrogen receptor9.  Thus, these 
progenitor cells can be differentiated in vitro to multiple cells of the hematopoietic 
lineage and provide an attractive tool for studying the factors required for cell 
differentiation.   
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Our collaborator Dr. Peter Laslo previously used PUER cells for studying factors 
for differentiation macrophages and neutrophils129.  Differentiation to macrophages can 
be induced by treatment with tamoxifen, rather than commonly-used differentiating 
cytokines M-CSF and GM-CSF that can alter gene expression of polarization-associated 
genes127.  Such in vitro polarization results in a highly controllable macrophage 
differentiation and polarization model subject to minimal in vivo polarizing stimuli or 
accumulation of relevant epigenetic changes, thereby, minimizing environment-induced 
factors.  We took advantage of this system to build on the differentiation factor studies to 
examine transcriptional regulation in M1- and M2-polarized macrophages. 
 
2.3.5.  Summary 
This project investigates the hypothesis that Batf2 controls M1-specific gene 
expression, thus contributing to the inflammatory functions of these cells.  To achieve 
this end, we use an in vitro model in which CMPs are first differentiated to macrophages 
in vitro to avoid potential polarizing stimulation present in in vivo models.  We then 
polarize them to the M1 phenotype with LPS and IFNγ, producing M1-polarized 
macrophages with minimal environment-induced variability.  Gene expression analyses 
revealed Batf2 as a novel M1-associated transcription factor.  The role of Batf2 as a 
putative master transcription factor was explored by creating CMPs constitutively 
expressing Batf2.  Constitutive Batf2 expression alone does not induce M1-specific gene 
expression, but it enhances IFNγ/LPS-induced Cxcl10 expression and suppresses IL-4-
induced Arg1 expression.  Further, the study begins to address the possibility of a 
required M1-associated cofactor or condition for Batf2's activity, including binding 
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partners.  In agreement with the recent studies on Batf2, Batf2 is an M1-associated 
transcription factor that likely controls gene expression in conjunction with an M1-
associated cofactor. 
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Table 2.1: Select mechanisms of gene expression regulation 
Level of Regulation Mechanism References 
Tested in this 
Study? 
Protein binding/ 
Cofactor 
AP-1 
Dimerization 
Partners 
Jun/Jun represses 
Mmp13, Jun/Fos 
activates52 
Yes 
(Figure 4.17) 
Non-AP-1 
Dimerization 
Partners 
Fos/Jun proteins prefer 
TREa and ATF/Jun 
proteins prefer CREa73 
No 
Ternary Complex 
Members 
Batf3/Irf4 activation 
complexes 
Yes 
(Figure 4.19) 
Post-translational 
modification 
Phosphorylation Phosphorylation of 
cFos76 
No 
SUMOylation Regulation of AP-1 
dimers77 
Redox state Regulation of cFos78 
Promoter/enhancer 
accessibility 
Epigenetic 
Modification 
PU.1 and Runx1 remodel 
chromatin to determine 
macrophage 
lineage6,7,57,58 
No 
  
aTRE: Phorbol Acetate-Responsive Element; CRE:cAMP-Responsive Element 
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Table 2.2: Compensatory ability of Batf2 for other Batf proteins. 
Cell Type 
Product/ 
Outcome 
Detecteda 
Original 
Inducer 
Means of Batf2 
Expressiona Compensates? a 
T cells IL17 BATF 
Retroviral  
in BATF-/- 
No 
B Cells 
Class Switch 
Recombination 
BATF 
Retroviral  
in BATF-/- 
No 
CD8α+cDCsa Development BATF3 
Retroviral  
in BATF-/-mice and 
bone marrow cells 
Yes 
CD103+CD11b- 
cDCsa 
Development BATF3 
BATF2 DBDc on 
BATF LZd 
Approx. 50% 
Th17 Development BATF 
BATF2 DBDc on 
BATF LZd 
No 
________________________________________________________________________ 
aData from Tussiwand, et al.83 
bCD8α+cDCs and CD103+CD11b- cDCs are largely the same except for tissue location 
cThe DNA-Binding Domain (DBD) mediates interaction with DNA 
dThe Leucine Zipper (LZ) motif mediates interactions with other proteins 
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Figure 2.1: Genes associated with various macrophage states.   
 
Figure 2.1: Genes associated with various macrophage states.  Common myeloid 
progenitor cells (CMPs) are directed to the macrophage lineage and various functional 
states by a handful of master transcription factors that induce the largest number of 
lineage- or function-specific genes and some major transcription factors the also induce 
several critical genes.  Many of the transcription factors and key functional genes 
defining macrophages and their functional states have been defined, although gaps 
remain.  Resting macrophages develop from high expression of transcription factors 
including SpiB, interferon regulatory factor 8 (Irf8), and runt-related transcription factor 
1 (Runx1) and express Cd11b and F4/80 (Emr1).  Treatment of resting macrophages with 
Th2 cytokine IL-4 leads to induction of master transcription factor Stat6, and major 
transcription factors Irf4, Signal Transducer and Activator of Transcription 3 (Stat3), 
Kruppel-Like Factor 4 (Klf4).  These in turn induce expression of genes including 
interleukin 10 (IL-10), transforming growth factor beta (TGF-β), mannose receptor C 
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(Mrc), transglutaminase 2 (Tgm2), dectin (C-type lectin domain family 7 member A 
[Clec7a]), arginase 1 (Arg1), Ym1 (chitinase 3-like-3 [Chi3l3]), found in inflammatory 
zone 1 (Fizz1), and IL1R.  These “M2a” polarized macrophages demonstrate decreased 
autophagy and increased arginase activity.  Treatment of resting macrophages with the 
Th1 cytokine IFNγ and bacterial cell wall component LPS, in contrast, polarizes 
macrophages to an M1 state.  The transcription factors for M1 polarization are less well 
defined.  Irf5, Irf1, and basic leucine zipper transcription factor, ATF-like 2 (Batf2), all 
have roles in broad M1-associated gene expression.  Other major transcription factors 
include Stat1, nuclear factor kappa B (NF-κB), the cFos and cJun proteins that form 
activator protein-1 (AP-1) dimers, and hypoxia inducible factor 1α (Hif1a).  M1 
macrophages express IFNγ, IL-12, IL-1β, H2-Aa, Cxcl10, and inducible nitric oxide 
synthase (iNOS).  Functionally, these cells increase pathogen phagocytosis, increased 
acidification of phagosomes, increased autophagy, increased nitric oxide (NO) 
production, and iron restriction. 
 
  
48 
 
Figure 2.2: Batf2 is a member of the AP-1 group of bZIP transcription factors. 
 
 
 
Figure 2.2: Batf2 is a member of the AP-1 group of bZIP transcription factors.  The 
diagram above shows the alignment of the Batf proteins, centered on the bZIP regions 
that mediate protein-protein and protein-DNA interactions.  cFos and cJun are included 
for reference.  The homology between Batf2 and Batf is 47% and between Batf2 and 
Batf3 is 43%. 
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Figure 2.3: Functions of Batf and Batf3 in immune cell development and function. 
A. B. 
 C. 
 
Figure 2.3: Functions of Batf and Batf3 in immune cell development and function.  A.  
Batf, present in B cells, Th17, Tfh, Th2, and Th9 cells, dimerizes with another AP-1 
protein, and further complexes with Irf1.  This ternary complex recognizes the AICE (5'-
TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA-3') and drives gene expression 
including AID (B cells, for class-switching); Rorc (encodes RORγt), IL17A, IL21, IL23R 
(Th17, development and function); V-Maf Avian Musculoaponeurotic Fibrosarcoma 
Oncogene Homolog (Maf), B cell CLL/lymphoma (Bcl6) (Tfh, development and 
function); GATA3, IL-4, IL-10, and Cytotoxic T-lymphocyte associated 4 (Ctla4) (Th2, 
development and function); IL9, Furin, Fes, Erg, IL-1RA (Th9, development and 
function).  B.  Batf3, present in CD8α+ cDCs, CD11b+CD103- cDCs, and Th2 cells, 
dimerizes with another AP-1 protein and further complexes with Irf4 or Irf8.  This ternary 
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complex recognizes the AICE and drives gene expression including CD103, Inhibitor of 
DNA binding 2 (Id2), chemokine (X-C motif) receptor 1 (Xcr1), Spib, Clec9a (CD8α+, 
CD11b+CD103+ cDC, development and function); GATA3, IL-4, IL-10, and Ctla4 (Th2, 
development and function).  C.  In CD8α+ cDCs and CD11b+CD103+cDCs, Batf2 can 
compensate for Batf3.  Batf3 or Batf2 dimerizes with an AP-1 protein; in vitro, Batf2 
binds cJun or JunB.  The heterodimer forms a ternary complex with Irf4 or Irf8 that 
recognizes the AICE (5'-TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA-3'), driving 
expression of critical genes for development and function including CD103, Id2, Xcr1, 
Spib, and Clec9a.  Macrophages express high amounts of Batf2 after M1 polarization; 
macrophages simultaneously express cJun, JunB, and Irf8, but Batf2's cofactors remain to 
be defined.   
 
 
 
 
  
51 
 
Chapter III 
MATERIALS AND METHODS  
3.1.   Reagents and antibodies 
The following cytokines and reagents were used to differentiate or polarize cells: 
4-Hydroxytamoxifen (tamoxifen/4-OHT) (Calbiochem, Billerica, MA), γ-irradiated 
lipopolysaccharide (LPS) from E.  coli 011184 (Sigma-Aldrich, St.  Louis, MO), murine 
rIFNγ, murine rIL-10, and murine rIL-4 (Peprotech, Rocky Hill, NJ).  PUER cells were 
provided by Dr.  Harinder Singh (University of Chicago) and maintained  in IMDM 
without phenol red (GIBCO, Grand Island, NY), supplemented with 10% fetal bovine 
serum (Advantage Grade, Atlanta Biologicals) 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 28.2 μg/ml L-glutamine (GIBCO).  Growth was maintained with the 
addition of 12.5ng/ml IL-3 (Peprotech).  Cultures were maintained at 37ºC, 5% CO2.  For 
transfections, Optimem-1 media was used (GIBCO) with TransIT2020 Reagent (Mirus, 
Madison, WI).  Transductions were perfumed with polybrene solution (Millipore, 
Billerica, MA).   
The following antibodies were used for Western blots: polyclonal rabbit anti-
human Batf2 (Aviva Systems Biology, San Diego, CA), mouse anti-rabbit GAPDH (71.1) 
(Sigma-Aldrich), and polyclonal rabbit anti-mouse iNOS/NOS Type II (BD Transduction 
Laboratories) and the secondary antibodies used were goat anti-rabbit IRDye680 and goat 
anti-mouse IRDye800CW (LI-COR Lincoln, NE). 
 
3.2  PUER macrophage differentiation and polarization 
PUER cells are myeloid progenitor cells with PU.1 under the control of the 
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estrogen receptor.  The cells were originally isolated from fetal liver of PU.1-/- mice, then 
transduced with the chimeric construct composed of a PU.1 derivative fused to the 
tamoxifen responsive ligand binding domain of the estrogen receptor by Walsh et al 5. 
To differentiate the PUER cells to macrophages, PUER were seeded at 0.2x106-
0.4x106 per cm2 in polystyrene tissue culture flasks.  One hundred nM tamoxifen was 
added to the IMDM-based growth media described above109 and cells were differentiated 
for 4 days.  On day 4, one set of flasks was used for analysis.  The remainder were treated 
with polarizing cytokines or were treated with fresh media as control.  At the time of 
polarization, cultures consisted of both non-adherent and adherent cells.  Non-adherent 
cells were pooled, pelleted, washed, and re-distributed evenly to the flasks that contained 
the adherent cells.  Earlier analysis in our lab and in Dr.  Singh’s lab were unable to 
identify any differences between adherent and non-adherent cells (data not shown).  To 
polarize cells to M1 phenotype, 20 ng/ml IFNγ and 100 ng/ml LPS were added.  To 
polarize cells to M2, 4 ng/ml IL-4 was added.  An additional group left unstimulated 
served as a negative congrol.  For alternative polarizations, recombinant murine IL-10 
was added at 1-100ng/ml.  Cells were then incubated for 2 days for typical experiments, 
or as otherwise described. 
 
3.3. Cloning and transduction of Batf2 expression vector 
Batf2 in the pCMV-SPORT6 plasmid was obtained from Open Biosystems and 
cloned into the pMigR1 murine retroviral vector (pMigR1 courtesy of Harinder Singh).  
The pMigR1 vector has previously demonstrated high efficiency cloning into 
hematopoietic lineage cells130.  This vector drives gene expression with a murine stem 
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cell virus (MCSV) long terminal repeat (LTR) and allows for GFP selection by following 
the MCS with an internal ribosomal entry site for simultaneous expression of GFP130.  To 
subclone Batf2, EcoRI and XhoI restriction enzyme recognition sequences were 
introduced in the flanking regions of the Batf2 open reading frame (ORF) by site-directed 
mutagenesis.  For site-directed mutagenesis, the QuikChange Lightning kit was used 
(Agilent Technologies, La Jolla, CA), following the manufacturer's protocol.  The Batf2 
ORF was isolated from pCMV-SPORT6 by EcoRI and XhoI digestion followed by gel 
purification.  At the same time, the vector pMigR1 was prepared by digestion with EoRI 
and XhoI and similarly purified by gel purification.  pMigR1-Batf2 was made by ligation 
of these gel-purified Batf2 ORF and pMigR1 vector.  The resulting plasmid (shown in 
Figure 3.1) was verified by sequencing and transfected into E.  coli for future 
experiments. 
To create PUER-Batf2 cells, pMigR1-Batf2 viral particles were created with a 
packaging cell line and then transduced into PUER at the progenitor (CMP) stage.  
Empty vector pMigR1 was transduced in parallel as a control.  Purified pMigR1-Batf2 
was transfected into the retroviral packaging cell line PLAT-E (Harinder Singh), resulting 
in the viral particles used for transduction.  At the time of transfection, PLAT-E were at 
80-90% confluency in a 15cm2 cell culture plate containing Optimem-1 media with 210 
µg of  and 63 µg of DNA per 15 ml media.  PLAT-E were incubated overnight at 32°C, 
then the media was removed and replaced with 14 ml cIMDM as prepared above but 
without antibiotics.  Transfected PLAT-E cells were then incubated an additional 3 days 
at 37 °C.  Supernatant containing viral particles was harvested the next day and 
immediately used for transduction.  PUER cells were transduced with virus by “spin 
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transduction.” For the transduction, PUER cells were seeded at 3x106 in 12 mls of viral 
supernatant total and 2 mL was placed into each well of a 6-well flat-bottom plates and 
spun at 2200 rpm for 2 hours at room temperature.  After spin, cells were incubated at 37 
°C for 30 minutes, washed, and then seeded in cIMDM supplemented with antibiotics 
and IL3 as described above.  After two days incubation at 37 °C, transduced cells were 
selected by flow cytometry sorting for GFP+ cells.  Sorting was done in the Flow 
Cytometry Core Facility of the University of Kentucky by Jennifer Strange.  After two 
rounds of sorting, the transduced cells were greater than 98% GFP+ and used for 
experiments.  Individual clones were created by sorting the cells a 3rd time for GFP into 
98-well plates, 1 cell/well.  These clones were used for some experiments, with similar 
results to the cells following 2 sorts. 
Constitutive expression of Batf2 mRNA is shown in Chapter 4 (Figure 4.12).  We 
were unable to confirm constitutive Batf2 protein, however, due to inconsistent antibody 
quality.  Initial Western blots confirming Batf2 protein in M1-polarized PUER were 
performed with one lot of AVIVA polyclonal anti-Batf2 antibody.  Subsequent batches of 
the anti-Batf2 from the same vender and from three other companies did not work with 
Batf2 Western blots.  I performed extensive troubleshooting with alternative antibody 
concentration, protein extraction methods, secondary antibodies, etc. and was unable to 
produce usable blots.  In these analyses, the M1-specific marker iNOS was clearly 
detectable, suggesting the problem lies with the antibodies and not with the methodology, 
polarization, or other reagents (Figure 4.13).  Thus, I was unable to do further analysis of 
Batf2 protein.  Recent commentaries suggest that this problem is increasingly 
common131.  Therefore, we cannot confirm constitutive protein expression in PUER-
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Batf2 cells. 
 
3.4. RNA extraction and analysis with RT-PCR 
 After 4 days of differentiation (D4) or 2 additional days of polarization (MØ, M1, 
and M2), RNA was extracted for analysis using TriReagent (Molecular Research Center, 
Cincinnati, OH) following the manufacturer's instructions.  Briefly, both suspended and 
adherent cells were collected for analysis: adherent cells were treated with TriReagent, 
while suspended cells were pelleted at 1000 xg, washed, and combined with the adherent 
cells.  RNA was separated by addition of chloroform (Sigma) followed by centrifugation 
at 20,000 xg for 15 minutes.  RNA was then precipitated by addition of isopropanol 
(Fisher), washed with 70% ethanol (maintained at -20 °C), and resuspended in 
RNAse/DNAse-free H2O (Ambion, Grand Island, NY).  RNA concentration was 
measured using a Nanodrop 2000 (Thermo). 
 cDNA was synthesized from 4ug of extracted RNA using a GE First Strand cDNA 
Synthesis Kit (GE Healthcare, Pittsburg, PA) following the manufacturer's instructions, 
using random primers.  mRNA levels were analyzed using  semi-quantitative reverse-
transcription polymerase chain reaction (RT-PCR).  Specific primers shown in Table 3.1 
were used for 28-35 amplification cycles, and products were visualized by ethidium 
bromide staining and digital photography.  For each primer pair the number of cycles 
used was based on prior analysis using known template amounts to determine a specific 
number of cycles that was near the 50% level on the amplification curve.  Band intensity 
was calculated using ImageJ and normalized to the average signal of the loading controls 
Gapdh, B-actin, and Hprt. 
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3.5.   Protein extraction and Western blot analysis 
 For protein extraction, both suspended and adherent cells were collected.  
Adherent cells were removed with a cell scraper.  Lysis of cells was performed by 
suspension in RIPA buffer (Pierce, Rockford, IL) with protease inhibitors (Sigma) and 
passage through a 28 ½ G needle, and 15 minute incubation on ice with occasional 
mixing.  Protein concentration was determined using BCA assay as per manufacturer's 
instruction (Pierce).  Forty µg of protein was used for Western blots under reducing 
conditions unless otherwise indicated.  Protein was mixed with sample buffer (Bio-Rad) 
supplemented with 2-mercaptoethanol (Sigma) and incubated at 90 C for 5 minutes.  
Samples were then run with appropriate standards on a 4-20% tris-glycine gel (Bio-Rad, 
Hercules, CA) at 100V, with buffer containing 0.1% sodium dodecyl sulfate.  Proteins 
were transferred to 0.2 µm nitrocellulose membrane.  The Odyssey Infrared Imaging 
System was used to visualize target proteins.  Following transfer, the membranes were 
blocked in Odyssey PBS blocking buffer (LI-COR) for 1 hour and incubated at 4ºC 
overnight with rabbit anti-human Batf2 at 1:200 dilution or iNOS at 1:2000 dilution and 
mouse anti-rabbit GAPDH clone 71.1, cross-reactive to  mouse GAPDH, at 1:40,000.  
Membranes were washed for 3 times with PBS-0.1% Tween for 5 minutes each, then 
incubated in blocking buffer with goat anti-rabbit IRDye690 and goat anti-mouse 
IRDye800 antibodies at 1:15000.  After washing, the membranes were imaged with 
Odyssey Infrared Imager. 
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3.6. Cxcl10 and Total Protein Assays 
Total protein was used as a correlate of cell number to normalize Cxcl10 that was 
measured in the culture supernatants.  To verify that total protein correlates with cell 
number, a 24-well flat-bottomed cell culture plate was seeded with various concentrations 
of PUER-pMigR1 and PUER-Batf2 cells and differentiated for 4 days with tamoxifen.  
After differentiation, the plates were spun at 1000 xg, 10 min, then analyzed for total 
protein or cell number.  For total protein, the cells from two series of aliquots were 
harvested, washed with PBS, and lysed in RIPA buffer (Pierce).  Total protein was 
quantified from lysate with BCA Protein Assay Kit (Pierce) as per manufacturer's 
protocol.  For cell number, cells were harvested from two parallel series of aliquots, 
washed in PBS, and counted using a hemocytometer.  As clearly shown in Figure 3.2, 
cell number correlates linearly with total protein, validating our use of total protein 
concentration to normalize Cxcl10 measurements. 
Secreted Cxcl10 was analyzed using the murine IP-10 Mini ELISA Development 
Kit (Peprotech), following manufacturer's protocol.  Cells in 24-well tissue-culture plates 
were differentiated for 4 days and polarized an additional day as described above.  Plates 
were spun at 1000xg, 10 min.  Supernatant was used for Cxcl10 analysis, and cells used 
for total protein analysis.  For Cxcl10, supernatant was added to 96-well plates coated 
with rabbit anti-mIP-10.  Biotinylated rabbit anti-mIP-10 were then added, followed by 
avidin-HRP conjugate and then ABTS liquid substrate.  Absorbance values correlating to 
substrate conversion for each kit were detected using a Spectramax M5 plate reader with 
SoftMaxPro software. Comparisons between PUER-MigR1 and PUER-Batf2 were done 
by 2-tailed Student's T test, 2-tailed (n =3), with equal variance.  Statistical significance 
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was accepted at P< 0.05.  
 
3.7. shRNA subcloning and transduction 
 To knock down Batf2 expression, three small-hairpin RNAs (shRNAs) were 
designed using a program created by the Hammond lab at RNAi Central 
(http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA) and subcloned into a 
retroviral vector (murine stem cell virus [pMSCV]), resulting in three different 
knockdown vectors (shBF2.1, shBF2.2, and shBF2.3).  pMSCV containing shRNA 
targeting firefly luciferase served as a negative control.   
 The 22mer shRNAs produced by the Hammond lab’s algorithm for shBF2.1, 
shBF2.2, and shBF2.3 contain two regions complementary to each other such that the 
resulting transcript forms a short hairpin.  These regions are also complementary to the 
Batf2 CDS such that the short hairpin, after process by the cell, targets Batf2 message for 
degradation.  The sequences are as follows:  
shRNA1 
TGCTGTTGACAGTGAGCGAACTCTCCAGCTGCTCTGGGACTAGTGAAGC
CACAGATGTAGTCCCAGAGCAGCTGGAGAGTCTGCCTACTGCCTCGGA 
shRNA2 
TGCTGTTGACAGTGAGCGAGTCCATGCTCTCATGAGTCTCTAGTGAAGC
CACAGATGTAGAGACTCATGAGAGCATGGACCTGCCTACTGCCTCGGA 
shRNA3 
TGCTGTTGACAGTGAGCGCCCACTCATTGGCAGAAGTCATTAGTGAAGC
CACAGATGTAATGACTTCTGCCAATGAGTGGATGCCTACTGCCTCGGA 
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Primers complementary to 5’ and 3’ ends containing restriction enzyme sites EcoR1 and 
Xho1 were used for amplification to produce oligos for subcloning.  Resulting oligos 
were purified by electrophoresis on an agarose gel, digested with Ecor1 and Xho1 and 
subcloned into the pMSCV vector similarly purified and enzyme-digested.  Correct 
insertion of the oligos was confirmed by sequencing.  The pMSCV vector is useful for 
transduction of hematopoietic cells, and contains the Lac operon for selection in bacteria 
and hygromycin resistance for selection in eukaryotic cells.  pMSCV-shBF2.1, -shBF2.2, 
and –shBF2.3 were transfected into E. coli for amplification, with successfully 
transfected cells selected by blue-white color selection.  Plasmids were later purified 
using plasmid purification kits (Qiagen), analyzed for the presence of the shRNA oligo, 
and purified using agarose gel purification.  Purified plasmids were packaged into 
retroviral virions using packaging cell line PLAT-E, and virions were used to transduced 
PUER cells by spin transduction as described above for creation of PUER-Batf2 cells.  
Unlike PUER-Batf2, successfully transduced cells were selected by growth in 
hygromycin-containing cIMDM.  Cultures grew from shBF2.2 and shBF2.3 –transduced 
cells, but these demonstrated levels of Batf2 equivalent with untransduced PUER after 
polarization with LPS/IFNγ (data not shown).  shBF2.1-transduced cultures failed to 
grow after multiple attempts using the pMSCV retroviral system or a lentiviral vector 
system in collaboration with the University of Kentucky Genetic Technology Core 
Facility.   
 
3.8. Nitrate detection and arginase activity assays 
 To determine iNOS activity, supernatants from control and polarized PUER 
macrophages were analyzed using a Griess Reaction in a colorimetric assay kit 
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(EnzyChrom Nitric Oxide Synthase Assay) as per manufacturer’s instructions (BioAssay 
Systems, Hayward, CA.)  Briefly, cells were seeded and differentiated to macrophages as 
described above in cIMDM with Tamoxifen and IL3.  Cells were then polarized with 
LPS/IFNγ (M1) or IL-4 (M2), or left unstimulated.  After 24 hours, supernatants were 
removed and centrifuged at 10,000 x g to remove cells.  Nitrate in these supernatants was 
analyzed using the kit reagents that employ the Griess reaction, in which nitrate is 
reduced to nitrite for 5 min at 60 °C.  The reaction generates proportional indicator 
product that can be quantified at 540 nm.  
 To determine arginase activity, conversion of L-arginine to urea in total cell 
lysates was analyzed using a kit as per manufacturer’s instructions (Sigma).  Briefly, cells 
were seeded, differentiated to macrophages, and polarized as described above.  After 24 
hours, cells were harvested by scraping and washed 1-2 times by pelleting cells at 1000 x 
g, 4 C, 10 minutes and resuspension in PBS.  Total cell lysates were made using the lysis 
buffer suggested in the kit containing 0.4% Triton X-100, pepstatin, and leupeptin at the 
recommended concentration of 100 ul per 106 cells.  Cells were incubated in the lysis 
buffer on ice for 10 minutes.  Insoluble material was then removed by centrifugation at 
14,000xg at 4 C, 10 minutes, and supernatants were aliquoted onto a 96 well plate for 
analysis.  The reaction of supernatants with reaction buffer and Mn solution and controls 
continued for 2 hours at 37 C, after which the urea detection reagent was added and the 
amount of urea was analyzed using a plate reader. 
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3.9. BMDM isolation  
Bone marrow harvested from BALB/c mouse femurs was suspended in PBS, then 
pelleted at 400 x g and resuspended in complete DMEM using a syringe with an 18 G 
needle. Cells were then counted on a hemocytometer and 4 x 106 cells were seeded in a 
10 cm tissue culture dishes with 50 ng/mL M-CSF (Peprotech).  Three days after seeding, 
additional complete RMPI media with M-CSF was added.  On day 7, cells were washed 
with PBS, washed with Ca/Mg free PBS with 0.5 mM EDTA, lifted with Cellstripper 
non-enzymateic cell dissociation solution ((Mediatech) pelleted at 450 x g for 5 min, and 
resuspended in complete DMEM at 0.5x106 cells/mL.  These cultures were polarized and 
used for mRNA analysis as described for PUER above.  
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Table 3.1: Primers used in RT-PCR analysis. 
  
A.    
Arg1 5'- CCCTGGGGAACACTATATAATAAAAA-3' 
5'- GTGTTCACAGTACTCTTCACCTCCT-3' 
Ccl5 5'- ACCATATGGCTCGGACACCACTCC-3' 
5'- AGATGCCCATTTTCCCAGGACCGA-3' 
Ccne1 
(Cyclin E) 
5'- ATTGCCAAGATTGACAAGACTGTG-3' 
5'- CGTCTCTCTGTGGAGCTTATAGAC-3' 
cFos 5'- CCAAACTTCGACCATGATGTTCTC-3' 
5'- GATAAAGTTGGCACTAGAGACGGA-3' 
cJun 5'- CATTTTCTCACCAACTGCTTGGAT-3' 
5'- TCTCCCTTTTCTTTACAGTCTCGG-3' 
Csf1r 5'- AGGCTAAAGTCCTTGACAGCAATA-3' 
5'- TTGAGGATAACGTTGAATCCCACT-3' 
Cxcl10 5'- CATGAACCCAAGTGCTGCCGTCAT-3' 
5'- AAAGGGGAGTGATGGAGAGAGGCT-3' 
Figf/Vegfd 5'- GAAACAACTGCTTAGTCATCGGTA-3' 
5'- CTTGAAGAATGTGTTGGTTGTCTT-3' 
Fizz1 5'- TGAGACCATAGAGATTATCGTGGA-3' 
5'- ACATTTAAAGGCACATGAGTCAGA-3' 
Fra1 5'- ACAGAGGTTCATCTGGAGAGGT-3'-3' 
5'- CAGTGGGTCCCAGGAAATGAG-3'-3' 
Fra2 5'- GAAGAAAACCACCCTGTTTCCTCT-3' 
5'- ATAGGGATTGGACATGGAGGTGAT-3' 
H2-Aa 5'-CAGCCTCTGTGGAGGTGAAGACGA-3' 
5'-TTGGGGAACACAGTCGCTTGAGGA-3' 
Hdac9 5'-GAGGCAAGAACAGGAAGTAGAGAG-3' 
5'-TGAATGAAGTGACAAGATTTCCAT-3' 
Id2 5'-GAGCTTATGTCGAATGATAGCAAA-3' 
5'-ATACTGGGTCCTTCTGGTATTCAC-3' 
Bcl6 5'-ACTTCATGTACACATCTAGGCTCAAC-3' 
5'-GTATTTCTCAGTGGCATATTGTTCTC-3' 
Ifi204 5'-ACCAAAGTTAGTGTGTGGAGAACA-3' 
5'-AGGAGTTGCATTAGCTCTTTGTCT-3' 
Ifi205 5'-ACTTCCACAGCCCAGAAAAGGAAAG-3' 
5'-TCAAACGGGTCTGTTGCAGTGAG-3' 
IL-1β 5'-AAGTGATATTCTCCATGAGCTTTGTA-3' 
5'-CTTTGCTCTTGACTTCTATCTTGTTG-3' 
iNOS 5'-GATGCTGCCACCTTGGAGTTCACC-3' 
5'-GTACCAACCATTGAAGGGGCAGGC-3' 
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Table 3.1 (cont.) 
  
Irf1 
 
5'-GGAAGTGAAGGATCAGAGTAGGAA-3' 
5'-TTCATAAGGTCTTCGGCTATCTTC-3' 
Irf2 
 
5'-AAGAAGATTTTCCAGATCCCCTGG-3’ 
5'- GGTTCTTGCTTGATGTGCTTAAC-3’ 
Irf3 5'- AGTGTATGAGTTTGTGACTCCAGG-3’ 
5'- GAACTCCCATTGTTCCTCAGCTA-3’ 
Irf4 5'-TTCCCTACCCGGACGACAATGGAC-3' 
5'-GGAGCGGTGGTAATCTGGAGTGGT-3' 
Irf5 
 
5'-AGCTGCTAGATGTCCTGGACCGTG-3' 
5'-ATGCTGTCTGCCGACCAAGAAAGC-3' 
Irf7 5'-AGCGAAGAGGCTGGAAGACCAACT-3' 
5'-CTTGGGGTTTGGAGCCCAGCATTT-3' 
Irf9 5'- GTAGAGATTTGGCCCAGTACTTC-3' 
5'- ACGGTGATAAGAACCATCACAGAA-3' 
JunB 5'- GCCTTTCTATCACGACGACTCTTA-3' 
5'- CTGATCCCTGACCCGAAAAGTAG-3' 
JunD 5'- GGGGTACAGAGTGAGATTCTGTTT-3' 
5'- TCATATTCCCAAGTGTGGCAGTAA-3' 
Mmp13 5'-AAGCAGTTCCAAAGGCTACAACT-3' 
5'-AGATAAACATAAGGTCACGGGATG-3' 
Mrc1 5'-TCAGAAATGGGAGTGTAAGAATGA-3' 
5'-ACAGCTTGTCTTTGTCGTAGTCAG-3' 
Parp12 5'-GGATGTGCCGTGCAGACCACA-3' 
5'-GGCCCAAAGAGCATCCCAGACTACT-3' 
Parp14 5'-GCCTCCTGGGGTGGACGAGT-3' 
5'-ATGCCAGAGAGCACTGCGGA-3' 
Prp 5'-CTCTTTGTGACTATGTGGACTGATGT-3' 
5'-GCCTGTAGTACACTTGGTTAGGGTAG-3' 
Stat1 5'-TGGACGACCAGTACAGCCGCT-3' 
5'-CCTTCTCTGTTCTGAGAGGTTTTGCA-3' 
Stat2 5'-TGGCCCTACCCAGTTGGCTGA-3' 
5'-TGGCTCTGATGGGGGTCTGAAGAC-3' 
Tcfec 
 
5'-TGCGCTGGAACAAAGGGACCATTC-3' 
5'-TTCCTCTCAGGATGGGTCTGCTGC-3' 
Tgfb1 5'-AAGCGGACTACTATGCTAAAGAGG-3' 
5'-ACGCCAGGAATTGTTGCTATATT-3' 
Tgtp 5'-TGCCTGGCATTGGGACCACTAACT-3' 
5'-GCTTGTGGGCTGGGAGATCCTGTA-3' 
Ym1 5'-AGAATCTGTGGAGAAAGACATTCC-3' 
5'-TAGAAGGGTCACTCAGGATAAAGG-3' 
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Table 3.1 (continued) 
  
B.  
1 F 5'- GGGCCTCCATAGGTCACTGG -3' 
1 R 5'- AAGGATTCGTGCTGGTGCAG -3' 
2 F 5'- GTCTTGTAGATCTCTTCTGTGCCA -3’ 
All F 5'- AAGAAGAAGCAGAAGAACCGAGT -3' 
All R 5'- CTAGAGGTGTCCTCACCATGAGA -3' 
3 F 5'- TGACTGAGACATTCTAGGCAGC -3’ 
3 R 5' -CGTGGTTCTGTTTCTCCAAGGATT -3’ 
 
A.  Sequences of primers used for gene detection. 
B.  Sequences of primers used for Batf2 isoform analysis. 
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Figure 3.1: Vector for constitutive Batf2 expression. 
 
Figure 3.1: Retroviral vector for constitutive Batf2 expression.  Batf2 in the pCMV-
SPORT6 (Open Biosystems) was modified by introducing EcoRI and XhoI restriction 
enzyme recognition sequences were introduced in the flanking regions of the Batf2 open 
reading frame (ORF) with site-directed mutagenesis.  The long terminal repeats (LTRs) 
are from the murine stem cell virus (MSCV). 
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Figure 3.2: Cell number correlates with total protein. 
 
Figure 3.2: Cell number correlates with total protein.  As cell number increases, total 
protein extracted also increases linearly.  PUER-MigR1 and PUER-Batf2 cells were 
seeded at various concentrations in a 24-well plate and polarized with tamoxifen as 
described elsewhere in this section.  After differentiation, cells were harvested washed 
with PBS, then either counted with a hemocytometer or lysed.  Lysed cells were analyzed 
by BCA analysis for total protein.   
  
67 
 
 
Chapter IV 
RESULTS  
4.1.  Transcriptional programs of resting, LPS/IFNγ-activated (M1), and IL-4-activated 
(M2) PUER macrophages 
 The overall goal of this project is to understand the mechanisms governing 
macrophage polarization to an inflammatory phenotype by describing putative novel 
master transcription factors required for key M1 gene expression.  In this study, I 
investigate and rule out the ability for the highly expressed, M1-associated, and novel 
transcription factor Batf2 expression by itself to induce expression of key genes for M1 
polarization.  I demonstrate a role for Batf2 in enhancing LPS/IFNγ induction of key 
inflammatory chemokine Cxcl10 mRNA and suppressing the IL-4 induction of the anti-
inflammatory effector protein Arginase 1.  I further postulate reasons for the failure of 
Batf2 alone to induce major M1 gene expression or alter phenotype, the most likely 
possibility being a requirement for a cofactor such as an Irf family member. 
 
4.1.1. Differentiation and polarization of the PUER cell line provides an in vitro 
system for determining gene changes due to polarization 
 Macrophage cells have a wide repertoire of functions, from phagocytosis of 
pathogens to secretion of growth factors.  Macrophages have different functional states 
tailored to specific environments, named ‘polarization states.’ During infection, 
macrophages can be divided into two polarization states based on the T cell response type 
that produces their polarizing cytokines2.  M1 polarized macrophages support 
inflammatory Th1 type immune responses that function in elimination of microbial 
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pathogens.  This state is associated with cytokines such as Ccl5 and IL-1β, enzymes such 
as iNOS and chemokines such as Cxcl1022.  M2 polarized macrophages more often 
participate in repair and can counteract M1 responses.  These cells secrete cytokines such 
as TGF-β1, enzymes such as Arg1 and MMPs, and downregulation of Th1 type 
responses.  Typically, the bacterial cell wall component LPS and the inflammatory Th1-
associated cytokine IFNγ are used to imitate an infection and polarize cells to M1, while 
Th2-associated cytokine IL-4 or closely-related IL13 are used to imitate an anti-
inflammatory M2 response in experimental systems2. 
 Gene expression and thus function in response to polarizing stimuli occurs under 
the guidance of transcription factors.  Given that a few master transcription factors 
govern each stage of development and differentiation of most cells, such as PU.1, Runx 
and Irf8 during macrophage development, it follows that macrophages likely require a 
master transcription factor for polarization.  Our overall goal is to identify these master 
transcription factors for M1 polarization.  Although master transcription factors have 
been determined for development, identification of factors guiding polarization states has 
been complicated by the unique plasticity of mature macrophages in that many non-
polarizing stimuli present in the environment alter gene expression.  Therefore, my 
studies use the PUER cell line, a system which provides a highly controllable 
environment. 
 PUER cells are IL3-dependent common myeloid progenitor (CMP) cells with 
PU.1 under the control of the estrogen receptor9.  PUER cells uniquely permit study of 
macrophages differentiation without the previous epigenetic programming, polarizing 
stimulation during purification, or commonly-used differentiating cytokines M-CSF and 
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GM-CSF that can alter gene expression, and with controls for time in culture. These are 
described in Chapter 3, page 52127,128.  Briefly, Walsh et al. created these cells by 
isolating fetal liver cells from PU.1-/- mice, then transducing them with a chimeric PU.1 
transcription factor attached to a modified estrogen receptor regulatory domain9.  These 
cells have the ability to differentiate into multiple hematopoietic cell lineages after 
treatment with appropriate cytokines.  PUER are differentiated to resting macrophages by 
tamoxifen with IL-3, then polarized to inflammatory phenotype (M1) with IFNγ/LPS, or 
to alternative phenotype (M2, sometimes referred to as M2a) with IL-49,132.  This use of 
PUER produces polarized macrophages in a highly controlled environment. 
 Our collaborator, Dr. Peter Laslo (University of Leeds) used the PUER cell 
system to study macrophage and neutrophil differentiation and identify factors that 
regulate their differentiation129.  We extend use of this system to analysis of macrophage 
polarization.  We first validated the PUER system for studying macrophage polarization 
by confirming expression of known key M1- and M2-associated genes and activity of key 
M1- and M2-associated enzymes.  To do this, PUER cells were differentiated to 
macrophages and polarized, and expression of M1 and M2 specific genes was analyzed.  
PUER CMPs were first differentiated for 4 days with tamoxifen and IL3, then treated to 
produce three groups.  Treatments  included: i) additional 2 day culture in new media in 
parallel with polarized cells (MØ), ii) 2 days in fresh media supplemented with 20ng/ml 
IFNγ and 100 ng/ml LPS (M1), and iii) 2 days in fresh media supplemented with 4 ng/ml 
IL-4 (M2) (Figure 4.1).  An additional control, macrophage differentiated for 4 days and 
immediately processed, ruled out any shifts in gene expression due to time in culture.  
RNA and protein analyses were performed at the MØ, M1, and M2 state for known 
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markers.  To analyze RNA, we use semi-quantitative reverse-transcription PCR.  This has 
the advantage of being a rapid and inexpensive method to roughly quantify gene 
expression when the sensitivity of real-time reverse-transcriptase PCR is unnecessary.  
This method was used for several known M1- and M2-associated genes.   
As shown in Figure 4.2, M1-polarized macrophages expressed high levels of 
established M1-associated genes iNOS and Ccl2, and M2-polarized macrophages 
expressed high levels of M2-associated genes Arg1 and Fizz1.  Our lab extended this 
analysis to a wider panel of M1 and M2 specific genes and found that most are 
appropriately upregulated in the PUER model systems, including H2-Aa, Irg1, Stat1, and 
Mrc1 (data not shown).  To confirm that PUER macrophages polarized to M1 or M2 
states are functional macrophages, activity of the key enzymes iNOS (M1) and Arg1 
(M2) were measured.  Nitric oxide production, indicative of iNOS activity, was minimal 
in resting or M2-polarized macrophages, but increased in M1-polarized macrophages 
(Figure 4.2).  Similarly, Arginase activity was undetectable or low in lysates from resting 
or M1-polarized macrophages, but increased in M2-polarized macrophages.  Taken 
together, these results indicate that PUER-derived macrophages polarize to M1 or M2 
states after stimulation with LPS/ IFNγ or IL-4, respectively. 
 To comprehensively survey gene expression changes in polarized PUER 
macrophages, a microarray analysis was performed at the UK Microarray Core Facility 
using the GeneChip ® Mouse Exon 1.0 ST Array to analyze gene expression in PUER 
macrophages in the MØ, M1, and M2 state.  Microarray analysis confirmed that PUER 
cells express macrophage-specific but distinct transcriptional programs for differentiated 
resting, M1-polarized, or M2-polarized macrophages.  All states expressed macrophage 
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markers Emr1 (F4/80) and Itgam (CD11b) (data not shown) confirming previous studies 
using PUER to study macrophages9,129,132.  M1-polarized PUER macrophages compared 
to unpolarized macrophages revealed an expected increase in M1-associated genes, 
including Irf1, Stat1, Cxcl10, and key M1 enzyme iNOS and lack of upregulation of M2-
associated genes including Mmp13, Fizz1, Mrc1, and the key M2 enzyme Arg1 (Table 
4.1).  Many were confirmed by semi-quantitative reverse-transcriptase PCR (RT-PCR) 
(data not shown).  Similarly, M2 -polarized PUER macrophages upregulated M2-
associated genes Mmp13, Fizz1, Mrc1, and key M2 enzyme Arg1.  Likewise, many were 
confirmed with RT-PCR including Fizz1 and Arg1.  M2-polarized PUER macrophages 
did not increase expression of M1-associated genes Irf1, Stat1, Cxcl10, and key M1 
enzyme iNOS.  Importantly, there were no significant gene expression changes between 
the day 4 and the MØ unpolarized macrophages.  Therefore, PUER cells differentiate to 
macrophages and polarized to M1 and M2 states not only express the appropriate 
markers, but also display established M1 and M2 function. 
 Originally, many investigators thought that macrophage polarization to  
M1or M2 states was more stable or permanent.  However, macrophages are now 
appreciated to be more plastic and exist along a spectrum of idealized polarization states.  
For example, adequate stimuli can drive a macrophage cell from an inflammatory state to 
an anti-inflammatory state133.  To determine whether PUER macrophages also exhibit this 
ability, PUER cells were polarized with M1 or M2 stimuli followed by the opposing 
stimuli.  PUER cells were differentiated to macrophages with tamoxifen and then 
polarized for 2 days with LPS/ IFNγ or IL-4 as before.  These resulting polarized 
macrophages were then treated with the same stimuli or with opposite stimuli for an 
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additional 48 hours (M1 with IL-4, M2 with LPS/IFNγ).  Lanes 1 to 3 in Figure 4.31 
show that tamoxifen-differentiated PUER macrophages strongly express mRNA for the 
M1 marker iNOS after 48 hours of polarization with LPS/IFNγ, or strongly expressed 
mRNA of M2 marker Arg1 after 48 hours of polarization with IL-4, as expected.  To 
determine whether polarization was reversible, M1-polarized macrophages were then 
treated with IL-4 and M2-polarized macrophages were treated with LPS/IFNγ for an 
additional 48 hours.  M1 polarized cells treated with IL-4 slightly upregulated Arg1 and 
downregulated iNOS, while M2 polarized cells treated with LPS/IFNγ strongly 
upregulated iNOS and strongly downregulated Arg1 (Figure 4.3).  These results suggest 
polarized PUER macrophages exhibit plasticity, with M2-polarized macrophages more 
readily reversible than M1- polarized macrophages under the conditions used in this 
study. 
 In summary, our studies provide proof of concept that PUER cells can be used as 
a model system to study macrophage polarization.  Therefore, PUER-derived 
macrophages present a good model for my studies on transcription factors involved in 
macrophage polarization.  Moreover, PUER macrophage repolarization to M1 and 
somewhat to M2, demonstrate a plasticity that is a feature of macrophages in the animal.   
 
4.1.2. Identification of novel transcription factors during sustained M1 or M2 
polarization 
 Many studies on macrophage transcription factors analyze gene expression at 
early time points after polarization.  We focused on transcription factors altered at 48 
                                                 
1 The data shown in Figure 4.3 are from an experiment done with the assistance of Mr. Ben Taylor and Dr.  
Joe McGillis 
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hours after stimulation to identify transcription factors involved in long-term maintenance 
of polarization.  Moreover, transcription factors may be altered briefly due to fresh serum 
(such as serum response factors) or serve only a temporary role during initial polarization 
while not playing a long-term role maintaining polarization.  It is important to distinguish 
between these two phases because in vivo inflammatory responses are often beneficial 
during initial clearance of infection but damaging to the host in the long term.  Having 
established the PUER macrophage model as useful for analyzing polarization-associated 
gene expression, we used this system to identify transcription factors highly increased or 
decreased at 48 hours after polarization.  Twenty-three total transcription factors were 
increased in M1-polarized macrophages, and 5 were increased in M2-polarized 
macrophages (Figure 4.4).  M1-associated macrophage transcription factors included the 
previously known Irf1 and Stat1, but also novel Ifi204, Id2, and Batf2.  M2-associated 
transcription factors included known Tcfec and novel Hdac9 and Zpf609.  Batf2 was one 
of the most highly upregulated transcription factors upon M1 polarization, increasing 
nearly 10-fold relative to unpolarized macrophages.  Moreover, it belongs to the AP-1 
group of transcription factors, interacts with AP-1 signaling in non-immune cells, and 
bears close resemblance to key transcription factors important for development of other 
hematopoietic cells, Batf and Batf3.  These last observations also support the case for 
Batf2/s potential as a key M1 transcription factor.  We therefore selected Batf2 for further 
investigation as a putative master transcription factor during M1 polarization. 
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4.2.  Batf2 expression in PUER common myeloid progenitors and macrophages 
4.2.1. Batf2 is rapidly upregulated in IFNγ-stimulated macrophages 
 Our initial hypothesis was that Batf2 is a master transcription factor for LPS/IFNγ 
(M1) polarization.  The first goal was to confirm the microarray data that Batf2 
selectively increases in M1-polarized PUER macrophages.  To do this, PUER 
macrophages were differentiated and polarized as in the microarray analysis (Figure 4.1).  
PUER macrophage progenitors were differentiated to macrophages for 4 days with 
tamoxifen, then polarized to M1 with LPS/IFNγ or to M2 with IL-4 for an additional 2 
days.  Total RNA was extracted and analyzed by semi-quantitative RT-PCR.  
Undifferentiated monocytes and unpolarized or IL-4 polarized macrophages express little 
or no Batf2, while macrophages stimulated with classical activation stimuli IFNγ and 
LPS highly upregulate Batf2 mRNA and protein, shown in Figure 4.5 A and B, 
respectively.  These results confirm that Batf2 is selectively induced in M1 PUER 
macrophages at 48 hours.  In our model system we were interested in this later time point 
for sustained polarization as explained in the previous section, but it is also important to 
know whether Batf2 plays a role in the initial polarization.  We therefore stimulated 
PUER macrophages with LPS/IFNγ and analyzed Batf2 mRNA expression at various 
time points from 0.5 hours to 24 hours.  As shown in the representative experiment in 
Figure 4.6, Batf2 message appears 1 hour after polarization with LPS/IFNγ, peaks 
between 2 and 8 hours, but remains sustained at 48 hours.  These results support a role 
for Batf2 in both the transition from resting to the M1 polarized state as well as sustained 
M1 polarization. 
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 To confirm that Batf2 expression in the PUER M1-polarized macrophages is 
relevant to the induced M1 state in primary macrophages, a study was done with murine 
bone-marrow-derived macrophages (BMDMs).  BMDMs were purified from mice and 
polarized to M1 with LPS/IFNγ, polarized to M2 with IL-4, or left unstimulated for 24 
hours.  Confirming the results in PUER, M1-polarized cells strongly upregulated Batf2 
mRNA as seen in Figure 4.72.  In contrast to PUER, the BMDMs also expressed Batf2 
after IL-4 stimulation.  Batf2 expression by IL-4 polarization was moderate compared to 
the strong upregulation by LPS/IFNγ polarization.  These cells may have been 
epigenetically programmed or primed to M1-associated gene expression in vivo, altering 
gene expression, or the stress of purification and stresses in cell culture may have driven 
all treatment groups towards M1.  The data demonstrates, however, that Batf2 is induced 
in macrophages in response to LPS/IFNγ, agreeing with previous reports of Batf2 as part 
of an IFN response1,83,95. 
 For many genes, multiple isoforms exist and may have different functions.  The 
National Center for Biotechnology (NCBI) database contains sequences for four different 
Batf2 mRNA isoforms and proteins, but no studies have reported on the representation of 
isoforms in any cell type or the functionality of the different isoforms.  To determine 
which isoforms are present in macrophages during peak Batf2 mRNA expression and 
sustained polarization, cells were polarized for 8 hours (peak Batf2 mRNA expression) 
and 48 hours (sustained Batf2 mRNA expression).  Total RNA extracts from polarized 
cells were analyzed by RT-PCR using isoform-specific primers.  Note that no primers can 
be made specific to the reference sequence since X1 isoforms include the entire reference 
                                                 
2 The data shown in Figure 4.7 are from an experiment done with the assistance of Mr.  Robert Hayman IV 
and Dr. Joe McGillis 
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sequence (Figure 4.8).  Two isoforms were detected: X1 and X3.  Since universal Batf2 
primers produced a robust product while X1 and X3 are only weakly detectable, it is 
likely the reference sequence makes up part of the total isoforms, but this remains to be 
conclusively determined.  Most differences in message lie outside the reading frame, and 
protein products differ only in a brief segment at the C-terminal region.  A notable 
exception is the truncated isoform “CRA_a” (NCBI accession EDL33225.1).  X1 differs 
from the reference sequence in a missing Q residue in the bZIP region.  No functional 
correlations are known.  This data provides the first report of the existence of multiple 
Batf2 isoforms in any cell type.  For protein isoforms, the antibody to Batf2 has not been 
tested.  The antibody was raised to a region of the human Batf2 overlapping a C-terminal 
segment of bZIP region common to all isoforms except the truncated “CRA_a.” The 
isoforms share 94% pairwise identity in this region.  Therefore, the antibody should 
recognize products of the reference, X1, and X3 message present in macrophages.  
However, this remains unverified.  This data suggests that LPS/IFNγ activation 
upregulates multiple isoforms, including X1 and X1, and possibly the reference sequence.  
The functional consequences remain unknown. 
 
4.2.2. Batf2 is upregulated in response to IFNγ or IL-10, but not LPS 
 Typically, LPS and IFNγ are used as in vitro inflammatory stimuli to model M1 
polarization, and both are required for full M1 polarization.  In vivo, however, 
macrophages see a wide variety of stimuli that polarize them to variations of the 
inflammatory and anti-inflammatory phenotypes, depending on the environment.  In 
some contexts, for example, IFNγ may be present without TLR4 agonists like LPS, 
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activating different macrophage functions than LPS/IFNγ in combination.  IFNγ signals 
through JAK/Stat pathways, and LPS signals through MyD88/AP-1 and MyD88/NF-κB.  
IFNγ activates a receptor composed of IFNγ-receptor 1 (IFNGR1) and IFNGR2, which 
activates JAK2, which then activates Stat1 transcription factor homodimers.  TLR4 and 
MyD88 activate IKK, PI3K, and MAPKKs, which activate NF-κB and AP-1 transcription 
factors.  To determine which pathway(s) control Batf2 in PUER macrophages, we tested 
for Batf2 mRNA in response to LPS alone, IFNγ alone, or LPS/ IFNγ.  Expression was 
analyzed at 8, 24, and 48 hours using semi-quantitative RT-PCR with specific primers.  
The 8 and 24 hour timepoints were included to account for possible differences in peak 
gene expression in response to LPS vs IFNγ.  Figure 4.9 shows that IFNγ alone induced 
Batf2 at 8, 24, and 48 hours, while LPS did not.  Additionally, IFNγ-induced Batf2 
message roughly compares to IFNγ /LPS-induced Batf2 message quantitatively.  Taken 
together, the results suggest that IFNγ induces Batf2 in PUER macrophages, while LPS 
does not contribute to Batf2 expression. 
 Like IL-4, IL-10 also opposes inflammatory stimuli29,33,57.  However, the 
transcriptional repertoire of IL-10- activated macrophages differs somewhat from IL-4-
actived macrophages, and overlaps partly with the IFNγ-induced repertoire26,31.  IL-4 
activated macrophages express IL-10, for example, while IL-10 activated macrophages 
express FceRII26.  Both induce the mannose receptor (Mrc1) and Arg1.  IL-4 stimulates 
the IL-4 receptor, resulting in activation of Stat3 and Stat6.  IL-10 stimulates the IL-10 
receptor, resulting in activation of Stat3 but not Stat629,30,32,33.  To determine whether the 
IL-10-activated pathway differed from the IL-4 pathway in Batf2 induction, we polarized 
PUER macrophages as before with LPS/ IFNγ or IL-4, and in parallel stimulated 
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macrophages with 1, 10, or 100ng/ml IL-10.  In contrast to the minimal expression of 
Batf2 in unstimulated or IL-4-polarized macrophages, all three IL-10-treated 
macrophages expressed Batf2 at 48 hours (Figure 4.10).  Expression was not dose-
dependent and not as robust as LPS/IFNγ treatment.  It is possible that the minimum dose 
used, 1 ng/ml, elicits the maximal response for IL-10.  In this case, this suggests that the 
maximal LPS/IFNγ response surpasses the maximal IL-10 response. 
 In summary, LPS/IFNγ induces three isoforms of Batf2 mRNA in PUER 
macrophages, although protein products remain unknown.  IFNγ and, unexpectedly, IL-
10 induce Batf2, while LPS does not.  After LPS/ IFNγ stimulation, Batf2 mRNA appears 
within one hour, peaks before 16 hours, and is maintained for over 48 hours.  This data 
demonstrates that Batf2 expression in macrophages is controlled by signaling pathways 
activated by both IFNγ and IL-10, but not by IL-4 or LPS. 
 
4.2.3. Batf2 expression precedes select M1 genes 
If Batf2 is important for generating the M1 phenotype in macrophages, we would 
expect that Batf2 expression would proceed expression of genes selectively upregulated 
in M1 macrophages.  To determine whether Batf2 is induced prior to induction of major 
M1-related genes, we compared the timecourse of the expression of various M1-
associated genes with expression of Batf2.  In these studies PUER macrophages were 
differentiated with tamoxifen and IL-3 and polarized with LPS/IFNγ or left unstimulated.  
Total RNA was extracted at time points from 0 to 24 hours and analyzed by semi-
quantitative RT-PCR with specific primers. 
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Shown in Figure 4.11 are two genes consistently and highly upregulated in our 
M1-polarized PUER macrophages, Cxcl10 and interferon-activated protein 204 (Ifi204).  
Cxcl10, a chemokine attracting inflammatory cells, is a major marker for M1-polarized 
macrophages28,44,51,134 .  Ifi204/human myeloid nuclear differentiation antigen (MNDA) 
belongs to the p200 family of transcription factors, expressed in response to IFNα, IFNγ, 
or LPS in mature granulocytes, in monocytes, and in activated macrophages (reviewed in 
Gariglio et al.)135.  The p200 family of transcription factors participates in cell cycle 
inhibition, apoptosis, and differentiation in some cells including monocytes.  While its 
specific role in M1 polarization remains unclear, it is consistently and robustly induced 
and therefore serves as a good indicator of M1 polarization.  Expression of both Cxcl10 
and Ifi204 is low or absent in unpolarized PUER macrophages (Figure 4.11).  For 
Cxcl10, a slight increase was seen at 30 minutes after polarization and peaked from 1 to 8 
hours.  These kinetics are similar to Batf2, which is expressed at 30 minutes but strongly 
expressed at 1 hour.  This does not support an argument for Batf2-induced Cxcl10.  
However, there is a marked enhancement of Cxcl10 at 1 hour, subsequent to induction of 
Batf2, allowing for a role of Batf2 in enhancement of Cxcl10.  In contrast, Ifi204 
induction occurs much later after polarization, about 2 hours after treatment, after Batf2 
induction.  Therefore, Batf2 mRNA induction in polarized cells occurs prior to induction 
or enhancement of select M1 genes, allowing the possibility that Batf2 lies upstream of 
these genes during M1 polarization. 
 
4.2.4. Summary of Batf2 expression data 
80 
 
 To summarize this data on Batf2 expression, Batf2 is highly induced in LPS/IFNγ 
(M1) -polarized macrophages within 1 hour of polarization, and expression is dependent 
on IFNγ but not LPS.  Batf2 induction correlates with expression of Th1-supportive gene 
expression, but not IL-4-induced Th2-associated gene expression.  Surprisingly, the anti-
inflammatory cytokine IL-10 also moderately induced Batf2 expression, suggesting Batf2 
induction occurs by multiple signals.  After LPS/IFNγ, Batf2 induction precedes select 
genes important for the M1 phenotype.  Overall, mRNA analysis of Batf2 in response to 
multiple stimuli and in relation to other M1-associated genes supports the possibility that 
Batf2 contributes to M1-associated gene expression. 
 
4.3.  Constitutive Batf2  expression alone does not drive gene expression, but enhances 
select M1 genes or suppresses select M2 genes 
4.3.1. Constitutive Batf2  expression may enhance select LPS/IFNγ-induced M1 
genes in conjunction with other factors 
Having established that Batf2 is strongly induced in M1-polarized macrophages, 
but not M2-polarized macrophages, and induced prior to at least some M1-associated 
genes, we set out to identify genes regulated by Batf2.  I therefore created a PUER cell 
line that constitutively expresses Batf2, herein called PUER-Batf2.  I hypothesized that 
genes induced by Batf2 in M1-polarized macrophages would be induced in PUER-Batf2 
cells in the absence of cytokine and LPS stimulation.  To test this, expression of several 
M1-associated genes was analyzed by semi-quantitative RT-PCR.  Forced expression of a 
single transcription factor in this way has successfully been used to identify genes 
downstream of other transcription factors, such as Klf4 overexpression enhancing 
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expression of Arg1, Mrc1, Pdcd1lg2, Pparg, and others (reviewed in Liao et al.)136.  
Based on the mRNA analyses described in the previous section placing Batf2 within M1-
associated response, I hypothesized that many key M1-associated genes such as Cxcl10, 
iNos, Ifi204, and H2-Aa would be induced PUER cells constitutively expressing Batf2. 
To construct cells that constitutively express Batf2, PUER cells were transduced 
with a retroviral vector containing a Batf2 cDNA (pMigR1-Batf2).  A murine Batf2 
cDNA was subcloned in the multiple cloning site of the pMigR1 vector130.  The pMigR1 
vector drives gene expression with a MCSV LTR, and allows for GFP selection by 
following the multiple cloning site with an internal ribosomal entry site for simultaneous 
expression of GFP.  This vector was transfected into the packaging cell line PLAT-E, and 
PUER (at progenitor stage) were treated with the resulting supernatant containing 
retroviral particles as described in Chapter 3.  Cells then underwent two rounds of 
fluorescence-activated cell sorting to select for GFP+ cells.  First, expression of Batf2 was 
confirmed in these cultures at the common myeloid progenitor stage (undifferentiated) 
and unpolarized macrophage stage (tamoxifen and IL-3 treated) by RT-PCR.  While 
undifferentiated and tamoxifen-differentiated PUER or vector-transduced (PUER-
pMigR1) cells expressed undetectable to minimal Batf2 message, Batf2-transducaed 
(PUER-Batf2 cells) had significant expression of Batf2 message, as shown in Figure 4.I2 
B.  This suggests that PUER-Batf2 cells constitutively express Batf2 mRNA at levels 
surpassing LPS/IFNγ-induced Batf2.   
In order to identify genes potentially induced by Batf2, we analyzed expression of 
multiple M1-associated genes in PUER-Batf2 compared to the vector-transduced PUER-
pMigR1 using RT-PCR.  Unexpectedly, undifferentiated and tamoxifen-differentiated 
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PUER-Batf2 cells did not demonstrate expression of any of the multiple M1-associated 
genes, including the key M1 gene Cxcl10 (lane 1 of Figure 4.14 and data not shown).  
Table 4.2 contains a list of all genes tested.  This suggests that Batf2 alone does not 
induce M1 gene expression, as predicted for an M1 master transcription factor.   
Although high constitutive Batf2 mRNA expression alone did not drive gene 
expression, this does not entirely rule out a role for Batf2 as a part of a transactivating 
transcription complex in M1 polarized macrophages.  The activity of AP-1 family 
members is highly sensitive to context, so activity often requires not only expression of 
the factor in question but also a permissive intracellular environment composed of 
dimerization partners, cofactors, post-translational modification enzymes, and chromatin 
modifications.  For example, cFos requires cJun for both activity as activator and as 
inhibitor, depending on the cell type and gene examined, and phosphorylation of specific 
residues in both cFos and cJun64,87.  Moreover, many functions of this family require 
additional cofactors for their DNA binding activity.  The closely related Batf and Batf3, 
for example, requires Irf4 or Irf8 for transactivation of genes necessary for several T cell 
subsets including Th17, Tfh, Th2, and Th976,111.  Therefore, Batf2 activity may require 
necessary cofactors or conditions absent in the CMP stage or resting macrophage stage.   
 To examine this possibility, we tested gene expression in conditions permissive 
for Batf2 activity.  Since Batf2 is expressed in M1-polarized macrophages, M1-polarized 
macrophages must contain the necessary cofactors and conditions for Batf2 function if 
Batf2 is important for M1 polarization.  Enhanced Batf2 expression in the M1 state such 
as in M1-polarized PUER-Batf2 cells might act with other regulatory factors to increase 
downstream gene expression in M1-polarized cells.  To determine whether this occurs, 
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we next analyzed select M1-associated gene expression in M1-polarized PUER-Batf2 
cells compared to controls.  PUER, PUER-pMigR1, and PUER-Batf2 were polarized as 
in previous gene expression assays.  Cells were differentiated with tamoxifen for 4 days 
then polarized with LPS/IFNγ to M1 or IL-4 to M2 or left unstimulated.  We first 
analyzed the protein production of key M1 enzyme iNOS to ensure that cells 
constitutively expressing Batf2 polarized normally.  iNOS protein was detected in PUER-
Batf2, demonstrating that these cells functionally polarize to M1 (Figure 4.13).  Next, we 
asked whether PUER-Batf2 upregulated M1-associated gene expression (see Figure 4.14 
for Cxcl10, Figure 4.16 for Csf1r, and Figure 4.19).  After polarization, high constitutive 
Batf2 mRNA expression enhanced LPS/IFNγ induced Cxcl10 expression, suggesting 
there is an additional condition or factor required for Batf2 activity, as clearly shown in 
Figure 4.14.  However, as also shown in this figure, this increase in message failed to 
translate into increased protein.  No other M1-associated genes tested demonstrated 
consistent enhancement in M1-polarized PUER-Batf2 compared to PUER and vector 
controls, including key M1-associated genes Irf1 and iNOS and (refer to Table 4.2 for the 
list of all genes tested).  Interestingly, Batf2 does not seem to enhance Cxcl10 mRNA 
except in the context of M1 polarization, when the cellular environment expresses 
multiple different factors, shifts in metabolism, different enzymes, etc.  This suggests that 
Batf2 requires an additional condition such as a dimerization partner, cofactor, post-
translational modification, or chromatin modification for its activity.  These data show 
that constitutive high levels of Batf2 expression alone does not induce expression of key 
M1-associated genes, but in M1-polarized cells enhances select LPS/IFNγ-induced 
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expression of select M1-associated genes, suggesting that Batf2 requires a cofactor or 
condition. 
 
4.3.2. Constitutive Batf2  expression may downregulate select IL-4-induced 
genes in conjunction with other factors 
 Based on the data in the previous sections, the modified hypothesis is that Batf2 
induces M1-associated gene expression in concert with a necessary cofactor or condition 
present only in M1-polarized cells.  However, constitutive Batf2 expression only 
enhanced Cxcl10 in M1 state out of the genes tested.  This could be due to Cxcl10 being 
very sensitive to Batf2 induction.  Another explanation, however, could be that Batf2's 
main activity is as a repressor of M2 functions rather than an activator of M1 functions.  
In cancer studies, for example, Batf2 suppresses activity at the AP-1 element by 
sequestering cJun into an inactive dimer, suppressing transcription of genes including 
Cyclin E in HeLa cells95 (see Chapter 2 page 34 for more detail).   
 To determine if Batf2 suppresses M2-associated genes, we analyzed gene 
expression in IL-4-polarized M2 PUER-Batf2 macrophages compared with PUER and 
PUER-pMigR1 cells.  Cells were differentiated for 4 days with tamoxifen and IL3, then 
polarized with IL-4 or left unstimulated.  M2-associated genes as defined in this study 
refers to either absent/minimal in PUER macrophages and upregulated upon IL-4 
treatment, or expressed in resting state and downregulated in M1 stimuli but upregulated 
or maintained in M2 state.  This is shown in Figures R2 for Arg1 and Fizz1 and Irf4 in 
Figure 4.19 A.  It is worth noting that resting macrophages are more similar in many 
respects to M2-polarized macrophages, and M2-associated genes are sometimes 
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expressed in the resting stage to a lesser extent than M2-polarized macrophages.  As 
shown in Figure 4.15, PUER-Batf2 cells failed to upregulate Arg1 mRNA after IL-4 
stimulation compared to PUER and PUER-pMigR1.  This effect was consistent across 
three experiments.  Thus, Batf2 expression reduces IL-4-induced Arg1 mRNA 
expression. 
 Of note, an experiment suggested that unpolarized macrophage PUER cells with 
forced Batf2 expression also express higher levels of the M2-associated gene Mmp13 
(discussed further in the context of AP-1 activity below, see Figure 4.16).  This may give 
hints to pathways Batf2 interacts with in macrophages, but is not useful to our goal of 
identifying factors involved in the M1 polarization since Mmp13 is absent in M1 state.  
Overall, constitutive high levels of Batf2 message as seen in PUER-Batf2 suppresses IL-
4-induced Arg1 message but does not significantly suppress multiple other IL-4-induced 
gene expression.  This data does not support the hypothesis that Batf2 alone promotes M1 
polarization by suppressing M2-associated gene expression, but Batf2 might suppress 
M2-associated gene expression with a necessary cofactor or condition. 
 
4.3.3. Constitutive Batf2 expression does not alter expression of genes that are 1) 
Batf2-regulated in non-immune cells, 2) cJun-regulated in macrophages, 3) 
compensatorally regulated by Batf2 in DC subsets  
 We initially hypothesized that Batf2 by itself promotes M1 polarization as a 
master transcription factor inducing M1-associated gene expression.  Alternatively, since 
this does not seem to be the case, Batf2 could promote M1 polarization as a factor 
downregulating M2-associated genes such as Arg1, Tcfec, and Mrc1.  However, while 
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Batf2 alone enhances Cxcl10 and suppresses Arg1 mRNA, it fails to cause the broad 
changes we expected.  Most of the M1 or M2-associated genes I examined support other 
immune cells or are involved in microbicidal activity.  Another possibility is that Batf2 
controls genes that encode more supportive functions such as stress responses to the 
microbicidal reactive species released during inflammation, or structural changes 
supporting chemotaxis, etc.92,93,137,138.  AP-1 has well described roles in cellular stress 
responses in other cells, responding to stimuli such as intracellular oxidative stress92,93.  
Moreover, Batf2 exhibits anti-tumorigenic activity through integrin signaling and 
anchorage-independent cell growth124.  Based on this information, Batf2 might 
reasonably play a critical role in M1 polarization by regulating antioxidants, extracellular 
matrix, cell cycle, etc.  We therefore explored whether Batf2 impacted three categories of 
non-immune genes: 1) genes regulated by Batf2 in non-immune cells, 2) genes regulated 
by cJun (which Batf2 represses) in macrophages, 3) genes regulated by Batf and Batf3, 
with which Batf2 shares function in some situations.  These three categories of genes 
were investigated in tamoxifen-differentiated PUER, PUER-pMigR1, and PUER-Batf2 in 
unpolarized, LPS/IFNγ (M1)-polarized, and IL-4 (M2)-polarized cells at 48 hours after 
stimulation. 
 
4.3.3.1.  Genes directly regulated by Batf2  
 Batf2 suppresses Ccne1 (encoding Cyclin E protein) in non-hematopoietic cells 
by sequestering cJun95.  Cyclin E is needed for  cell cycle progression from the G1 to S 
phase139,140.  Macrophages undergo cell cycle arrest upon activation with LPS or IFNγ141.  
Thus, Batf2 might support polarization in part through inhibiting Cyclin E and 
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subsequent cell cycle progression.  Cyclin E expression was therefore compared in 
PUER, PUER-pMigR1, and PUER-Batf2.  M1-polarized and M2-polarized cells were 
also compared to resting macrophages, to determine whether Batf2-mediated cJun 
enhancement or suppression requires an M1-associated cofactor or condition.  In this 
case, suppression would occur in M1-polarized PUER-Batf2 but not resting macrophages 
and possibly not M2-polarized macrophages.  As seen in Figure 4.16 A, high constitutive 
Batf2 mRNA expression did not markedly suppress levels in unpolarized, M1-polarized, 
or M2-polarized cells.  This data demonstrates that Batf2 expression alone does not 
regulate Cyclin E in macrophages.  Moreover, the failure of Batf2 to suppress Cyclin E 
here, in contrast to previous studies on non-hematopoietic cells, suggests that Batf2 has 
differential activity in different cell types. 
 
4.3.3.2. Genes regulated by Batf2’s dimerization partner cJun  
 Because Batf2 suppresses cJun activity in some cells and transactivates genes as a 
heterodimer with another AP-1 member (possibly cJun or JunB) in CD8α+ and 
CD103+CD11b- cDCs, Batf2 could be acting as an inhibitor or an activator in 
macrophages. That constitutive Batf2 expression alone failed to activate expression of 
major M1-associated genes was not necessarily surprising given the literature suggesting 
that Batfs requires cofactors.  Batf2's suppressive activity, however, has not been reported 
to require a cofactor, and forced expression of Batf2 does suppress AP-1 activity in prior 
studies 95,124.  Therefore, I expected constitutive Batf2 expression to suppress genes 
downstream of cJun in macrophages.  Three genes regulated by cJun in macrophages 
were specifically tested for induction or suppression by Batf2: Csf1r, IL-1β, and Mmp13.  
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Behre et al. demonstrated that cJun/PU.1 complexes induce M1-associated Csf1r in M1-
polarized macrophages87.  PUER macrophages contain PU.1, so it is reasonable to expect 
that PU.1/cJun complexes drive Csf1r expression in our cells and that Batf2 might 
suppress cJun and thus Csf1r expression.  However, Batf2 expression did not markedly 
alter Csf1r expression in M1 PUER macrophages (Figure 4.16 B).  Grondin et al. 
demonstrated that cJun/PU.1 also regulates IL-1β, but in complex with the additional 
factor C/EBP that is also present in PUER macrophages 80.  Therefore, Batf2 might also 
suppress IL-1β message expression by suppressing cJun.  PUER-Batf2 did not, however, 
express markedly different levels of IL-1β in the M1 state compared to control cells in 
the resting MØ state (Figure 4.16 A).  Finally, cJun also regulates Mmp13 in 
macrophages by a mechanism more complex than simple transactivation, described in 
Ogawa, et al. and Glass, et al. For Mmp13 regulation, unphosphorylated cJun (inactive) 
normally negatively controls Mmp13 through recruitment of the corepressor NCoR1 and 
subsequent silencing histone modifications.  TLR signaling leads to phosphorylated 
(active) cJun in macrophages63,98.  Like Csf1r and IL-1β, M1-polarized PUER-Batf2 did 
not display markedly suppressed Mmp13 expression compared to M1-polarized controls 
(Figure 4.16 B).  Interestingly, PUER-Batf2 cells display markedly increased basal IL-1β 
and Mmp13.  This may provide insight into pathways with which Batf2 interacts, but 
requires further studies to identify binding partners.  With relevance to our study, failure 
of high constitutive Batf2 mRNA expression to alter these three representative cJun-
regulated genes suggests that Batf2 does not alter cJun's activity in M1-polarized 
macrophages.   
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4.3.3.3. Genes regulated by Batf2 in compensation of Batf2 deficiency 
 Batf2 or Batf compensate for Batf3 in CD8α cDCs and the related 
CD103+CD11b- cDCs by forming complexes with Irf4/Irf8 that transactivate transcription 
at AP-1-Irf Composite Elements (AICE)110 (see Figure 2.2, page 48).  Irf8 is present in 
macrophages under all conditions, and Irf4 is present in M2-polarized macrophages (see 
Irf discussion on page 148 for further analysis, as well as Figure 19 A).  Constitutive 
expression of Batf2 might therefore support M1 polarization by enhancing expression of 
genes controlled by these Batf-Irf complexes, including Id2 142.  Id2 plays a role in fetal 
liver macrophage differentiation by countering differentiation-promoting Retinoblastoma 
protein (Rb)143 and is expressed in PUER macrophages as shown in Figure 4.16 C 
although its function in polarization has not been described.  This figure shows that 
PUER-Batf2 cells do not show enhanced expression of Id2 in unpolarized, M1-polarized, 
or M2-polarized states, suggesting that Batf2 expression alone does not enhance the same 
genes as Batf-Irf complexes in the cDC subsets.  Additionally, although Batf2 cannot 
compensate for loss of Batf in Tfh cells, macrophages may contain factors necessary for 
Batf2 and absent from Tfh cells.  We therefore tested the Batf-induced T cell gene Bcl6 
83.  Bcl6 induction might assist macrophage polarization by promoting the necessary 
structural changes needed for cytokinesis, cell motility, and other functions138.  However, 
high constitutive Batf2 mRNA expression Batf2 expression fails to enhance Bcl6 
expression in unpolarized, M1-polarized, or M2-polarized macrophages (Figure 4.16 C).  
Therefore, Batf2 expression alone in macrophage cells does not regulate genes 
downstream of Batf2 in CD8α and CD103+CD11b- cDCs, nor does it induce expression 
of genes controlled by Batf or Batf3 in T cells. 
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 In this survey of select genes, Batf2 did not induce genes regulated by Batf2 in 
non-hematopoietic cells (Cyclin E), by cJun in non-hematopoietic cells or macrophage 
cells (Csf1r, IL-1β, and Mmp13), by Batf2 compensationally in CD8α and 
CD103+CD11b- cDCs (Id2) or Tfh cells (Bcl6).  These results suggest that Batf2 
regulation differs between cell types and that BAT2 function differs in macrophages from 
other cell types.  However, whether Batf2 functions overlap in macrophages and other 
cells requires a much more extensive analysis. 
 
4.3.4.  Possibility that Batf2 plays a role in growth or survival 
Batf2 appears to require a cofactor or condition present in M1-polarized cells to 
enhance gene expression, but in these cells Batf2 activity from naturally-induced protein 
may be at maximum.  This could account for the lack of changes to the array of M1 genes 
tested here.  Therefore, we attempted to examine genes induced by Batf2 by knocking 
down Batf2 using small-hairpin RNA (shRNA).  Three different shRNA constructs were 
transduced into PUER cells using the retroviral vector pMSCV.  Although all three 
shRNA constructs were successfully transduced into PUER as well as the control plasmid 
encoding shRNA against firefly luciferase, two of the resulting shBatf2-transduced 
cultures displayed normal Batf2 expression and one failed to grow (data not shown).  
Batf2 mRNA is normally only minimally detectable in healthy PUER cells (see Figure 
4.5).  However, Batf2 amounts in newly-transduced cultures remain unknown.  Batf2 
expression may be important for growth and survival shortly after transduction.  
 
4.4.  Regulation of Batf2 activity: Requirement for additional M1-associated factors 
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Based on the survey of gene expression in the previous sections, high constitutive 
Batf2 mRNA expression alone does not appear to suppress cJun activity (Csf1r, IL-1β, 
and Mmp13) as in other cells, or enhance transcription at the AICE (Id2) as in subsets of 
cDCs143.  This does not rule out a role for Batf2 protein in macrophage polarization, 
however, given the many layers regulation of gene expression in general and AP-1 
activity in particular (Table 4.2).  The complex requirements for activity of the AP-1 
related transcription factors provide a means of fine control over transcription for any 
given downstream gene.  Some of the mechanisms for regulation include: presence of a 
positively-regulating dimerization partner (although appropriate cofactors may 
compensate), absence of any negatively regulating dimerization partners, non-AP-1 
cofactors (if necessary), post-translational modifications, mainly phosphorylation but also 
avoidance of SUMOylation, and redox potential64–66,77,80,92,93,144,145.  Moreover, gene 
expression in general requires correct epigenetic landscape through modification of the 
DNA or chromatin, exemplified by  PU.110.  If our PUER cells or PUER-Batf2 cells lack 
activating factors or have an overabundance of repressive factors, then this could prevent 
us from detecting any changes in genes that are usually regulated by Batf2 in vivo. 
Using gene expression studies, we began to explore possible restrictions of Batf2 
activity by analyzing the presence or absence of factors that interact with AP-1.  AP-1 
proteins interact with a complex network of factors.  These interactions include multiple 
categories, including dimerization with AP-1 proteins, dimerization with more distantly 
related bZIP proteins, ternary complex formation with DNA-binding transcription factors, 
and complex formation with non-DNA binding transcription factors.  Our preliminary 
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study examined select representative genes from two categories: 1) other AP-1 
dimerization partners, and 2) ternary complex members. 
 
4.4.3. Other AP-1 members are present and may dimerize with Batf2 or a Batf2 
partner  
 AP-1 family members require dimerization with another AP-1 member which 
provides an opportunity to regulate DNA binding specificity and activity63,73,75,80–83.  
Some members, such as cJun, recognize the AP-1 consensus elements when in a dimer 
and contain transactivation domains, and thus more often activate than repress gene 
expression79,81,82 .  Other members, such as cFos, activate transcription in a heterodimer 
with a DNA-binding member but cannot bind DNA as a homodimer.  Other members, 
such as JunB, lack a transactivation domain and may decrease activity.  Still other 
members may prevent DNA recognition entirely at some consensus elements.  Batf2 
itself, for example, prevents cJun from binding to the AP-1 consensus95,112,124.  Which 
homo- or hetero-dimers form is in part determined by relative levels of possible partners.  
Therefore, Batf2 activity in macrophages could be limited by available activating partners 
or overabundance of repressive partners. 
 We first looked for the presence or absence of known in vitro Batf2 partners cJun 
and JunB.  Multiple studies support Batf2-cJun dimerization95,112,113,124.  JunB binds Batf2 
FRET assays but lacks direct evidence in the cell.  Expression of AP-1 family members 
was analyzed as above by RT-PCR in unpolarized, LPS/IFNγ (M1)-polarized, or IL-4 
(M2)-polarized PUER, PUER-pMigR1, and PUER-Batf2.  Unlike previous analyses, the 
important data here is the presence or absence of the binding partner rather than the effect 
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of Batf2 expression on the relative levels: either the factor is absent and unavailable for 
Batf2 interaction, or the factor is present and Batf2 could interact.  Additionally, gene 
expression was assessed for M1 or M2 association: an M1-associated gene may be more 
likely to be the dimerization partner for Batf2.  Both cJun and JunB message are 
detectable in macrophages, but are not associated with M1 polarization at 48 hours 
(Figure 4.17).  Therefore, Batf2 activity in the M1 state does not appear to result from 
increased Batf2/cJun or Batf2/JunB dimers.  However, the activity of these proteins may 
be regulated in ways not detectable by message analysis.  First, they may be bound up by 
another dimerization partner and thus be unavailable to Batf2.  Second, they may be 
regulated post-transcriptionally.  To explore whether cJun or JunB might be dimerizing 
with another AP-1 member in the M1 state, shifting dimer balance to Batf2/cJun or 
Batf2/JunB, we tested many other AP-1 members.  JunD, Batf, cFos, and Fra2 were all 
present in macrophages under all conditions at 48 hours, and were not altered by 
polarization (Figure 4.17).  This does not support a role for these factors in macrophage 
polarization, but they also may be regulated post-transcriptionally or through 
dimerization with other bZIP proteins.  Batf3, on the other hand, is M2-associated.  
Figure 4.17 shows that Batf3 message is downregulated in M1-polarized cells and 
upregulated in M2-polarized cells.  Fra1, in contrast, was not detected at 48 hours, but is 
upregulated in M1 polarized macrophages at 8 hours.  Batf3 and Fra1, at early time 
points, may have a role in macrophage polarization.  None of the patterns of expression 
change in PUER-Batf2 cells. 
Fra1, which transiently increased in M1-polarized macrophages, binds both cJun 
and JunB and so could potentially sequester a dimerization partner of Batf2 in PUER-
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Batf2, thus limiting activity at early time points.  Other interactions may also exist in vivo 
that are not predicted by in vitro screening, and a homo- or hetero-dimer with activity in 
one context may have different activity in another.  Therefore, downstream genes were 
examined as a better correlate of activity.  High constitutive Batf2 mRNA expression 
does not alter Figf/Vegfd, a gene reportedly regulated by Fra1, suggesting no change in 
Fr-1 activity (Figure 4.18)146.  Although constitutive Batf2 expression might be predicted 
to inhibit cJun activity as in other cells, Csf1r , reportedly regulated by PU.1/cJun 87, also 
did not change, suggesting no significant negative interaction of Batf2 with PU.1-cJun 
complexes.  Interestingly, a cJun-regulated genes IL-1β and Mmp13 appear to be 
upregulated in M2-polarized PUER-Batf2 (Figure 4.16 B).  IL-1β and Mmp13 are not 
normally expressed simultaneously with Batf2, being M2-associated genes.  Future 
investigation into the pathways by which Batf2 enhances Mmp13 expression under these 
conditions might be helpful in defining the activity of Batf2. 
 Overall, analysis of AP-1 factors reveals that only Batf3 and Fra1 message change 
with polarization.  In vitro Batf2 binding partners cJun and JunB remain stable, but could 
interact with Fra1.  Figf/Vegfd and Csf1r, reportedly controlled by Fra1 and PU.1-cJun, 
respectively, remain unaltered by high constitutive Batf2 mRNA expression.  This 
suggests that Batf2 may not interact significantly with these proteins in macrophages.  
However, Batf2 might interact with cJun/cFos pathways in non-physiologically relevant 
context, as suggested by derepression of cJun/cJun-repressed Mmp13 in unpolarized 
macrophages. 
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4.4.2. Presence of possible ternary cofactors 
In addition to dimerization, transcriptional activation by AP-1 at some sites 
requires ternary complex formation.  AP-1 consensus TREs were the first AP-1 target 
sites to be defined and AP-1 heterodimers alone possess high affinity for these sites; 
however, this transcriptional repertoire expands when AP-1 dimers complex further with 
cofactors important for immune cell development and function such as Irf4/8, Ets, 
nuclear factor of activated T cells (NFAT) family, SMAD family, C/EBPB and PU.1 62,87.  
These complexes expand the transcriptional repertoire to genes with AP-1-Irf composite 
elements (AICE) Ets-Irf composite elements (EICE), C/EBPB promoter sequences, and 
PU.1 promoter sequences, respectively.  Defining the Batf2 cofactors present in 
macrophages allows predictions of which ternary complexes form and which genes can 
be activated by those complexes.  Moreover, lack of a Batf2 cofactor might explain the 
failure of constitutive high Batf2 expression to activate genes. 
To begin to explore which cofactors are present in M1-polarized PUER 
macrophages, we began with expression analysis of the Irf family members.  Irf1, 4, and 
8 bind to Batf2.  Batf2/Irf1 complexes have been tested directly by immunoprecipitation 
assays in mouse-derived macrophages, while Batf2-Irf4 and Batf2-Irf8 interactions can 
be implied by its ability to compensate for Batf3 deficiency in CD8α/CD103+CD11b- 
cDC development in vivo, described in Chapter 2, Table B21,83.  Moreover, Irf1 is 
important for macrophage polarization and the induction of inflammatory genes including 
iNOS, in part by complexing with cJun and NF-κB (see Gunthner et al. for a review of Irf 
functions in macrophages)1,4,99,147–149.  Irf5 has previously been proposed as a master 
regulator of M1 polarization, but not reported to interact with AP-1 factors 70.  Irf7 
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contributes to M1 polarization in microglia1,150.  Irf2, 3, and 9 were also tested, although 
there are no reports of these interacting with AP-1 or playing a large role in M1 
macrophage polarization.  As before, PUER macrophages were differentiated for four 
days with tamoxifen, then polarized an additional 8 or 48 hours with LPS/ IFNγ to 
inflammatory/M1 phenotype or with IL-4 to alternative/M2 phenotype or left 
unstimulated (Figure 4.1).  Following polarization, mRNA was extracted and analyzed 
using semi-quantitative RT-PCR for the presence or absence of the binding partners using 
specific primers. 
The results shown in Figure 20 indicate that Irf4 and Irf8 are not associated with 
long-term M1 polarization.  Irf4 message is strongly associated with M2 polarization in 
both PUER-Batf2 and control cells at 8 hours and 48 hours (Figure 4.19 A).  Irf8, on the 
other hand, is only minimally expressed in polarized cells.  Irf1, in contrast, is highly 
associated with M1 polarization, confirming previous reports.  Irf7 appears to be M1-
associated, but in 2 out of 4 experiments PUER cells expressed similar levels of Irf7 
mRNA in M1-polarized state as in resting state (data not shown).  Unexpectedly, Irf5 was 
not expressed.  Irf2, 3, and 9 expression does not vary markedly between conditions. 
This data supports the recent suggestion that Irf1 plays a role in macrophage 
polarization, suggests Irf7 might also support polarization, and contradicts reports of 
Irf5's importance for macrophage polarization.  Irf1 and Irf7 may both function in part by 
binding to Batf2, although more study is needed.  Moreover, other non-Irf proteins may 
well serve as cofactors for Batf2.  Future protein-protein and protein-DNA binding 
studies are needed to further define interactions. 
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4.5.  Summary: Batf2 is an M1-associated transcription factor not regulating select 
genes alone, but requiring additional factors 
 In this study, we describe Batf2 as an LPS/IFNγ-induced, M1-specific 
transcription factor with activity likely dependent on additional M1-associated factors or 
processes.  Constitutive high Batf2 expression alone enhanced LPS/IFNγ-induced Cxcl10 
message but not protein, and suppressed IL-4-induced Arg1 message.  Since AP-1 
proteins in general require additional factors for activity, including proper dimerization 
partners, non-AP-1 cofactors, adequate chromatin modifications, and post-translational 
modifications, Batf2 also likely requires a necessary cofactor that is limiting Batf2 
activity in our cells.  An Irf, possibly Irf1, may play this role, especially considering 
recent reports showing Batf2 interaction with Irf1 in macrophages. 
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Table 4.1: Microarray analysis of select novel and established M1 or M1 associated genes  
 
in polarized PUER macrophages. 
A. 
Type Gene 
Established or Novel M1 
or M2-Associated 
Fold change 
M1/MØ Pa 
Transcriptional 
Regulator 
 
Irf1 Established M11,109,151,152  21.8 6.76e-9 
Stat1 Established M1151,153 15.4 6.44e-7 
Batf2/SARI Novel 10.0 8.28e-7 
Ifi204/p204 Novel 8.3 2.67e-7 
Id2 Novel 3.5 6.54e-5 
Chemokine Ccl5/Rantes Established M1154,155 68.8 4.4e-10 
 Cxcl10/IP-10 Established M144,109,134,151  101 4.3e-9 
 CXCL9 Established M1 109,151,156 28.0 6.1e-8 
Cytokine IL-1β Established M1151,157–159 4.5 6.4e-7 
Enzyme iNOS/NOS2 Established M1 55,57,109,160 55.4 1.7e-10 
T-Cell Ligand H2-Aa Conflicting109,161 36.6 1.2e-7 
Transcriptional 
Regulators 
Hdac9 Novel 0.94 5.9e-3 
ZFP609 Novel 0.96 2.9e-3 
 Tcfec/Tfec Established M2162 0.34 2.7e-4 
Enzymes Arg1 Established M257,160 0.99 1.9e-3 
 Mmp13/Collagenase 3 
 
Conflicting 1.0 3.0e-4 
Mitogen Figf /Vegfd Novel 1.1 2.3e-8 
Regulator Protein Myc EstablishedM2163  0.27 9.6e-5 
Receptor Mrc1/Mmr Established M2164 0.11 1.7e-7 
Secreted Proteins Ym1/Chil3 Established M2160,165,166 0.71 4.5e-6 
 Fizz1/Retnlb Established M2160,165 0.89 2.6e-4 
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Table 4.1 (continued) 
B. 
Type Gene 
Established or Novel M1 
or M2-Associated 
Fold change 
M2/MØ P 
Transcriptional 
Regulator 
 
Irf1 Established M1 1,109,151,152   6.76e-9 
Stat1 Established M1151,153 0.94 6.44e-7 
Batf2/SARI Novel 0.82 8.28e-7 
Ifi204/p204 Novel 0.84 2.67e-7 
Id2 Novel 1.1 6.54e-5 
Chemokine 
 
Ccl5/Rantes Established M1154,155 1.1 4.4e-10 
Cxcl10/IP-10 Established M144,109,134,151  1.1 4.3e-9 
CXCL9 Established M1 109,151,156 1.3 6.1e-8 
Cytokine IL-1β Established M1151,157–159 0.74 6.4e-7 
Enzyme iNOS/NOS2 Established M1 55,57,109,160 1.2 1.7e-10 
T-Cell Ligand H2-Aa Mixed109,161 1.1 1.2e-7 
Transcriptional 
Regulator 
Hdac9 Novel 3.9 5.9e-3 
ZFP609 Novel 2.4 2.9e-3 
 Tcfec/Tfec Established M2162 2.0 2.7e-4 
Enzymes 
 
Arg1 Established M257,160 1.4 1.9e-3 
Mmp13/Collagenase 3 
 
Mixed 0.79 3.0e-4 
Mitogen Figf /Vegfd Novel 29.8 2.3e-8 
Regulator Protein Myc Established M2163  1.13 9.6e-5 
Receptor  Mrc1Mmr Established M2164 0.42 1.7e-7 
Secreted Proteins Ym1/Chil3 Established M2160,165,166 1.65 4.5e-6 
 Fizz1/Retnlb Established M2160,165 3.97 2.6e-4 
aP-value determined by ANOVA for comparison of day 4, MØ, M1, and M2 groups (n=3) 
A.  M1-polarized gene changes compared to MØ. 
B.  M2-polarized gene changes compared to MØ. 
  
100 
 
Table 4.2: Genes tested by microarray and RT-PCR analyses 
 
Gene Relevance 
Microarray 
M1/MØa          M2/MØb  
RT-PCR 
M1/ MØc    M2/MØd 
Ccne1 
(Cyclin E) 
Decreased by forced Batf2 
in  HeLa cells 
Var1
e
 NC
f
 
Var2 ND/NC 
Var1 NC 
Var2 ND/NC 
NCe 8hr 
↓ e 48hr 
NC 8hr 
NC 48hr 
Csf1r M1-associated cytokine 
receptor 
Induced by PU.1-AP-1 in 
macrophages 
3.2 0.2 NT 8hr 
↑ e 48hr 
NT 8hr 
NC 48hr 
IL-1β Induced by cJun/PU.1-
CEBPB in macrophages 
4.5 0.7 NT 8hr 
↓/↑ e 48hr 
NT 8hr 
↓/ND 48hr 
Mmp13 
 
Induced by cJun in 
macrophages 
1.2 
 
5.9 
 
NT 8hr 
↓/NC 48hr 
NT 8hr 
↑ 48hr 
Figf Induced by Fra1 1.1 29.8 NC 8hr 
↓/↑ 48hr 
↑ 8hr 
↑ 48hr 
cJun AP-1 family member, binds 
Batf2 in vitro 
Batf2 suppresses activity 
0.9 0.7 NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
JunD AP-1 family member NC 0.6 NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
JunB AP-1 family member, binds 
Batf2 in vitro 
NC NC ↑ 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
Fra1 AP-1 family member 
Induces Figf expression 
NC NC ↑ 8hr 
↓/↑  48hr 
↓ 8hr 
↓/↑ 48hr 
Fra2 AP-1 family member 0.8 0.4 NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
cFos AP-1 family member 0.3 0.2 NC 8hr 
↓/↑ 48hr 
↓ 8hr 
↓/↑ 48hr 
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Table 4.2 (Continued) 
Gene Relevance 
Microarray 
M1/MØa       M2/MØb  
RT-PCR 
M1/ MØc      M2/MØd 
Arg1 M2-associated enzyme
g
 
IL-4-induced message 
suppressed in pMigR1-
Batf2 
NC/ND NC/ND NC 8hr 
↓ 48hr 
NA 8hr 
↑ 48hr 
Cxcl10 M1-associated cytokine
g
 
LPS/IFNγ-induced message 
enhanced in pMigR1-Batf2 
101 NC NT 8hr 
↑ 48hr 
NT 8hr 
ND4 8hr 
Batf Batf family members76 NC NC NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
Batf3  NC/ND 1.4 NT 8hr 
ND/NC 48hr 
NT 8hr 
↑ 48hr 
Id2 
 
 
Bcl6 
Potential Batf2-inducible 
genes 
3.4 
 
 
2.8 
NC 
 
 
NC 
NC 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
↑ 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
Irf1 
 
 
Irf5 
 
 
Irf7 
 
 
Irf9 
 
M1-associated Irf
g
 
transcription factors 
Potential Batf2 
cofactors76,83,86 
21.8 
 
 
ND 
 
 
7.7 
 
 
3.2 
NC 
 
 
ND 
 
 
1.2 
 
 
0.7 
↑ 8hr 
↑ 48hr 
 
ND 8hr 
ND 48hr 
 
↑ 8hr 
↑ 48hr 
 
NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
 
ND 8hr 
ND 48hr 
 
↑ 8hr 
NC 48hr 
 
NC 8hr 
NC 48hr 
Irf4 Known Batf2 cofactors83,86 NC/ND NC/ND ↑ 8hr (minor) 
ND 48hr 
↑ 8hr 
↑ 48hr 
Irf4  NC/ND NC/ND ↑ 8hr 
NC/ND 48 hr 
NC/ND 8 hr 
NC/ND 48 hr 
Irf2 Potential Batf2 
cofactors76,83,86 
 
1.8 0.9 NC 8hr 
NC 48hr 
NC 8hr 
NC 48hr 
Irf3 NC NC NC 8hr 
↓/↑ 48hr 
 
NC 8hr 
NC 48hr 
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Table 4.2 (continued) 
 
Gene Relevance 
Microarray 
M1/MØa       M2/MØb  
RT-PCR 
M1/ MØc      M2/MØd 
Ccl5 
 
 
H2-Aa 
 
 
Id2 
 
 
Ifi204 
 
 
Ifi205 
 
 
iNOS 
 
 
Tgtp 
 
 
Parp12 
 
 
Parp14 
 
 
Stat1 
 
 
Stat2 
M1 or inflammatory-stimulus 
associated cytokine, 
established or tentative
g
 
68.1 
 
 
36.6 
 
 
3.4 
 
 
8.3 
 
 
8.8 
 
 
5.4 
 
 
97.8 
 
 
7.8 
 
 
12.8 
 
 
12.7 
 
 
6.6 
1.1 
 
 
1.1 
 
 
NC 
 
 
0.8 
 
 
NC 
 
 
1.2 
 
 
1.2 
 
 
0.9 
 
 
NC 
 
 
9.8 
 
 
0.9 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
ND 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT8hr 
NC 48hr 
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Table 4.2 (continued) 
 
Gene Relevance 
Microarray 
M1/MØa       M2/MØb  
PUER 
M1/ MØc      M2/MØd 
Fizz1 
 
 
Hdac9 
 
 
Mmp13 
 
 
Mrc1 
 
 
Prp 
 
 
Tcfec 
 
 
Tgfb1 
 
 
Ym1 
M2-associated proteins, 
established or tentative
g
 
 
 
0.9 
 
 
0.9 
 
 
1.2 
 
 
0.1 
 
 
1.1 
 
 
0.3 
 
 
NC 
 
 
0.7 
4.0 
 
 
3.2 
  
 
5.9 
 
 
0.4 
 
 
1.6 
 
 
2.0 
 
 
NC 
 
 
1.6 
NC 8hr 
↓ or ND 48hr 
 
NT 8hr 
↓ 48hr 
 
NT 8hr 
↓ or NC 48hr 
 
NT 8hr 
↓ 48hr 
 
NT 8hr 
↓/↑ 48hr 
 
NT 8hr 
↓ 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
↓ or NC 48hr 
↑ 8hr 
↑ 48hr 
 
NT 8hr 
↑ or NC 48hr 
 
NT 8hr 
↑ 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
↓/↑ 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
NC 48hr 
 
NT 8hr 
↓ or NC 48hr 
 
aM1/MØ for microarray data: Fold change in signal of M1 over MØ 48 hours after 
polarization  
bM2/MØ for microarray data: Fold change in signal of M2 over MØ 48 hours after 
polarization  
cM1/MØ for RT-PCR data: Direction of change in signal from MØ to M1 8 or 48 hours 
after polarization 
dM2/MØ for RT-PCR data: Direction of change in signal from MØ to M2 8 or 48 hours 
after polarization 
eCyclin E has two variants  
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fNC=No change (includes slight changes that not clearly significant); ND=Not detected; 
NT=Not Tested; ↑=Increased; ↓=Decreased; ↓/↑ = Variable across multiple experiments 
and cell types 
g References for established M1/M2 markers or novel M1/M2-associated genes are 
included in Table 4.1 
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Figure 4.1: Schematic of macrophage differentiation and polarization. 
 
Figure 4.1: Schematic of macrophage differentiation and polarization.  To differentiate 
the PUER cells to macrophages, PUER were seeded at 2x105-4x105 cells per cm2 in 
polystyrene tissue culture flasks and tamoxifen was added to media supplemented with 
5ng/ml IL-3 for 4 days.  On day 4 cells were treated with fresh control media (M0 group) 
or fresh media with cytokines for an additional 48 hours, or at times indicated in 
individual experiments.  In some cases, experiments lasting 24 hours or less did not 
receive fresh media in order to minimize the short-term effects of adding fresh media.  To 
polarize cells to M1 phenotype, 20 ng/ml IFNγ and 100 ng/ml LPS were added.  To 
polarize cells to M2, 4 ng/ml IL-4 was added.  Cells were analyzed after 2 days, or as 
otherwise described. 
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Figure 4.2: PUER macrophages polarize to M1 or M2. 
A. 
 
B. 
 
Figure 4.2: PUER macrophages polarize to M1 or M2.  M1/M2 polarization of PUER 
macrophages was confirmed by expression of M1 and M2 specific genes and enzyme 
activities.  Briefly, PUER cells at the common myeloid progenitor stage (CMP) or 
differentiated to macrophages and polarized by treatment with 100 ng/ml LPS and 20 
ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), were 
analyzed as described in Chapter 3.  A.  Expression of M1 and M2 specific genes was 
measured by RT-PCR.  Total cellular RNA was isolated 48 hours after treatment, reverse 
transcribed and specific genes for M1 (iNOS and Ccl2) or M2 (Arg1 and Fizz) were 
amplified by PCR using the primers listed in the materials and methods.  The PCR 
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products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images were inverted for clarity.  LPS/IFNγ or IL-4 treatment 
resulted in the expected upregulation of M1 specific genes iNOS and Ccl2 and M2 
specific genes Fizz1 and Arg1.  B.  Enzyme activities of the M1 specific enzyme iNOS or 
M2 specific enzyme Arginase 1 were measured in PUER cells 24 hour after treatment 
with LPS/IFNγ or IL-4.  For iNOS activity, nitrate concentration in the culture 
supernatants was measured using the Griess reagent, which measures nitrate in the 
supernatant.  For Arginase 1 activity cell extracts were prepared and arginase activity was 
measured by urea production, a product of arginase activity.  LPS/IFNγ treatment caused 
an approximately 23 fold selective upregulation of iNOS activity, whereas IL-4 treatment 
selectively upregulated arginase activity by about 6 fold.  
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Figure 4.3: PUER macrophage polarization is reversible. 
 
Figure 4.3: PUER macrophage polarization is reversible.  PUER cell re-polarization after 
initial polarization and repolarization was measured by gene expression of iNOS or Arg1.  
100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left 
unstimulated (MØ), as described in Chapter 3.  For baseline comparison, cells in the first 
three lanes were polarized for 48 hrs as in Figure 4.2, RNA was extracted and iNOS and 
Arg1 expression were detected by RT-PCR.  The products were separated on agarose 
gels, stained with ethidium bromide and photographed.  The images have been inverted 
for clarity.  The cells in lanes 4 to 8 were polarized for an additional 48 hours with the 
same stimuli (lanes 4, 5 &7) or the opposing stimuli (lanes 6 & 8).  iNOS and Arg1 
expression in PUER cells repolarized from M1 to M2 or M2 to M1 shows an almost 
complete reversal for M2 to M1 and a partial reversal of M1 to M2.  (credit:  B. Taylor 
and J. McGillis) 
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Figure 4.4: Transcription factors upregulated in M1 or M2 polarized PUER macrophages. 
 
Figure 4.4: Transcription factors upregulated in M1 or M2 polarized PUER macrophages.  
Transcription factors upregulated in M1 or M2 polarized macrophages were identified by 
microarray analysis.  Cells were treated with100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 
ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), as described in Chapter 3.  At 
48 hours, mRNA was extracted and a microarray analysis performed in the UK 
Microarray Core Facility using the GeneChip® Mouse Exon 1.0 ST Array.  Transcription 
factors upregulated or downregulated more than two fold were selected.  Numbers 
indicate fold increase compared to unstimulated.  Irf1 and Stat1 were previously reported 
to be upregulated in M1 and Tcfec found to be upregulated in M2.  Batf2, Ifi204, and Id2 
are novel transcription factors in M1 polarized macrophages.  Hdac9 and ZFP609 are 
novel transcription factors in M2 polarized macrophages.  A full list of genes in the 
microarray is found in Table 4.1.  
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Figure 4.5: Classical activation upregulates Batf2 mRNA and protein. 
A. 
 
B. 
 
Figure 4.5: Classical activation upregulates Batf2 mRNA and protein.  Batf2 mRNA (A) 
and protein (B) were confirmed in PUER macrophages by RT-PCR (A) and Western blot 
(B).  PUER cells were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml 
IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as described in Chapter 
3.  A.  Total RNA was extracted and analyzed using RT-PCR with specific primers.  The 
products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  B.  Total protein extracts were 
analyzed by Western blot with fluorescence detection methods.  Standards denoting 37 
kDa and 20 kDa are marked on the right, and Batf2 and Gapdh bands are marked on the 
left.  Batf2 expression is unique to M1-polarized macrophages.   
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Figure 4.6: Kinetics of Batf2 induction by LPS/IFNγ.   
 
Figure 4.6: Kinetics of Batf2 induction by LPS/IFNγ.  Batf2 mRNA at various time 
points was confirmed in PUER macrophages by RT-PCR.  PUER cells were polarized 
with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left 
unstimulated (MØ), then analyzed as described in Chapter 3.  Total RNA was extracted 
and analyzed using RT-PCR with specific primers.  The products were separated on 
agarose gels, stained with ethidium bromide and photographed.  The images have been 
inverted for clarity.  Batf2 message appears 1 hour after polarization and seems to peak 
around 8 hours.  Marked expression above baseline is shown here up to 26 hours. 
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Figure 4.7: Classical activation upregulates Batf2 mRNA in BMDM. 
 
Figure 4.7: Classical activation upregulates Batf2 mRNA in BMDM.  Batf2 expression in 
bone marrow derived macrophages (BMDM) was determined by RT-PCR.  BMDM were 
polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 
hours, or left unstimulated (MØ), then analyzed as described in Chapter 3.  Total RNA 
was extracted and analyzed using RT-PCR with specific primers.  The products were 
separated on agarose gels, stained with ethidium bromide and photographed.  The images 
have been inverted for clarity.  Both M1 and M2 polarization induced Batf2 expression; 
however, Batf2 expression in M2 polarized cells did not reach the amounts in M1 
polarized cells.  Moreover, additional gene analysis suggested that BMDMs were 
partially M1 polarized, even after M2 stimulus (data not shown).  (Credit: R. Hayman IV 
and J.  McGillis). 
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Figure 4.8: Classical activation upregulates multiple Batf2 mRNA isoforms.
 
 
B. 
 
 
C.        
 
Figure 4.8: Classical macrophage activation upregulates multiple Batf2 mRNA isoforms.  
A.  Known and predicted mRNA isoforms and protein variants in the National Center for 
Biotechnology (NCBI) database.  Four mRNA isoforms are predicted to exist for Batf2: 
the reference sequence NM_028967, isoform X1, isoform X2, and isoform X3.  Colors of 
the RNA correspond to sequence similarities (for example, the dark blue is shared by all 
A. 
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isoforms).  These translate into four protein variants: the reference sequence, variant X1 
(which differs from the reference sequence by a glutamine residue in the bZIP region), 
variant X2, and variant X3.  The isoform specificity of the antibody used in Figure 4.5 is 
unknown, but was raised to the indicated region (**) that is conserved in all full-length 
products with 94% identity.  B.  Detection of Batf2 isoforms X1 and X3.  PUER cells 
were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 8 
or 48 hours, or left unstimulated (MØ), then analyzed as described in Chapter 3.  Total 
RNA was extracted and analyzed using RT-PCR with isoform-specific primers.  The 
products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  Isoforms were confirmed by 
sequencing (data not shown).  The product indicated as “X3” could be produced from 
both X2 and X3; however, reactions using primers “1 F” and “All R” yielded no product 
the length of isoform X2.  C.  Alignment of primers to the three mRNA isoforms detected 
in M1-polarized PUER cells: X1, X2, X3, and the reference sequence.  Dark areas 
indicate regions of variation between isoforms.  Triangles indicate the primers used to 
detect the isoforms and correspond to the primers on the left in (B).   
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Figure 4.9: IFNγ, but not LPS, induces Batf2 expression 
A. B. 
 
Figure 4.9: IFNγ, but not LPS, induces Batf2 expression.  Batf2 expression in response to 
LPS or IFNγ alone (A) or compared to LPS/IFNγ combination (B).  PUER cells were 
polarized with 100 ng/ml LPS and/or 20 ng/ml IFNγ for 8, 24, or 48 hours, or left 
unstimulated (MØ), then analyzed as described in Chapter 3.  Total mRNA was extracted 
and analyzed using RT-PCR with specific primers.  The products were separated on 
agarose gels, stained with ethidium bromide and photographed.  The images have been 
inverted for clarity.  Unstimulated and LPS-stimulated cells had minimal Batf2 mRNA, 
while cells treated with IFNγ by itself expressed Batf2 at roughly comparable levels to 
cells treated with LPS and/IFNγ. 
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Figure 4.10: Both LPS/IFNγ and IL-10 induce Batf2 expression. 
 
Figure 4.10: Both LPS/IFNγ and IL-10 induce Batf2 expression.  IL-10-induced Batf2 
expression vs LPS/IFNγ-induced Batf2 expression.  PUER cells were polarized with 100 
ng/ml LPS and 20 ng/ml IFNγ (M1), 4 ng/ml IL-4 (M2), or IL-10 at the listed 
concentrations for 48 hours, or left unstimulated (MØ), then analyzed as described in 
Chapter 3.  Total RNA was extracted and analyzed using RT-PCR with specific primers.  
The products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  Concentrations of IL-10 from 
1-100 ng/ml induce Batf2 expression. 
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Figure 4.11: Induction of select M1-associated genes occurs subsequent to Batf2 
induction. 
 
Figure 4.11: Induction of select M1-associated genes occurs subsequent to Batf2 
induction.  Two M1-associated genes, Cxcl10 and Ifi204, increase markedly subsequent 
to Batf2 induction.  PUER cells were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ 
(M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as 
described in Chapter 3.  Total RNA was extracted and analyzed using RT-PCR with 
specific primers.  The products were separated on agarose gels, stained with ethidium 
bromide and photographed.  The images have been inverted for clarity.  Chemokine 
Cxcl10 and transcription factor Ifi204 are induced by IFNγ and LPS in macrophages with 
slightly different kinetics.   
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Figure 4.12: PUER-Batf2 constitutively express Batf2 mRNA. 
A. 
 
B. 
 
Figure 4.12: PUER-Batf2 cells constitutively express Batf2 mRNA.  PUER cells were 
transduced with retroviral vector pMigr1-Batf2 to create cells that constitutively express 
Batf2 (PUER-Batf2).To control for off-target effects due to the retroviral vector, PUER 
cells were also transduced with the empty vector pMigr1 (PUER-pMigR1).  Batf2 and 
Gapdh expression were also analyzed as described in Chapter 3.  Total RNA was 
extracted and analyzed using RT-PCR with specific primers.  The products were 
separated on agarose gels, stained with ethidium bromide and photographed.  The images 
have been inverted for clarity.  A.  PUER, PUER-pMigR1, and PUER- Batf2 were 
analyzed at common myeloid progenitor stage (D0) or differentiated to resting 
macrophages with tamoxifen for the 1 or 4 days.  In contrast to unpolarized PUER cells 
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or macrophages that express little Batf2 message in resting state, PUER-Batf2 
constitutively express abundant Batf2 message at all stages.  B.  PUER-Batf2 comparison 
to resting or M1-polarized PUER.  Batf2 message is highly expressed even compared to 
M1-polarized PUER levels. 
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Figure 4.13: PUER-Batf2 cells polarize to M1 phenotype after LPS/IFNγ.   
 
Figure 4.13: PUER-Batf2 cells polarize to M1 phenotype after LPS/IFNγ.  M1 
polarization was verified by detection of the M1-associated iNOS protein.  PUER cells 
and Batf2-transduced cells (PUER-Batf2) were analyzed in cells differentiated for 4 days 
and analyzed immediately (MØa) or differentiated to macrophages with tamoxifen 
treatment and then were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 
ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØb).  iNOS protein in cell extracts 
was analyzed by Western blot with fluorescence detection as described in Chapter 3.  
Gapdh was used as a loading control.  M1-polarized PUER and PUER-Batf2 produce 
iNOS, indicating proper M1 polarization. 
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Figure 4.14: Constitutive expression of Batf2 enhances LPS/IFNγ-induced Cxcl10 gene 
mRNA expression. 
A.   
 
 
B. 
 
 
Figure 4.14: Constitutive expression of Batf2 enhances LPS/IFNγ-induced Cxcl10 
mRNA expression.  M1-associated chemokine Cxcl10 mRNA and protein in 
macrophages constitutively expressing Batf2 compared to controls was detected by RT-
PCR and Western blot, respectively.  A.  Cxcl10 mRNA.  PUER cells, vector-transduced 
cells (PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100 
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left 
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unstimulated (MØ), then analyzed as described in Chapter 3.  Total RNA was extracted 
and analyzed using RT-PCR with specific primers.  Gapdh was included as a loading 
control.  The products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  Similar results were observed 
in 3 out of 4 independent experiments.  While there was a clear trend, the enhancement of 
Cxcl10 message in PUER-Batf2 M1-polarized macrophages from these three 
experiments pooled was not significant after quantitation with Image J due to high 
standard deviation.  B.  Cxcl10 protein.  Vector-transduced cells (PUER-pMigR1) and 
Batf2-transduced cells (PUER-Batf2) were polarized for 24 hours with 100 ng/ml LPS 
and 20 ng/ml IFNγ or left unstimulated (MØ), then Cxcl10 levels in the medium were 
analyzed as described in Chapter 3.  Supernatant was removed for Cxcl10 analysis and 
the cells were harvested for total protein quantification for normalization.  Cxcl10 protein 
in supernatant was assayed by ELISA, and total protein was extracted from cell fraction 
and used as a correlate of cell number (see Chapter 3) for the correlation of protein and 
cell number).  The difference between PUER-MigR1 and PUER-Batf2 is not statistically 
significant (p=0.204) demonstrating that Batf2-enhanced LPS/IFNγ-induced Cxcl10 
mRNA does not translate into enhancement of Cxcl10 protein secretion. 
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Figure 4.15: Constitutive expression of Batf2 downregulates IL-4 induced Arg1 mRNA. 
 
Figure 4.15: Constitutive expression of Batf2 downregulates IL-4 induced Arg1 mRNA.  
Arginase 1 (Arg1) in macrophages constitutively expressing Batf2 compared to controls 
was determined by RT-PCR.  PUER cells, vector-transduced cells (PUER-pMigR1) and 
Batf2-transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20 ng/ml 
IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed 
as described in Chapter 3.  Total RNA was extracted and analyzed using RT-PCR with 
specific primers.  Gapdh was analyzed as a loading control.  The products were separated 
on agarose gels, stained with ethidium bromide and photographed.  The images have 
been inverted for clarity.  Similar suppression of Arg1 expression compared to 
unpolarized macrophages was observed in 3 out of 4 independent experiments.  PUER-
Batf2 cells suppress Batf2-induced Arg1 expression relative to PUER and PUER-
pMigR1.  While there was a clear trend, the suppression by Batf2 from these three 
experiments combined was not significant after quantitation with ImageJ due to high 
standard deviation. 
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Figure 4.16: High constitutive Batf2 mRNA expression does not alter known or potential 
genes downstream of Batf2 in macrophages. 
 
 
 
 
 
 
 
 
A. 
B. 
125 
 
Figure 4.16 (continued) 
 
C. 
 
 
 
Figure 4.16: High constitutive Batf2 mRNA expression does not alter known or potential 
genes downstream of Batf2 in macrophages.  PUER cells, vector-transduced cells 
(PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100 
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left 
unstimulated (MØ), then analyzed as described in Chapter 3.  Total RNA was extracted 
and analyzed using RT-PCR with specific primers.  Either Gapdh or Hprt were included 
as a loading control.  The products were separated on agarose gels, stained with ethidium 
bromide and photographed.  The images have been inverted for clarity.  A.  Expression of 
cJun-suppressible Ccne1 (Cyclin E).  Batf2 suppression of cJun suppresses expression of 
expression of Ccne1 (encoding the Cyclin E cell cycle protein) in multiple cell types.  
Expression in PUER-Batf2 cells compares to control cells, suggesting Batf2 does not 
interfere with cJun-driven gene expression.  Lack of induction in PUER-Batf2 was 
observed in 2 out of 2 independent experiments.  B.  Expression of cJun-inducible Csf1r, 
Il1b, and Mmp1.3 Csf1r, Il1b, and Mmp13 are induced in macrophages by cJun and the 
cofactors pictured to the right of the gel.  cJun homodimer induces Il1b in conjunction 
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with macrophage transcription factors PU.1 and C/EBP, cJun and an undefined AP-1 
dimerization partner to induce Csf1r in conjunction with  PU.1.  Phosphorylated 
cJun/cFos activates Mmp13 transcription while unphosphorylated cJun/cJun represses 
Mmp13.  Basal expression of Mmp13 is increased in PUER-Batf2 cells but not enhanced 
by LPS/IFNγ treatment, suggesting Batf2 does not enhance these genes in M1-polarized 
macrophages.  Lack of suppression in PUER-Batf2 was observed in 3 out of 3 
experiments for Csf1r and Mmp13, and 2 out of 2 experiments for Il1b.  C.  Expression 
of Batf2-inducible Id2.  Id2 is induced by forced Batf2 in compensation for a deficiency 
of Batf3 in cDC subsets.  Bcl6 is induced by Batf in Tfh cells, but Batf2 cannot 
compensate in these cells.  PUER-Batf2 express Id2 and Bcl6 comparably in PUER-
Batf2 and controls, suggesting Batf2 activity differs in macrophages and the cDC subsets 
and that Batf2 does not have similar activity in macrophages as Batf3 or Batf in other 
cells. Lack of enhancement in PUER-Batf2 relative to controls was observed in 3 out of 4 
experiments for Id2 and 2 out of 2 experiments for Bcl6. 
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Figure 4.17: Dimerization partners are present in PUER cells. 
 
A. 
 
B. 
 
 
C. 
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Figure 4.17: Dimerization partners are present in PUER cells.  Presence of mRNA for 
other AP-1 proteins was determined by RT-PCR.  PUER cells, vector-transduced cells 
and Batf2-transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20 
ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then 
analyzed as described in Chapter 3.  Total RNA was extracted and analyzed using RT-
PCR with specific primers.  Either Gapdh or Hprt was included as a loading control.  The 
products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  One representative experiment 
out of three to four (for the 48-hour polarizations) or two (for 8 hour polarization) is 
shown for clarity.  A.  Summary of the representation of AP-1 proteins in PUER 
macrophages, determined by RT-PCR at 8 and 48 hours.  cJun dimerizes with Batf2 
functionally in vivo, and JunB dimerizes with Batf2 in fluorescence resonance energy 
transfer (FRET) assays by Reinke et al.113.  The remaining AP-1 proteins did not bind to 
Batf2 in FRET assays.  B.  Batf, cFos, Fra2, and JunD are not associated with any 
polarization state.  Batf3 is associated with M2 polarized cells during sustained M2 
polarization.  The presence of the AP-1 factors leave open the possibility that Batf2 
interacts with their activity either directly by dimerization with them or indirectly by 
sequestering a binding partner.  C.  Fra1 is associated with M1-polarized cells at 8 hours 
but not during long-term maintenance of polarization (data not shown).  This suggests 
Fra1 may be involved with early M1 polarization, either in conjunction with Batf2 or 
alone, but does not necessarily suggest involvement during sustained polarization.  It is 
worth noting that AP-1 proteins are highly regulated by post-translational modifications 
and therefore activity may not correlate to mRNA expression.   
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Figure 4.18: Constitutive Batf2 expression does not appear to interfere with Fra1 
signaling. 
 
Figure 4.18: High constitutive Batf2 mRNA expression does not appear to interfere with 
Fra1 signaling.  The Fra1-inducible gene Figf was detected in PUER cells constitutively 
expressing Batf2 compared to controls by RT-PCR.  PUER cells, vector-transduced cells 
(PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100 
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left 
unstimulated (MØ), then analyzed as described in Chapter 3.  Total RNA was extracted 
and analyzed using RT-PCR with specific primers.  Gapdh was included as a loading 
control.  The products were separated on agarose gels, stained with ethidium bromide and 
photographed.  The images have been inverted for clarity.  Similar results were observed 
in 3 independent experiments.  Figf is induced by Fra1 in macrophage cells, and Fra1 
dimerizes with Batf2 in vitro.  Figf expression was not suppressed in PUER-Batf2 cells 
that highly express Batf2 constitutively compared to controls in 3 out of 3 experiments, 
suggesting Batf2 does not interfere with Fra1 activity.   
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Figure 4.19: mRNA expression of known and potential Batf subfamily cofactors, the Irf 
transcription factors. 
A.   B. 
 
C.   
 
Figure 4.19: mRNA expression of known and potential Batf subfamily cofactors, the Irf 
transcription factors.  Expression of Irf family members in PUER, PUER-pMigR1, and 
PUER-Batf2 cells.  PUER cells, vector-transduced cells (PUER-pMigR1) and Batf2-
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transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ 
(M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as 
described in Chapter 3.  Total RNA was extracted and analyzed using RT-PCR with 
specific primers.  Gapdh was included as a loading control.  The products were separated 
on agarose gels, stained with ethidium bromide and photographed.  The images have 
been inverted for clarity.  Similar results were observed in 3 independent experiments for 
the 48 hour timepoints.  A.  Expression of known Batf family cofactors Irf4 and Irf8.  Irf4 
and Irf8 form a ternary complex with AP-1 dimers containing Batf family members and 
subsequently bind to the AP-1/Irf Composite Element (AICE) (5'-TTTCnnnnTGACTAA-
3' or 5'-GAAATGAnTCA-3').  At 8 hours, Irf8 and Irf4 are both expressed in M1-
polarized macrophages, although Irf4 is more strongly expressed in M2-polarized 
macrophages.  At 48 hours, Irf8 is minimally expressed and Irf4 is not detectable in M1-
polarized macrophages.  Therefore, Irf4 and Irf8 may interact with Batf2 at 8 hours but 
not 48 hours in M1-polarized PUER macrophages.  B.  Expression of M1-associated Irf1, 
Irf7, Irf9, and Irf5.  Irf1 binds to Batf2 in macrophages and plays a role in expression of 
M1associated genes.  Irf7 and Irf 9 have no demonstrated interactions with Batf2.  Irf1 
and Irf7 are expressed in M1-polarized macrophages at 48 hours, while Irf5 is not 
detectable.  Therefore, Irf1, Irf7, and Irf9 could potentially interact with Batf2 at 48 hours 
in M1-polarized PUER macrophages.  C.  Irf2 and Irf3 are not M1-associated.  Irf2 and 
Irf9 are expressed in M1-polarized macrophages at 48 hours, while Irf3 is not detectable.  
Therefore, Irf2 could potentially interact with Batf2 at 48 hours in M1-polarized PUER 
macrophages, but not Irf3. 
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Chapter V 
DISCUSSION  
5.1.  Summary  
 The major question addressed in this project is how specific genes affect 
macrophage polarization; more specifically, the role of the transcription factor Batf2 in 
sustained inflammatory (M1) polarization.  My initial hypothesis was that Batf2 alone is 
a master regulator of M1 polarization.  However, this was not the case.  Constitutive high 
Batf2 expression alone did not drive expression of M1-associated genes, but did 
moderately enhance LPS/IFNγ-induced Cxcl10 mRNA and suppress IL4-induced Arg1 
mRNA.  Additionally, Batf2 activity in macrophages does not appear to be similar to its 
roles in other cells.  These results considered alongside the previously established 
importance of cofactors to the activity of Batf subfamily members activity suggests that 
Batf2 activity requires a necessary cofactor, and lead the way for future studies 
investigating the cofactors that interact with Batf2 and the genes regulated by Batf2-
cofactor complexes in sustained M1 polarization state. 
 In this discussion I address first the evidence suggesting Batf2 drives M1-specific 
gene expression.  Next, I address the moderate polarization-dependent effects of Batf2 
and extrapolate those results to hypothesize functions of Batf2 during immune responses.  
I then present possible implications of the inability of Batf2 alone to drive M1-associated 
gene expression, as well as differences in Batf2 activity between other cells and 
macrophages.  Finally, I consider several potential factors that might contribute to the 
lack of Batf2 activity from constitutive high expression alone, and focus in on the most 
likely solution: that Batf2 requires a necessary cofactor.  Based on previous studies, I 
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focus on the Irf family members, discussing the potential of each for being the necessary 
cofactor of Batf2. 
 
5.2.  Batf2 is rapidly induced in M1-polarized macrophages 
 Several pieces of evidence strongly support Batf2 as a master transcription factor 
in sustained M1 polarization.  First, Batf2 expression is specific to the M1 state.  Second, 
Batf2 is highly expressed relative to other M1-specific transcription factors.  Third, Batf2 
mRNA appears early after LPS/IFNγ stimulation.  Finally, Batf2 subfamily members 
have established roles as master transcription factors in development and function of 
other immune cells. 
 Batf2's specificity to the M1 polarization state in the PUER model system 
supports the hypothesis that it regulates genes important for M1 functions.  In general, 
LPS/IFNγ-activated M1 functions support a type 1 inflammatory response involving the 
production of effector proteins such as nitric oxide, activation of effector functions such 
as phagocytosis, and recruitment and support of Th1-type T cells.  In our PUER cells, 
Batf2 correlated with upregulation of the anti-microbial and phagocytosis-supporting 
enzyme iNOS, inflammatory cell-recruiting chemokine Cxcl10, and multiple genes 
consistently associated with multiple models of M1 macrophages including Irf1, Irf7 and 
Ccl5.  In contrast, Batf2 was not expressed in IL-4-activated M2 polarization (denoted 
specifically by some authors as M2a).  M2 polarization supports type 2 inflammatory 
responses with effector proteins such as NO-antagonizing Arg1 and with proteins 
supporting Th2-type T cells.  Batf2 expression inversely correlated with multiple M2a-
associated genes including Arg1, Fizz1, and Irf4.  In PUER cells, resting macrophages 
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displayed only minimal amounts of Batf2, if any.  On the other hand, bone marrow 
derived macrophages (BMDMs) did express Batf2 mRNA in the M2-polarized state.  
This could be due to previous in vivo influences, the isolation procedures, or stresses 
from cell culture partially polarizing the highly plastic macrophage partially to M1.  
Although we use a reductionist model with discrete M1/M2 subsets for study, in reality 
macrophages fall on a spectrum.  Some M2 subsets, such as BMDM in our study, may be 
closer to M1 on the spectrum.  In vivo, macrophages likely exist in states with some M1 
functions and some M2 functions.  Roy et al. and Tussiwand et al. examined 
macrophages and dendritic cells ex vivo and found low basal Batf2 expression compared 
to infected mice or in vitro stimulated cells1,83.  Whether this compares to the level in our 
BMDMs is not clear.  Batf2 expression in basal levels or M2-associated macrophages in 
vivo requires further exploration.  The analyses in human cancer studies and IFN-
associated diseases (see Background section) suggest that Batf2 is indeed somewhat 
variable in vivo.  As future studies define the genes induced or repressed by Batf2, the 
consequences of Batf2 expression in macrophages exposed to M2 stimuli such as IL-4 
will become clearer.  For the purposes of this study, we are focusing on the fact that Batf2 
associates highly with IFNγ but not IL-4 activation in our reductionist and highly 
controllable model, and this agrees with previous reports on Batf2’s correlation with 
inflammatory responses1,83,95,108,109,119. 
 Typically, LPS and IFNγ are the model in vitro inflammatory stimuli for the M1 
state.  In vivo, macrophages see a wide variety of stimuli that polarize them to variations 
of the inflammatory phenotype depending on the environment.  In some contexts, for 
example, IFNγ may be present without TLR4 agonists such as LPS, activating different 
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macrophage functions than LPS/IFNγ in combination.  IFNγ signals through IFNGR1/2 
and activates the JAK1/2 and Stat1/1 pathway, while TLR4 signals through MyD88, 
which then activates the MAPK pathway and transcription factor AP-1, or activates the 
transcription factors NF-кB or Irf3.  Our study began to address the potential for Batf2 
activity in multiple environments by assessing differential induction by LPS or IFNγ.  
TLR4 stimulation by LPS was not necessary for Batf2 expression in PUER macrophages, 
so Batf2 may have activity in contexts where TLR4 stimulation is minimal but IFNγ is 
high.  This is consistent with the developing understanding on Batf2 expression.  Batf2 
was initially discovered as an IFNβ -inducible gene in multiple cell types, and IFNβ has 
continued to be the main stimulus in studies on Batf2's tumor-suppressing effect95,112,114.  
These studies demonstrate that Batf2 has a role in functions outside of bacterial infections 
and TLR4-stimulating damage, and open the possibility that IFN-induced Batf2 might 
drive damaging inflammatory genes in situations when inflammation is inappropriate.  
For example, Batf2 is highly upregulated in common variable immune deficiency patients 
with autoimmune complications versus those without, and in fibromyalgia with high pain 
versus low pain123,167.  In these cases, Batf2 might be a good target for anti-inflammatory 
therapeutics.   
Two previous studies have examined Batf2 expression in macrophages in 
response to LPS and/or IFNγ, in part agreeing and in part disagreeing with our results.  
Tussiwand et al. found that IFNγ alone can induce Batf2 in BMDM, similar to our PUER 
cells83.  Contrary to our results, however, Batf2 was also induced by LPS, although this 
experiment was in peritoneal macrophages.  Roy et al. has recently done further studies 
on the effects of Batf2 in macrophages.  As in our study and in Tussiwand et al., Batf2 
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was induced by IFNγ alone.  Contrary to our results but agreeing with Tussiwand et al.’s 
experiments with BMDM cells, Batf2 was also inducible by LPS1,109.  Further, a genome-
wide association study by Chmielewski et al. found synergism between IFNγ and TLR4 
for Batf2 induction in vascular smooth muscle cells121.  It is possible that the 
macrophages in the Roy et al. and Tussiwand et al. studies, being isolated from mice or 
human patients, experienced some mildly polarizing stimuli in vivo or during the 
isolation procedure that primed them for Batf2 expression in response to LPS, or were 
epigenetically programmed.  One of the advantages of PUER cells is the ability to 
differentiate and polarize the cells with minimal polarizing stimulation.  Future studies 
could examine these pathways with a wider variety of macrophage cells to determine the 
consistency of LPS-induced Batf2 expression.  Regardless, Batf2 clearly belongs to in an 
LPS/IFNγ-induced M1 and not an IL-4-induced M2 transcriptional program in PUER 
cells. 
 Interestingly, Batf2 also increased in response to IL-10 stimulation, demonstrating 
that Batf2 may also be induced by factors more often associated with M2 phenotypes.  
IL-10 in combination with TGF-β and glucocorticoids activates macrophages to an 
alternative phenotype.  IL-10/TGF-β/glucocorticoids-induced macrophages produce IL-
10, TGF-β, and Ccr2.  This polarization state functions in wound healing and cell debris 
scavenging, and has more in common with the IL-4-induced M2 state than the LPS/IFNγ-
induced M1 state31,33,34,128.  LPS/IFNγ activates Stat1, while both IL-4 and IL-10 activate 
Stat3, so Batf2 induction by IL-10 was unexpected.  Nevertheless, IL-10-activated 
macrophages do express some overlapping genes with IFNγ and LPS31,33.  Therefore, 
Batf2 may be induced by an IL-10-activated pathway distinct from Stat3.  Additionally, 
137 
 
IL-10-induced Batf2 was not dose-dependent in the experiment shown in Figure 4.10, 
suggesting that all three concentrations of IL-10 (1, 10, and 100ng/ml) elicited maximal 
Batf2 expression on the plateau of the dose-response curve.  Therefore, the pathway 
inducing Batf2 in response to IL-10 may have a lesser maximal response than LPS/IFNγ, 
or the maximal response in response to LPS/IFNγ may be from a combination of the IL-
10-induced pathway and an LPS/IFNγ-exclusive pathway.  Our study and those of other 
support an important role for Batf2 in polarization to an M1 phenotype, but Batf2-
induced gene expression may also have functions in other contexts (as discussed in the 
Background section on Batf2’s role in cancers).  IL-10-induced Batf2 may induce some 
functions needed in specific environments containing IL-10 as well as environments 
containing LPS and IFNγ.  Future studies may seek to confirm IL-10 induction of Batf2 
and examine the pathways inducing Batf2, as well as the role of IL-10-induced Batf2 in 
the context of wound healing and debris scavenging.  Batf2 may serve in this context to 
activate phagocytic abilities during scavenging, or receptors detecting foreign molecules 
such as bacterial mannose by the mannose receptor (Mrc1).   
 In addition to its association with the LPS/ IFNγ-induced M1 state, the rapid 
induction of Batf2 message and high expression levels at later time points support a role 
for Batf2 in the MØ to M1 transition and sustained M1 polarization.  Batf2's appearance 
as early as 1 hour after stimulation suggests it may be an immediate-early gene as well 
for M1 polarization.  This would mean that the factor inducing Batf2 is constitutively 
present and rapidly activated upon stimulation, allowing Batf2 among other immediate-
early genes to activate downstream gene expression early after stimulation when 
macrophages are shifting out of a resting state and into an inflammatory state.  The 
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approximately10-fold increase in Batf2 after polarization approaches the major 
inflammatory transcription factor Stat1, which was increased 12.7-fold.  This robust 
expression of Batf2 may support our hypothesis that Batf2 is important for sustained M1 
polarization.  It is worth considering, however, that Batf2 does not necessarily need to be 
an immediate-early gene to be critical for sustained M1 polarization.  Several 
transcription factors are expressed early but transiently such as Fra1168.  Another 
transcription factor could have conceivably fulfilled Batf2's role initially, with Batf2 
being a critical factor only later.  Instead, the data suggest that Batf2 seems to be 
important for initial polarization as well as long-term polarization.  Once genes 
downstream of Batf2 are identified, studies knocking down Batf2 and examining early 
expression of these genes could clarify the timeframe of Batf2 importance and confirm 
whether it indeed is important for initial polarization, as this data suggests. 
  The hypothesis that Batf2 is important for M1 polarization, sustained in 
particular but likely also immediate, is backed by a large body of research demonstrating 
the importance of Batf subfamily members in immune cell differentiation and function.  
Batf3 drives genes for the differentiation of CD8α+ cDCs and CD103+CD11b- cDCs, 
inducing Clec9a, Xcr1, Id2, and Spib.  Batf induces genes for CSR in B cells (Aid), and 
genes for differentiation of Th17, Tfh cells, and Th9 including Rorc, Il17A, Il21, Il23R, 
Maf, Bcl6, ILl9, Il21, Il10, Furin, Fes, Erg, and IL-1RA.  In Th2 cells Batf or Batf3 both 
induce GATA3, Il4, Il10, and Ctla4.  Batf, Batf2, and Batf3 all share homology and have 
partially overlapping functions in some cells 76,111.  Batf2's ability to compensate for 
Batf3 is discussed more in depth below.  Based on Batf2's association to M1 polarized 
macrophages, rapid and robust expression, and prior knowledge of the Batf subfamily 
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members, it is reasonable to predict that Batf2 could function as an inducer of an array of 
M1-associated genes in macrophages. 
 
5.3.  Constitutive Batf2 expression alone enhances select M1 genes or suppresses 
 select M2 genes 
 If Batf2 was a master transcription factor for M1 macrophage polarization as 
initially predicted, similar to the Th1 master transcription factor Tbet, then constitutive 
Batf2 expression in resting macrophages should have induced expression of M1-specific 
genes.  This turned out not to be the case.  On the other hand, Roy et al. recently 
uncovered a role for Batf2 in a broad array of M1-associated genes using knockdown 
studies 1.  This apparent contradiction, as well as our mild polarization-exclusive 
changes, can be most simply explained as a requirement for a necessary cofactor 
(discussed in more detail below).  In spite of the lack of broad changes, constitutive Batf2 
expression enhanced LPS/IFNγ-induced Cxl10 and suppressed IL-4-induced Arg1.  
Neither Cxcl10 nor Arg1 was mentioned in the knockdown studies by Roy et al. These 
results, along with prior studies on Cxcl10 and Arg1 regulation, provide a starting point 
for future studies on Batf2 control of these genes.  Batf2 is known to inhibit cJun activity 
at the AP-1 consensus by preventing DNA binding95.  The murine Cxcl10 promoter 
contains an AP-1 consensus site although it is not required for Cxcl10 expression in some 
contexts.  For example, Cxcl10 was not inducible by the AP-1 activator PMA40,51.  
Moreover, AP-1-mediated enhancement contradicts Batf2's known role as an inhibitor of 
cJun activity by preventing cJun binding to these sites95.  This would not contradict our 
results if Batf2 or a Batf2-containing complex recognizes and activates from a consensus 
140 
 
other than the AP-1 site.  In contrast to Cxcl10, Arg1 contains an AP-1 consensus on the 
promoter that significantly drives Arg1 expression in macrophages via cFos in response 
to macrophage stimulating protein (MSP), and another that drives expression in rat aortic 
endothelial cells via cJun/ATF2 in response to thrombin47,169.  Thus, Batf2 could inhibit 
Arginase 1 expression via the AP-1 consensus site in M2 associated genes. 
 Another explanation for our results that Batf2 message itself may be preventing 
Cxcl10 message degradation through RNA interference.  Currently, there is substantial 
interest in the importance of small interfering RNAs (siRNAs)  in macrophage 
polarization170 (siRNA)-mediated gene knockdown is now standard in mice and has 
potential for human therapies as well.  In consultation with Dr. Penni Black (College of 
Pharmacy, University of Kentucky) we asked whether it might be possible that the 
presence of Batf2 mRNA itself could regulate Cxcl10.  Interestingly, analysis using 
miRDB (http://www.mirdb.org) found that miR-296 is both predicted to bind both Cxcl10 
message and Batf2 message3.  Batf2 may, therefore, sequester and act as a sink for Cxcl0-
degrading miR-296.  This could contribute to the enhanced Cxcl10 mRNA induction in 
our cells, especially given the lack of enhancement of any other genes tested.  This type 
of regulation, by sequestering a regulatory miRNA, presents a novel mechanism of gene 
regulation and requires experimental verification.  An interesting further experiment 
would be to transduce a translation-defective Batf2 mRNA to analyze whether this can 
enhance Cxcl10.  Future studies could evaluate further the interaction of miR-293 with 
Cxcl10 and Batf2, and determine whether this interaction occurs in vivo.  This avenue of 
research, although departing from studies on Batf2, could lead to a deeper understanding 
                                                 
3 Personal communication, Dr. Penni Black, College of Pharmacy, University of Kentucky 
141 
 
of the ramifications of overexpression vectors in research, and to helpful therapeutics 
using miRNAs to decrease Cxcl10 and therefore decrease T and NK cell influx in 
inflammatory diseases.   
 One approach to confirm a role for Batf2 in enhancing LPS/IFNγ-induced Cxcl10 
and suppressing IL-4-induced Arg1 is to knock down Batf2 and analyze the changes in 
these genes.  Roy et al. successfully knocked down Batf2 and found decreased expression 
of an array of M1-associated genes1.  This study did not mention Cxcl10 or M2-
associated genes.  We did attempt to create PUER cells constitutively expressing small-
hairpin RNAs (shRNAs) to downregulate Batf2 message (see Section 4.3.3 on page 85).  
However, transduced cells from two shRNA sequences did not demonstrate decreased 
Batf2, and a third did not grow (data not shown).  Batf2 is minimally expressed in healthy 
PUER cells prior to polarization, but Batf2 levels have not been tested in newly 
transduced cells.  It is possible that Batf2 suppression by our specific shRNA strategy or 
vector system is toxic or growth-prohibitive in PUER cells.  This contrasts with the study 
by Roy et al. that successfully stably transduced BMDMs with shRNA knocking down 
Batf2, and with Batf2’s known role as a growth suppressant in cancer cells1,95.  Further 
studies could determine the lethality or growth inhibition of Batf2 in PUER cells by 
treatments with small interfering RNA treatments, which permit transient knockdowns. 
 
5.4.  Possible cofactor proteins or processes required for Batf2 activity 
 Surprisingly, constitutively high Batf2 expression in the common myeloid 
progenitor stage did not drive multiple M1-associated genes.  This approach has 
successfully uncovered other master regulators in particular in T cells such as Tbet (Th1 
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cells) Foxp3 (Treg), Bcl6 (Tfh), GATA2 (Th2) and RORγt (Th17)14–20.  Recently, Roy et 
al. confirmed the importance of Batf2 for the expression of multiple M1-associated genes 
and repression of multiple M2-associated genes in murine macrophages using 
knockdown studies1.  While constitutively high Batf2 expression in our study did 
enhance Cxcl10 mRNA expression and suppress Arg1 expression, this effect was 
moderate and specific to polarized cells.  Therefore, Batf2 must be undergoing some level 
of post-transcriptional regulation.  Transcription factors undergo multiple post-
transcriptional regulatory mechanisms (see Table 2.2 in Chapter 1).  In particular, the 
ubiquitous AP-1 proteins undergo many layers of regulation that provide fine control of 
transcription of any given downstream gene.  These layers include: presence of a 
positively-regulating dimerization partner (although appropriate cofactors may 
compensate80); absence of any negatively regulating dimerization partners; non-AP-1 
cofactors (if necessary); post-translational modifications, including phosphorylation, 
avoidance of SUMOylation, ubiquitination, and redox potential. 
 Based on our data and previous studies on Batf members, the simplest and most 
likely explanation is that a necessary cofactor, also upregulated upon polarization, is 
required for Batf2 activity.  First, Batf2 enhances Cxcl10 message only in the polarized 
state, when the cofactor would also be elevated.  Second, Batf proteins exert their known 
activities in other immune cells via protein-protein binding, presumably to a coregulatory 
factor.  Third, knockdown of Batf2 leads to changes in gene expression not seen in 
constitutive Batf2 mRNA expression1,76.  Cofactor binding also provides a mechanism for 
Batf2's cell specific activity and might explain why Batf2 suppresses Cyclin E in cancer 
cells and Id2 in CD103+CD11b- cDCs but suppresses neither in our macrophages (Figure 
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4.16A).  This evidence suggests not only that Batf2 functions in conjunction with a 
necessary cofactor, but that Batf2 target genes differ between different cell types.  This 
could be due to unique cofactors that modify Batf2 activity, or differences in gene 
accessibility through chromatin modification.  Finally, Batf2 must associate with Irf4/Irf8 
in order to compensate for Batf3 deficiency in CD103+CD11b- cDCs development and 
function83.  This evidence suggests that a cofactor is probably required for Batf2 activity 
in macrophages.  However, other mechanisms could also be at play.  Although Batf2 
sequesters cJun away from DNA binding, constitutive expression of excess Batf2 did not 
seem to seem to affect cJun activity, since the PUER-Batf2 cells expressed equal amounts 
of three genes downstream of cJun in macrophages (Csf1r, IL-1β, Mmp13).  This might 
be due to post-translational regulation of the Batf2 protein, cJun, or both.  Thus, it is 
worth considering other mechanisms that might alter the activity of Batf2. 
 In this study, we began to explore two of the likely mechanisms regulating Batf2 
activity by examining the presence, absence, and polarization state association of known 
or likely proteins with which Batf2 interacts and that lie downstream of pathways with 
which Batf2 interacts.  Two categories of interactants tested include a) dimerization 
partners and b) ternary complex cofactors. 
 
5.4.1. Dimerization partners 
 The balance of AP-1 proteins present in a cell may be a key factor regulating 
Batf2 activity.  Dimerization is necessary for activity of bZIP proteins 
ontranscription81,82.  Thus, the balance of binding partners present could regulate gene 
expression by shifting the predominant heterodimers, which have different transactivation 
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activity.  Activity of AP1 activity depends on relative ratios of binding partners, 
demonstrated in several instances by altering cJun, cFos, Fra2, and Batf 
proteins63,73,75,79,83,171,172.  cJun/cJun versus cJun/cFos dimers at the Mmp12 and Mmp13 
locus provide an example of the importance of correct partners.  cJun/cJun heterodimers 
repress transcription by recruiting repressors, while cJun/cFos heterodimers activate 
transcription through their transactivation domains63.  Batf2 itself provides another 
example of the influence of relative levels of dimerization partners; low levels of Batf2 in 
multiple cancer cell lines allow cJun to bind DNA and activate transcription, while high 
expression of Batf2 in those cells sequesters cJun from DNA binding and thereby inhibits 
transcription 95,124.  Based on these observations, I expect that Batf2 dimerization could 
alter activity of a dimerization partner in two ways, depending on interacting proteins or 
complexes present.  This could occur by 1) assisting a dimerization partner in DNA 
binding, directly activating or repressing of the downstream gene, or 2) preventing a 
dimerization partner binding to DNA, indirectly preventing activation or derepressing the 
downstream gene.  The former occurs when Batf2 replaces Batf3 (which heterodimerizes 
with cJun, JunB, or JunD) in Batf3-Irf4 ternary complexes driving CD103+CD11b- cDC 
development83.  The latter occurs when Batf2 sequesters cJun in multiple non-immune 
cells, preventing activation of tumor promoting genes 95.  Predicting the effect of Batf2 
on other AP-1 proteins in macrophages is complicated by the lack of in vivo information 
on Batf2's possible dimerization partners.  Batf2 binds to cJun in vivo and JunB in 
fluorescence resonance energy transfer  (FRET) protein-protein binding assays, while 
none of the other AP-1 proteins bound Batf2 strongly in FRET assays95,113.  cJun and 
JunB expression is not associated with M1 polarization, but either could be Batf2 binding 
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partners in PUER macrophages since they were both detectable at 48 hours, Batf2 
interacts with cJun, and JunB has been implicated previously in macrophage activation 
159.  However, the mRNA kinetics does not support a role for either in maintaining long-
term M1 polarization with Batf2, since neither cJun nor JunB increased in M1-polarized 
cells at 8 or 48 hours.  A previous study on BMDMs observed an increase in cJun at 24 
hours after IFNγ polarization109.  It is possible that these proteins play a transient role at 
early time points in PUER macrophage polarization.  Further, cJun message does not 
necessarily indicate activity, since post-translational modifications, largely 
phosphorylation, commonly regulate cJun activity.  Constitutive Batf2 expression even at 
the high levels in our PUER-Batf2 cells does not appear to be functionally sequestering 
cJun protein, however, as three genes downstream of cJun (Ccne1 [Cyclin E], Csf1r, and 
IL-1β) were comparable in control cells and in cells highly and constitutively expressing 
Batf2 mRNA. 
 In contrast to cJun and JunB, cFos, Fra1, Fra2, JunD, Batf, and Batf3 do not 
dimerize significantly to Batf2 in large-scale binding assays113.  Batf2 is more likely to 
interact with these by sequestering another binding partner.  Like cJun and JunB, 
expression of these factors is not M1-associated at later time points but mRNA levels do 
not necessarily correlate with activity.  cFos message was elevated transiently hours after 
IFNγ polarization in a separate study109, which might suggest a transient role at early time 
points, but not long-term maintenance of M1 polarization state.  Fra1 was the only factor 
increased markedly after M1 polarization, but at 48 hours was detected sporadically in 
unpolarized as well as polarized cells, with no correlation to any specific treatment.  
Constitutive, high Batf2 expression does not appear to interact with Fra1 activity since 
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PUER-Batf2 do not exhibit enhanced expression of Figf, a gene induced by Fra1 
transfection in mouse mammary epithelial carcinoma cells146.  Therefore, the AP-1 
proteins that do not likely dimerize with Batf2 but may be indirectly regulated by Batf2 
are not associated with sustained M1 polarization by mRNA analysis, and unlikely to 
play a significant role in M1-promoting gene expression changes mediated by Batf2. 
 Overall, mRNA analysis alone does not suggest either of the putative (JunB) or 
verified (cJun) Batf2 dimerization partners as a partner in long-term Batf2 activity.  
However, mRNA analysis at 8 and 48 hours alone may not be a good indication of 
activity.  In spite of a lack of significant message increase, the recent study mentioned 
above by Roy et al. reports that the kinetics of JunB most closely match the kinetics of 
enriched cJun/cFos consensus-driven message in IFNγ-polarized BMDMs at 2-24 hours, 
and the authors suggest that JunB plays a role in polarization 1.  This agrees with previous 
studies implicating JunB in macrophage polarization159.  JunB may well be the most 
likely candidate for Batf2 heterodimers, although this raises the question of how it 
continues to drive M1-associated gene expression after expression returns to baseline at 
later time points.  Future studies on the Batf2 activity must analyze the heterodimers that 
form in vivo at various time points after polarization and the activity of these 
heterodimers. 
 
5.4.2. Ternary complex cofactors 
 Alongside dimerization, ternary complex formation may also regulate Batf2 
activity during M1 polarization.  As mentioned above, the simplest interpretation of the 
evidence supports the existence of a necessary cofactor for Batf2.  Further, precedents in 
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other systems suggest that the cofactor is a ternary complex cofactor.  Ternary complex 
cofactors guide Batf proteins to specific consensus sites in other immune cells including 
T cells, B cells, and some subsets of DCs (reviewed in Murphy et al.76).  Cofactor 
binding also provides a mechanism for Batf2's cell specific activity and might explain 
why Batf2 suppresses Cyclin E in cancer cells and Id2 in CD103+CD11b- cDCs but does 
neither in macrophages. 
 Batf provides an example of the manner by which cofactors dictate different roles 
for Batf subfamily members in T cells and B cells (reviewed in Li et al.173).  In B cells, 
Batf is important for class-switch recombination107; while in T cells it is important for 
differentiation of various T cell subsets and for expression of various cytokines and 
transcription factors such as Rorc, Rora, and Ahr.  The major difference between these 
two cell lineages is the presence of the Irf4-binding proteins PU.1 and Spib in B cells.  
Irf4 monomers have autoinhibitory activity preventing DNA binding at the concentrations 
found in T and B cells, but PU.1, Spib, and Batf bind and disinhibit Irf4.  In B cells, Irf4 
binds PU.1 or Spib, and guides the complex to ETS-Irf consensus elements (EICEs) (5'-
GGAAnnGAAA-3'), leading to gene expression.  T cells, however, lack these factors so 
Irf4 binds instead to Batf-cJun heterodimers, and the complex subsequently binds AP-1-
Irf composite elements (AICEs) (TGAnTCAnnnnGAAA or GAAATGAnTCA).  AICE 
binding by Batf-cJun-Irf4 complexes also occurs in B cells, but to a much lesser extent, 
possibly due to relative abundance of each complex, or possibly due to another factor yet 
to be identified.  Thus, Batf2 activity in M1-polarized macrophages likely depends on the 
unique cofactor repertoire in these cells relative to other cells that use Batf2 and other 
Batfs. 
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 Irf family members are candidates for being Batf2 cofactors in PUER cells.  Irf1 
and Irf7 are most likely to have a role in long-term polarization based on mRNA 
expression analysis, since both are elevated during sustained M1 polarization.  Irf8 is 
associated with early M1 polarization, so potentially plays a role during early shift from 
resting to M1.  Previous studies suggest that Irf9 and Irf5 induce M1-associated gene 
expression, but Irf9 is not M1-associated in our study and Irf5 is not expressed.  Irf2, Irf3, 
and Irf4 are not likely to support M1 polarization.  Irf2 was constitutively expressed, Irf3 
was somewhat decreased upon M1 polarization, and.  Irf4 was associated with sustained 
M2 polarization.  Prior studies do not report roles for either of them in M1 polarization 
 
5.4.2.1. Irf4 and Irf8: Hematopoietic-specific known Batf subfamily cofactors 
 Irf4 and Irf8 are hematopoietic-specific Irf family members that bind with Batf-
subfamily proteins, including Batf2, and are therefore candidates for Batf2 cofactors in 
macrophages.  Batf-Irf4/Irf8 complexes are critical for development of other immune 
cells by driving transcription at AICEs.  Although no DNA-binding assays have been 
published demonstrating Batf2-Irf4/Irf8 complexes binding to AICE elements, previous 
data suggests Batf2 does have transactivation activity through DNA binding. For 
example, the protein-protein interaction domain (the leucine zipper) allows Batf2 to 
functionally compensate for Batf3 deficiency in CD103+CD11b-cDC/CD8α+  cDC 
development.  This suggests that it either activates gene expression from AICEs or an 
alternative site located in most of the same promoter or enhancer regions83.  Therefore, 
Irf4 has the potential to drive gene expression in PUER cells in concert with Batf2.  
However, Irf4 is M2-associated in our study and in previous reports, acting as an 
149 
 
antagonist in TLR signaling4,8.  Irf4 has known activity in macrophages both at the 
interferon stimulated response element (ISRE) by interacting with other Irf family 
members as well as at the Ets/Irf composite elements (EICE) by interacting with PU.1, 
but has no activity alone due to an autoinhibitory domain174–177.  In contrast, Irf8 is 
associated with M1 polarization in our study at earlier time points but expressed equally 
in unpolarized and polarized PUER macrophages at 48 hours.  Irf8 is induced by LPS 
and/or IFNγ and in turn induces M1-specific cytokines including IL-1β, TNFα,  IL-12, 
IL-6, and iNOS 178.  Irf8 contains a similar protein-binding domain to Irf4, and also 
interacts with other Irf family members to transactivate at ISRE or with PU.1 at EICE175–
177,177.  Notably, transactivation tends to be weaker than Irf4, and it seems to lack 
transactivation activity alone179,180.  If that is the case, then how Batf-Irf8 complexes 
activate transcription requires clarification, since Batf also lacks transactivation activity 
on its own83,180.  Unlike Irf4, Irf8 is IFNγ -inducible and associated with M1-polarized 
macrophages181.  It is important for FcgR1, LPS/IFNγ-induced IL-12p40, and iNOS, as 
well as directing myeloid progenitors to the macrophage instead of granulocyte 
lineage182.  In vivo Irf8 is important for proper development and response of macrophage 
populations in bone marrow183.  In PUER, we find Irf8 expressed under all conditions at 
48 hours, but it is M1-associated at early timepoints.  Irf8 may be important for initial 
polarization, and then sustained expression continues to contribute to maintenance of M1-
associated gene expression.  Therefore, although Irf4 is not M1-associated, Irf8 is an 
early M1-associated Batf-subfamily cofactor that may be a cofactor for Batf2. 
 Overall, although initially promising, the evidence does not suggest a role for the 
hematopoietic Irf family members Irf4 and Irf8 as Batf2 cofactors with roles in sustaining 
150 
 
M1 macrophage polarization.  Batf2 and Irf4 or Irf8 expression do not coincide, since 
CMPs, mature macrophages, and M2-polarized macrophages lack Batf2, while M1-
polarized macrophages cells lack Irf4 and do not upregulate Irf8 throughout sustained 
polarization.  Moreover, previous studies have detected Irf8 significantly upregulated at 2 
hours after IFNγ polarization, so it may be a factor at earlier time points, but Batf2 must 
interact with another cofactor for activity during sustained M1 polarization109. 
 
5.4.2.2.  M1-associated Irf1 and Irf7 may interact with Batf2 and play a role in 
M1 polarization 
 Although not supported as a Batf/Irf cofactor by the initial studies described 
above, Irf1 has recently become a likely candidate for driving gene expression in concert 
with Batf2 in macrophages.  Recent studies demonstrate that Irf1 interacts with Batf2 in 
M1-polarized macrophages.  Moreover, Irf1 is induced by IFNγ and TLR stimulation, 
strongly and consistently associates with M1 polarization, and is known to act in concert 
with cofactors including NF-кB and cJun1,4,109,184.  Roy et al made the discovery that Irf1 
binds to Batf2 in M1-polarized macrophages, and further demonstrated that loss of Irf1 
recapitulates many of the same changes as loss of Batf21.  Irf1 still lacks confirmation as 
a necessary cofactor of Batf2 in macrophages, however, and has some important 
differences with known Batf subfamily cofactors Irf4 and Irf8.  Irf1 binds to ISREs and 
drives gene expression without the necessity of a Batf member, while Batf-Irf complexes 
were originally found because Irf4 and Irf8 are necessary for cell development or 
function but do not drive gene expression alone.  In dendritic cells, Irf4/8 guides the Batfs 
preferentially from the conventional AP-1 consensus sequence to an AP-1/Irf consensus 
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element, termed the AICE83,86.  Glasmacher et al's study defining the AICE did explore a 
role for Irf1 along with Irf3, since they are structurally similar to Irf4 and Irf8.  They 
found that these factors did not assemble on AICE sites with Batf-JunB complexes as did 
Irf4 and Irf8.  Moreover, Irf1 is also found in B cells but Batf2 cannot compensate for 
Batf in these cells, suggesting Batf2-Irf1 complexes do not function like Batf-Irf4/8 
complexes83.  This evidence taken together suggests that Batf-Irf1 complexes do not have 
the same activity as Batf-Irf4/8 complexes. 
 However, if Irf1 can bind ISREs on its own and does not bind to AICEs in 
conjunction with Batfs, why does knockdown of Irf1 and Batf2 result in similar 
transcriptional profiles? One possibility is that Batf2-Irf1 complexes may recognize an 
alternative consensus.  In theory, this alternative consensus might be present in the 
critical promoters for DC development and macrophage polarization (where Batf2 has 
activity and interacts with Irfs), but not critical genes in T cell development and function 
and B cell activation.  There may also be another cofactor required to stabilize Batf2-Irf1 
complexes that is not present in T and B cells. 
 Our finding that Irf1 increases selectively in M1-polarized macrophages contrasts 
with other reports of Irf1 increased in M2-polarized cells, but agrees with Irf1's consistent 
association with M1 polarization4,109.  Irf1 could drive M1 associated genes in M1-
polarized but not M2-polarized cells if Batf2 mediates Irf1's effects, or if M1-specific 
post-translational modification activates Irf1184.  Future studies must examine the 
promoters of genes for Batf-Irf1 consensus binding, as well as exploring other potential 
cofactors that may be part of a larger transcriptional activation complex. 
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 Irf7 is also M1-associated at 48 hours in our PUER macrophages, and may have 
relevance to M1 polarization.  Unlike Irf1, Irf4, and Irf8, Irf7 is not specific to 
hematopoietic cells, but nonetheless is involved in macrophage differentiation and type I 
interferon induction, as well as M1-like polarization in microarray 4,150.  Interestingly, 
Irf7 basal expression is increased in PUER cell constitutively expressing Batf2.  Irf7-
interacting pathways would provide a reasonable start for future studies examining Batf2-
interacting pathways. 
 
5.4.2.3. M1-associated Irf5 and Irf9, and M1-unassociated Irf2 and Irf3 
 Irf5 and Irf9 both are notable as previously proposed master regulators of M1 
polarization and mediators of LPS-activated transcription4,70.  However, Irf5 was not 
detected in our PUER macrophages in resting or polarized states, suggesting this factor is 
dispensable for macrophage polarization.  In our study, Irf9 was not exclusive to M1 
state.  Irf9 might still have M1-promoting roles under some conditions by propagating 
type 1 IFN signaling and inducing Cxcl10 in concert with Stat1 homodimers185.  It might 
also be active selectively in M1-polarized macrophages without a change in mRNA 
expression by post-translational regulation or cofactor interaction. 
 Based on the literature, other ubiquitously-expressed Irf family members have 
activity in macrophages, but are unlikely to serve a broad role.  Irf2 and Irf3 were 
constitutively expressed under all conditions.  Irf2 is not a likely contributor to M1 
polarization because expression is not M1-associated and because it can inhibit Irf1101,186.  
Irf3 may promote either M1- or M2- associated cytokines.  On the one hand, Irf3 induces 
Ccl5; on the other, Irf3 suppresses IL-1A and IL-23187,188.  These Irf family members 
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provide examples of a minor importance of Irf family members and Irf-containing 
complexes inducing macrophage genes, but other Irf family members are more likely to 
play a role 
 In summary, studies on the Batf subfamily suggest that Irf family members 
present the most likely candidates for being cofactors for Batf2.  Irf1, Irf4, and Irf8 are 
established Batf2-interacting factors, but only Irf1 is strongly M1-associated.  
Batf2manipulation by itself may fail to alter genes in our cells simply due to limited 
availability of Irf1 or another Irf.  Still, Batf2's interaction with a cofactor or multiple 
cofactors has not been definitively determined.  Batf2-Irf1 has not yet been evaluated for 
DNA-binding.  Batf2's putative cofactor remains to be definitively determined.  Future 
studies should examine complexes formed with Batf2 in macrophages.  Knock-out and 
restoration methods could examine the ability of each of these complexes to drive 
macrophage polarization. 
 
5.4.3. Other regulatory mechanisms: Chromatin state and post-translational 
modification 
 Two more major regulatory mechanisms that likely regulate Batf2 activity merit 
some discussion: epigenetic modifications and post-translational modification.  
Chromatin modification regulates gene accessibility to multiple transcription factors, 
while post-translational modification regulate individual transcription factors.  
Phosphorylation is of particular importance to AP-1 proteins64–66,66,145.  Other regulatory 
modifications for AP (reviewed by Foletta et al.74,77) include SUMOylation of cFos,  
ubiquitination of cJun in Xia et al., and oxidation or reduction of cJun77,91–93.  Both 
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chromatin state and post-translational mechanisms likely mediate to a major extent some 
of the differences seen in Batf2 activity in various cell types. 
 Chromatin structure is an important determinant of cell specificity that presents an 
avenue of research for future studies on the differences in Batf2's activity in macrophages 
relative to other cells.  Chromatin structure refers to the modifications and tightness of 
the collective bundle of DNA-wrapped protein histones called nucleosomes.  Remodeling 
enzymes modify DNA or histones, tightening or loosening interactions of DNA with the 
proteins.  Tightening blocks access to transcription factors, and loosing permits access 
and transcription.  The pattern of closed and open chromatin is to some extent determined 
by lineage-specific 'pioneer factors' that can access regions inaccessible to other 
transcription factors and recruit remodeling enzymes that open specific regions.  This 
results in linage-specific gene, reviewed in Smale et al.6.  Additionally, external stimuli 
can to some extent cause remodeling, providing a means of environment-specific gene 
expression.  In macrophages, Runx1 transiently permits PU.1 transcription.  Macrophage 
lineage-determining pioneer factor PU.1 along with Runx1 mediate gene accessibility by 
facilitating H2K4me1 deposition via remodeling enzymes  expression10,11,68,69.  Thus, 
chromatin structuring during development by factors like PU.1 may open up different 
sets of enhancers and promoters to Batf2 in macrophages, CD103+CD11b-cDCs, and 
cancer cell lines.  It is also interesting to note that Hdac proteins also seem to be playing 
roles cell differentiation and our lab has strong evidence that Hdac9 is important for the 
M2 state (McGillis, unpublished data).  Thus interaction with chromatin modifying 
proteins and complexes may be another potential binding partner for Batf2 mediated 
regulatory activities. 
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 Not only may lineage-specific epigenetic modifications mediate differences in 
Batf2-induced or suppressed genes between different cells, it may also contribute to the 
differences in Batf2 expression in response to LPS stimulation seen in PUER cells 
compared to bone-marrow derived macrophages in the Roy et al study1.  LPS stimulation 
of PUER does not induce Batf2 expression, while Roy et al reported that LPS 
synergistically with IFNγ as well as independently induces Batf2 expression in murine 
BMDMs.  Green and Kerr et al. reported that epigenetic modifications control LPS-
responsive genes, so primary macrophages may be primed in vivo or during isolation to 
express inflammatory genes189.  PUER macrophages, in contrast, undergo minimal 
epigenetic programming compared to primary cells derived from animals.  Gene 
expression in PUER cells may more closely reflect a truly naïve macrophage seeing 
polarizing stimuli for the first time, whereas gene expression in primary cells may be 
partially due to epigenetic programming from stimuli in vivo, during isolation, or during 
growth in vitro.  On the other hand, PUER notably contain a modified PU.1 element: 
PU.1 attached to an estrogen receptor (ER) regulatory domain190.  This artificial PU.1 
may differ in remodeling ability; however, there has been no reason to suspect significant 
differences.  PUER macrophages have been successfully used for prior studies and found 
to exhibit similar gene expression as macrophages from other models 129,132,191.  
Therefore, Batf2 expression in other studies in response to LPS may result from external 
insults in vivo or during isolation.  Further studies on LPS responsiveness of Batf2 are 
required to further define the regulatory pathways controlling Batf2 expression. 
 Post-translational modifications including phosphorylation and SUMOylation 
strongly regulate AP-1 family members77.  M1-specific activating modifications may also 
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partially explain Batf2's M1-specific effects.  cJun and cFos must undergo appropriate 
phosphorylation at specific residues for transactivation activity64–66,144,145.  The antibody 
to Batf2 we used is a polyclonal antibody, raised to a peptide from human Batf2, and so 
the phosphorylation state of Batf2 remains unknown.  AP-1 factors are also regulated 
through ubiquitination and SUMOylation90,91.  These modifications tend to lead to 
degradation and thus reduce rather than enhance activity, and so are unlikely to mediate 
Batf2's M1-specific effects.  Redox state also mediates cJun92,93.  This regulation provides 
a mechanism for these proteins to mediate stress responses.  Batf2, in contrast, is not 
associated with stress response, so is less likely to be influenced by oxidation.  Of the 
post-translational modifications, phosphorylation state most likely regulates Batf2 
function.  Phosphorylation sites and their activities should be further explored in future 
studies to better understand post-translational regulatory mechanisms of Batf2 activity. 
 In summary, Batf2 likely undergoes regulation by a number of mechanisms 
including through cell-specific chromatin state and post-translational modifications.  
Thus, in contrast to our initial simple hypothesis, the mechanisms by which Batf2 
influences macrophage functions is complex and will require in-depth mechanistic 
studies to fully understand its role in M1 macrophages.  Our study did not explore these 
mechanisms, but they offer promising avenues of future research.  Chromatin states differ 
between cell types and may mediate part of Batf2's cell specificity.  PUER cells offer a 
good model for future Batf2 studies since they are relatively free of in vivo epigenetic 
modification.  Phosphorylation very likely mediates Batf2 activity.  Future studies could 
determine activating and repressing phosphorylation of Batf2, and the pathways 
mediating both. 
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5.5.  Batf2 as a therapeutic target 
 One reason to define master transcription factors in inflammation is to manipulate 
them therapeutically.  However, this study suggests that the effect of constitutively Batf2 
expression alone such as could be delivered through adenovirus treatments may not 
produce changes robust enough for clinical benefit.  For Cxcl10 in this study, the 
moderate enhancement of message failed to significantly increase protein levels 
(p=0.204).  Functional studies are required to determine whether constitutive Batf2 
expression alone has therapeutic applications.  However, simultaneously inducing Batf2 
and the limiting factor would likely induce more M1-specific genes than we detected in 
our study, including the genes inhibited by Batf2 knockdown.  This remains to be tested.  
With our current knowledge, we can speculate that in vivo transduction of Batf2 with the 
required factor might enhance Cxcl10 significantly and suppress Il4-induced Arg1 
significantly. 
On the other hand, if our modified hypothesis is correct and Batf2 interacts with a 
cofactor, Batf2 knockdown with siRNA may prove effective for modulating M1 
polarization.  Roy et al.'s knockdown study demonstrating broad suppression of M1-
associated genes supports this possibility1,108.  Further support of the use of Batf2 
suppression in inflammatory conditions arises from Tussiwand et al.’s report of Batf2-/- 
mice, which display abnormal phenotype after inducing IFNγ and IL-12-induced immune 
function after T. gondii  infection83.  These mice possessed both fewer lung-resident 
CD103+CD11b- cDCs and CD103-CD11b- macrophages after infection, but not during 
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homeostasis, suggesting that Batf2 knockdown might have minimal off-target effects 
when used as a target for excess inflammation.  This study did not report macrophage 
responses in depth, so further analyses are required to define the macrophage 
inflammatory phenotype in Batf2-/- mice. 
In spite of Batf2’s associating with inflammatory stimuli IFN and LPS in multiple 
studies, it is possible that Batf2 plays a role in a response that occurs in IFNγ/LPS-
activated M1 as well as some subsets of M2.  Macrophages in vivo exist on a spectrum, 
so it is indeed likely that Batf2 is expressed in in vivo macrophages that have seen M2-
associated stimuli such as IL-4.  Batf2’s expression in our BMDMs and IL-10 activated 
macrophages support this, as well as the highly variable expression of Batf2 isolated 
human cells and tissues in cancer studies115,116,119,120.  As further studies elucidate the 
functions of Batf2, the significance of Batf2 expression in vivo will become clearer. 
 Batf2-mediated manipulation of Cxcl10 would most likely impact local 
inflammatory cell influx.  Cxcl10, enhanced by Batf2 in our study, binds to CXCR3 that 
is found mainly on polarized Th1 cells and NK cells but also on macrophages, microglia, 
and dendritic cells128,192.  Cxcl10 activates chemotaxis to attract cells to the origin of 
infection.  To a lesser extent, it is associated with T cell development, T cell function, T 
cell adhesion to endothelial cells, NK cell cytolysis, angiogenesis inhibition, tumor 
growth inhibition, mitogenesis and chemotaxis on smooth muscle cells,  inhibition of 
development of bone marrow progenitor cells, and apoptosis and cell growth 51,193.  
Batf2-enhanced Cxcl10 production could therefore contribute to immune cell influx and 
function at sites of inflammation, and more rapid responses to infection.  Conversely, 
Batf2 suppression could reduce immune cell influx and function, and mitigate damaging 
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inappropriate inflammatory responses.  This might be useful in cases of high-pain 
fibromyalgia and common variable immune deficiency (CVID), where Batf2 is highly 
expressed but inflammation is inappropriate123,167. 
 Argininase 1 (Arg1), in contrast to Cxcl10, generally associates with anti-
inflammatory macrophages.  Arginase activity shuttles L-arginine into the pathway for 
ornithine, a cell growth promoter and building block for tissue repair, and urea54, away 
from its potential conversion to the inflammatory nitric oxide by iNOS in M1-polarized 
cells.  Thus, it not only provides metabolites for growth and repair but also actively 
counters inflammatory responses.  Arginase competes with iNOS for arginine, and low 
arginine pools do indeed decrease iNOS activity as well as arginase activity.  During 
infection, arginase prevents excess inflammation and fibrosis in the case of some 
pathogens such as S.  mansonii56.  Batf2 transduction with the limiting cofactor may 
suppress Arg1 induction and thus increase inflammation by blocking the shunting of 
arginase into alternative pathways, allowing its use in the iNOS pathway.  Alternatively, 
Batf2 knockdown could enhance Arginase 1 activity, promoting tissue repair with 
ornithine production and decreasing tissue damage from nitric oxide production.  Thus, 
manipulation of Batf2 may have therapeutic potential. 
 
 
5.6.  Conclusions 
 Batf2, a bZIP transcription factor in the AP-1 family of proteins, is highly and 
rapidly upregulated in LPS/IFNγ-polarized macrophages.  This dissertation initially 
hypothesized that Batf2 was a master regulator of LPS/ IFNγ-stimulated (M1) 
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polarization, driving expression of several M1-associated genes.  However, constitutive 
high Batf2 expression did not induce or enhance expression of most of the M1-associated 
genes tested.  Batf2 also did not broadly suppress IL-4-induced (M2-associated) genes, 
nor enhance or suppress potential downstream genes based on Batf2 activity in other cell 
types.  Batf2 did mildly enhance LPS/IFNγ-induced M1 chemokine Cxcl10 mRNA and 
mildly suppress IL-4-induced M2 enzyme Arginase 1 mRNA expression.  Based on this 
data and previous Batf2 studies, Batf2 likely requires a necessary cofactor for its role in 
M1 macrophages, which remains largely undefined.  An Irf family members, especially 
Irf1, is one of the most likely candidates for a Batf2 interacting factor.  More research is 
needed to determine the factors that interact with Batf2.  Clearly the evidence from my 
studies and others suggest that Batf2 plays a role in M1 polarization.  Defining the 
mechanisms of Batf2 induction and activity may offer in the future ways to approach 
therapies targeting macrophage inflammatory responses. 
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